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Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) is a chronic 
necrosis of the jawbone that occurs in 1-5% of patients receiving 
bisphosphonate medication for conditions such as osteoporosis and certain 
cancers.  Although the pathogenesis of BRONJ is still uncertain, several recent 
theories have emerged; these include vascular disruption of the jaw tissue; 
inappropriate osteoclast activation; and direct cytotoxicity of jaw epithelium.  
However, despite bisphosphonates having well-documented stimulatory effects 
on immune cells, and BRONJ being associated with oral microbial infections, an 
immune-mediated pathology for BRONJ has largely been ignored. 
Bisphosphonates activate human  T cells, specifically those that use T cell 
receptor (TCR) -chain variable-region-9, and TCR -chain variable-region-2 
(V9V2 T cells).  These unconventional T cells typically account for 1-5% of 
circulating lymphocytes, make protective responses to microbial challenge, and 
are promising candidates for cancer immunotherapy.  In the context of BRONJ, 
we have hypothesised that bisphosphonate-mediated activation of jaw-
associated V9V2 T cells, in the presence of oral microbiota, may drive the 
disruption of bone turnover that is central to the disease process. 
On initiation of these studies, it quickly became apparent that traditional 
characterisation of V9V2 T cells using CD27/CD45RA was demonstrably sub-
optimal, while phenotypic analysis of 63 healthy volunteers revealed an 
unexpected and surprising degree of V9V2 T cell heterogeneity; both of which 
are likely to confuse assessment of disease scenarios.  Thus, this thesis 
describes the novel phenotypic and functional characterisation of V9V2 T 
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cells using alternative surface markers and methods of analysis.  This reveals 
that different sets of individuals have different V9V2 T cell “profiles” that 
predict very different functional capabilities and responses to 
immunotherapeutic interventions.  Using this improved definition of V9V2       
T cells, this thesis then describes preliminary investigations of V9V2 T cell 
development in the human neonatal thymus, and assesses the involvement of 
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Chapter 1 Thesis overview 
The oral cavity presents a unique anatomical micro-environment in that it is the 
only site in the body where hard tissues (teeth) protrude through lining mucosa.  
This unusual anatomical environment coupled with the richly diverse bacterial 
biofilm that colonises the oral cavity soon after birth makes the mouth one of the 
most immunological dynamic regions of the body (Tlaskalová-Hogenová et al. 
2004). 
The innate and adaptive immune responses have evolved defensive 
mechanisms over a huge evolutionary period to protect the teeth, gingivae, 
mucosa and underlying bone from common infections that result in caries (tooth 
decay) and periodontal disease (gum disease).  But despite these protective 
responses, there are a large number of oral diseases that manifest when the 
infective burden becomes overwhelming or when immunological responses 
become defective or inappropriate (Hamzaoui 2011, Fye et al. 1976). 
In the last 10-12 years, Bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) has emerged as one of the most enigmatic and difficult to treat 
conditions in the mouth.  It is a chronic jaw disease that first presented as a 
surprising side-effect in a minority of patients on long-term bisphosphonate 
medication (Marx 2003).  Bisphosphonates are a widely prescribed drug to 
prevent skeletal bone loss in the treatment of osteoporosis and cancer.  
However, the reason why BRONJ specifically targets the jawbones and why it 
only affects certain individuals is still unclear.  BRONJ is typically characterised 
by exposed necrotic and infected jawbone that fails to heal and persists 
unpredictably for long periods of time (O'Ryan and Lo 2012).  The condition can 
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progress and in severe cases lead to chronic infection, pain and jaw fracture 
which can severely affect the quality of life of patients (Miksad et al. 2011).  
Whilst many consider the condition to result from a disruption of normal bone 
turnover or due to the anti-angiogenic or toxic properties of the drug, others 
have postulated a bacterial aetiology (Allen and Burr 2009).  However, it is 
somewhat surprising that to date an immunological cause has not been 
extensively investigated, and even more so given the widely accepted effects of 
bisphosphonates on the immune system.  In particular, bisphosphonates are 
known to cause indirect activation of a specific unconventional immune cell 
known as the  T cell.  Thus, the initial aim of the study was to characterise  
T cell biology in the blood and tissues of BRONJ patients and to examine 
whether there was any evidence to support their role in this disease. 
At this point, it became quickly apparent that there were a number of challenges 
in studying  T cells in BRONJ.  Firstly, the challenge of studying a relatively 
rare disease in a unit with no designated BRONJ clinic would make recruitment 
of enough patients difficult and obviously required involvement of an external 
collaborator to help in patient recruitment.  To achieve this, the process of 
gaining ethical approval at multiple sites needed to be tackled, and a local 
collaboration with the Eastman Dental Hospital was established.  Secondly, a 
further challenge in studying BRONJ as an immune-related condition was going 
to be the lack of tissue samples available to investigate the immune cells 
present in these lesions.  This is due to the general treatment consensus 
currently within the UK that BRONJ should be managed conservatively with a 
focus on anti-infective and symptomatic management as opposed to surgical 
intervention and removal of necrotic tissue.  Indeed, a simple, symptomatic and 
non-surgical management strategy is a prudent one in many of the cancer 
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patients with BRONJ, as they often suffer with a number of different co-
morbidities as a direct result of their cancer therapy. 
Due to these initial practical issues that would obviously delay direct 
assessment of BRONJ patients, the initial work of the thesis sets out to 
characterise  T cells in the peripheral blood of healthy individuals to serve as 
an important baseline for further studies on the role of  T cells in disease. 
Anonymised frozen human blood donor derived leukocyte cones were initially 
investigated due to their ease of availability.  However, it quickly became 
apparent that the study of these cells was not straight forward due to the 
following initial observations: 
 V9V2 T cells varied markedly in their phenotypic profile as defined by 
the conventional phenotyping strategy of these cells that used the surface 
expression of CD27 and CD45RA; this describes four populations; Naïve 
TN [CD27
(+)CD45RA(+)], Central Memory TCM [CD27
(+)CD45RA(-)], Effector 
Memory TEM [CD27
(-)CD45RA(-)] and Terminally differentiated Effector 
Memory TEMRA [CD27
(-)CD45RA(+)]. 
 The system of phenotyping using this conventional system (CD27 and 
CD45RA) was problematic, first due to the wide range of expression levels 
of CD45RA, and second because this method did not seem to divide cells 
into four distinct populations as described in the literature. 
 V9V2 cells from different individuals responded differently following 
stimulation with phosphoantigen/bisphosphonates. 
 The use of anonymised frozen blood samples was not helpful in 
elucidating the factors affecting V9V2 T cell heterogeneity, as it was not 
possible to know the age, sex, ethnicity, infectious history etc. of the 
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samples.  In addition, there were too many unknown variables associated 
with these samples including the significance of freeze-thaw cycles as well 
as the transportation, storage and age of each sample (Germann et al. 
2013, Olson et al. 2011, Weinberg et al. 2009).  These factors are known 
to effect levels of extracellular marker expression and functional 
responses leading to the conclusion that it was vital that fresh blood 
samples should be used in the study. 
These initial observations along with the practical issues regarding the study of 
BRONJ, led to a reconsideration of the focus of the thesis.  It was clear that the 
wide range of  T cell phenotypes and functional activity, along with the 
difficulty in phenotyping cells, warranted further investigation using fresh healthy 
blood samples.  It was also apparent that it would be important to establish a 
better understanding of V9V2 T cell biology in healthy individuals before 
moving on to consider the significance of V9V2 T cells in BRONJ when 
ethical approval was obtained. 
In beginning to review the literature, it also became apparent that V9V2         
T cells were implicated in a range of diseases and had a range of different 
effector functions.  V9V2 T cells have properties of both innate and adaptive 
immune cells and can mount significant and rapid immune responses to the first 
signs of immune danger (Kistowska et al. 2008).  In addition they have a 
multifunctional immune role in antigen presentation, cytotoxic responses to 
tumour cells, killing of activated macrophages, as well as in regulating wound 
healing (Pang et al. 2012, Havran 2000).  V9V2 T cells are also implicated in 
a number of systemic diseases including malaria and tuberculosis and are now 
also being targeted as a potential immunotherapy in certain cancers 
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(Kunzmann et al. 2012).  It is therefore clear that an improved understanding of 
 T cell biology will benefit the study of several human diseases. 
This thesis begins by re-evaluating human V9V2 T cells in healthy individuals 
in an attempt to reconcile the confusion that exists in the literature regarding 
their identification, and to fully document and assess the variability of this T cell 
population between individuals.  The thesis suggests an improved methodology 
for the assessment of V9V2 T cells, and explores the functional 
characteristics of the newly described V9V2 T cell subsets. 
Finally these findings will be applied to the chronic disease Bisphosphonate-
related osteonecrosis of the jaw (BRONJ) in a small patient cohort to examine 
whether there is preliminary evidence to suggest that V9V2 T cell could be 




1.1 The Immune System 
The human immune system has evolved over many years to protect the host 
against infection from pathogens (Danilova 2006).  In general, the skin and 
mucous membranes of the body are extremely effective non-specific barriers to 
infection.  However when these vital structures are breached, it is important that 
the immune system can then identify foreign pathogens from self tissues and to 
manage their clearance from the body. 
However, as fast as the immune system adapts to combating these foreign 
pathogens, these same pathogens also adapt and evolve mechanisms to evade 
host defences (Martínez-Borra et al. 2012).  Thus, there is a constant “arms 
race” between the mammalian immune system and the microbial world that has 
resulted in the immune system seen today. 
1.1.1 The Innate Immune System 
In basic terms, the human immune response can be subdivided into innate and 
adaptive processes that coordinate to effectively eliminate a foreign challenge.  
Innate immune responses are evolutionary conserved mechanisms shared by 
both simple and complex organisms and are commonly described as a non-
specific, first line of defence against infection.  They are typically mounted 
rapidly in response to common danger motifs found in viruses, bacteria, 
parasites etc. known as Pattern Associated Molecular Proteins (PAMPs).  
These are sensed by Pattern Recognition Receptors PRRs such as Toll-like 
receptors (TLRs) on host cells (Arancibia et al. 2007).  The main processes 
under the umbrella of innate responses include:  
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 Skin and mucosal surface barrier function (Doran et al. 2013). 
 The recruitment of innate immune cells such as neutrophils and 
macrophages to the site of infection (Foxman et al. 1997). 
 Neutrophil functions, phagocytosis and release of anti-microbial hydrolytic 
enzymes and proteins. In addition neutrophils can produce extracellular 
Neutrophil Extracellular Traps (NETs) which are DNA structures that 
resemble a web to trap and lyse pathogens (Brinkmann et al. 2004). 
 Complement protein activation cascade; this leads to the cytolysis of 
pathogens through the complement cascade that culminates in the 
formation of a membrane attack complex (MAC) (Daha 2010). 
 Phagocytosis of foreign bodies within the tissues by cells such as 
macrophages, dendritic cells and neutrophils (Underhill and Goodridge 
2012). 
 The uptake, processing and presentation of antigens in preparation for 
initiation of adaptive immune responses (Jensen 2007). 
Essentially, these non-specific immune processes attempt to keep an infection 
under control while more specific and targeted processes are being initiated. 
1.1.2 The Adaptive Immune System 
In contrast to the immediate and non-specific innate response, the adaptive 
immune response is very antigen specific and is targeted to specific invading 
pathogens.  However, the generation of these responses can take several days 
to reach their maximum effect.  The main cells that coordinate adaptive immune 
responses are T cells (largely CD4(+) and CD8(+) T cells).  T cell receptor (TCR) 
and B cell receptor (which when secreted is referred to as antibody) diversity 
results from a process known as somatic recombination (V(D)J recombination) 
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as the cells develop.  This random genetic recombination event generates a 
large number of unique receptors capable of recognising distinct foreign 
antigen, a feature that endows the adaptive immune response tremendous 
power to tackle a huge array of pathogens (Oltz 2001). 
Unlike the B cell receptor/Immunoglobulin (Ig) that can recognise soluble 
antigen, the TCR can only recognise antigen that is presented by Major 
Histocompatibility Complex (MHC) molecules.  MHC Class I molecules on the 
surface of antigen presenting cells (e.g. macrophages and dendritic cells) 
present antigen to CD8(+) cytotoxic T cells, while MHC Class II molecules 
present antigen to CD4(+) T-helper cells.  Once activated by specific recognition 
of antigen through their antigen receptors, lymphocytes must undergo a phase 
of clonal expansion that takes several days.  For this reason, effective adaptive 
responses do not take immediate effect, allowing a window of time in which 
pathogen expansion may cause disease.  Nonetheless, once fully primed, the 
adaptive response can efficiently clear most infections. 
Another important property of the adaptive immune system is the acquisition of 
immunological memory.  It is now well-established that immune responses on 
re-exposure to the same antigen are more rapid and effective and can be 
deployed for many years after first exposure.  Memory cells are thought to be 
generated as part of the clonal expansion process and retained within the B/T 
cell pool following the effective initial clearance of the primary infection.  It is 
apparent that memory cells can persist for many years after the initial encounter 
of the antigen and probably without re-exposure to antigen during that period 
(Hudu et al. 2013). 
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In summary, both B and T cell responses coordinate to provide appropriate and 
measured primary immune responses through specific recognition of non-self 
antigen, while also being capable of quicker and better secondary “memory” 
responses if and when these antigens are encountered again.  The major cell 
types of the immune system are shown in (Figure 1.1). 
1.2 Human  T cells 
Gamma delta T cells ( T cells) are unconventional T cells that typically 
constitute between 1-5% of lymphocytes in the peripheral blood of human 
adults (Parker et al. 1990).  They are considered as the prototypic 
unconventional T cell because they; are predominantly tissue-located; respond 
to stressed tissues, and; do not require priming nor conventional MHC-based 
antigen presentation to facilitate activation (Fisch et al. 1992).  They also have 
properties common to both the innate and adaptive immune systems and hence 
have been described as bridging both systems.  As evidence of this,  T cells 
can on the one hand respond rapidly to danger signals in tissues and display 
potent cytotoxic responses without the need for priming, while on the other 
hand also act as antigen presenting cells, provide B cell help, and even display 
evidence of genuine memory recall responses (Brandes et al. 2005, Maniar et 
al. 2010, Wu et al. 2009, Bansal et al. 2012, Worku et al. 2001b, Worku et al. 
2001a). 
In terms of evolution, it has been argued that  T cells may be an older cell 
type than conventional TCR(+) T cells, and may even be a vestige of more 
primitive immune cells that are now functionally redundant (Cooper and Alder 








Figure 1.1  Major cell populations of the Immune System. 
A diverse number of different immune cells with a variety of phenotypic characteristics develop from a common pluripotent haemopoietic stem 
cell in the bone marrow and together make up the innate, adaptive and transitional immune systems.  Transitional immune cells exhibit 




over many millions of years and in all jawed vertebrates alongside the more 
specific and targeted adaptive immune system perhaps reflects their importance 
to early and rapid immune responses against invading pathogens.  Indeed, this 
is best demonstrated by the fact that these cells appear to play a vital role in 
immune responses to some of the most significant human infectious disease 
such as malaria and tuberculosis (TB) (Inoue et al. 2013, Kabelitz et al. 1990). 
1.2.1 Human  T cell subsets 
Human  T cells are generally divided into two major subsets based on the 
usage of the TCR chain, using either TCR variable region-1 (V1 T cells) or 
TCR variable region-2 (V2 T cells).  V1 and V2 cells are found 
predominantly in different locations in the body, and are known to respond 
through their TCRs to different types of ligand.  Because of these features V1 
and V2 cells are thought to have significantly different functions, and are likely 
to be required in significantly different scenarios. 
1.2.2 V1 T cells 
V1(+) T cells are the predominant tissue resident  T cells and are found at 
much lower levels in the blood compared to V2 T cells.  Functionally they are 
thought to have a role in preventing opportunistic infiltration of commensal 
bacteria, and in tissue homeostasis and repair (Ismail et al. 2009).  They have 
also been identified as having opposing roles in both promoting and preventing 
tissue inflammation (Holtmeier 2003), and are also thought to be key cells in 
maintaining adaptive tolerance towards self-antigen including food antigen in 
the intestine (Locke et al. 2006, Bhagat et al. 2008). 
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The antigen specificity and the mechanisms by which V1(+) T cells recognise 
antigen are still unclear (Kalyan and Kabelitz 2013).  The greater diversity of 
receptor chains in V1(+) T cell in comparison to V2 T cells has led many to 
postulate that they recognise diverse antigens.  Possible V1(+) T cell ligands 
include the stress-induced molecules MICA/MICB that are found on the surface 
of many tumour cells, and that bind to NKG2D.  CD1c and endothelial protein C 
receptor (EPCR) are also putative ligands that perhaps present foreign antigen.  
However, the recognition and binding of the V1 TCR is not thought to be via 
the presented ligands.  Instead, these molecules probably act as classic stress 
ligands that are up-regulated when tissues are infected or damaged (Willcox et 
al. 2012, Haig et al. 2011).   
1.2.3 V2 T cells 
V2 T cells are the predominant  T cell subset in the blood (approximately 1-
5% of total CD3(+) lymphocytes) and are almost exclusively co-expressed with a 
TCR chain that uses variable region-9, so are commonly called V9V2 T cells.  
They are unique to higher primates and have no direct equivalent in non-
primate models, which makes their experimental study more difficult.  In 
contrast to conventional  T cells, V9V2 T cells show limited receptor 
diversity by adulthood (McVay and Carding 1999).  In addition, they also show 
more restricted diversity in comparison to V1(+) T cells. 
V9V2 T cells respond directly to non-proteinaceous, low-molecular weight 
compounds known as phosphoantigens, e.g. 1-Hydroxy-2-methyl-2-buten-4-yl 
4-diphosphate (HMB-PP) and iso-pentyl pyrophosphate (IPP).   HMB-PP is 
produced as an essential intermediate metabolite in the non-mevalonate 
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pathway of isoprenoid biosynthesis by many pathogenic bacteria.  Eukaryote 
cells in contrast only produce isoprenoids via the mevalonate pathway and do 
not produce HMB-PP.  However, IPP is generated by the mevalonate pathway 
and is often unregulated in situations of stress and infection, that then can 
potently activate V9V2 T cells. 
V9V2 T cells are thought to respond to phosphoantigen through the TCR in a 
MHC class II-independent mechanism i.e. without the need for conventional 
antigen presentation.  Although, the exact mechanism of TCR recognition is still 
not fully understood, it is now thought to involve the widely expressed molecule 
butyrophilin-3 (BTN3A or CD277; a B7-like protein) that is found on the surface 
of a large range of cell types.  Studies using activating and inhibitory antibodies 
to CD277 have suggested that binding of phosphoantigen to the intracellular 
region of a CD277 dimer induces an extracellular conformational change, that 
then permits binding of the V9V2 TCR (Harly et al. 2012).  However, more 
work is required to confirm this. 
Nitrogen-containing bisphosphonates like zoledronate and pamidronate are 
also believed to drive phosphoantigen production.  They do this by inhibiting a 
key enzyme in the mevalonate pathway known as farnesyl pyrophosphate 
synthase (FPPS).  This leads to increased intracellular accumulation of IPP 
(Roelofs et al. 2009).  It is the intracellular accumulation of IPP in 
monocytes/dendritic cells that is believed to cause V9V2 T cell activation via a 
mechanism similar to that described above.  In the absence of 
monocytes/CD14(+) cells, bisphosphonates show reduced ability to activate 
V9V2 T cells, an observation that supports the requirement of antigen 
presenting cells in facilitating V9V2 T cell activation (Nussbaumer et al. 2013). 
 
43 
1.3 Development of human  T cells 
Our knowledge regarding human  T cell development is to a large extent 
inferred from murine experiments, as direct experiments on human thymic 
tissue are obviously limited for ethical reasons.  Despite these problems, there 
is evidence that rearrangement of the  TCR can be detected as early as 8 
weeks in utero in the human thymus and has also been reported at some extra-
thymic sites including the fetal liver (McVay and Carding 1999).  Initially, there is 
a relatively diverse repertoire of  TCRs that populate the blood with a range of 
differing TCR chain pairings.  However, as human development progresses 
after birth there is a significant shift to a more restricted  TCR repertoire 
(McVay and Carding 1999).  This is exemplified by a shift from a predominance 
of V1(+) T cells at birth to V9V2 T cells becoming the major population during 
early years of development (Parker et al. 1990).  This change in terms of chain 
dominance is also accompanied by a shift from cells expressing typical “naïve” 
markers such as CD45RA, to those of effector and memory characteristics (De 
Rosa et al. 2004).  This early shift from a naïve to an effector phenotype and 
post-thymic expansion is in contrast to conventional  T cells where 
differentiation to effector and memory phenotypes are only observed when 
these cells are activated in specific immune responses in the secondary 
lymphoid organs. 
1.4 Function of  T cells 
The precise function of  T cells in immune responses has been debated since 
the cells were first inadvertently identified during experimental characterisation 
of the  TCR (Saito et al. 1984).  Their functions and characteristics can be 
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sub-divided into four broad areas that include; unique responses to microbial 
infection; protective responses in young animals; immunesurveillance of cancer; 
and immunoregulation.  These individual functions are explored in turn below. 
1.4.1 Unique responses to microbial infection 
Certain bacterial and parasitic infections in humans can have dramatic effects 
on V9V2 T cells, which can expand to completely dominate the lymphocyte 
population in the blood (Kroca et al. 2000).   Bacterial infections with Listeria 
monocytogenes and Mycobacterium tuberculosis as well as parasitic infections 
like malaria and toxoplasmosis have all been reported to have potent effects on 
V9V2 T cells via low-molecular weight phosphoantigens that are produced by 
these pathogens (Munk et al. 1990, Perera et al. 1994, Scalise et al. 1992). 
1.4.2 Protective response in young animals 
Immune responses in the first few weeks of life very much depend on inherited 
maternal immunoglobulins either acquired passively from the mother or 
alternatively via the breast-milk.  At this stage of life, the immune system is 
under-developed and is unable to make the complex and coordinated 
responses seen in mature adults.  As an example of this,  T cells have been 
shown to be deficient in both cytokine production and cytotoxic and helper 
responses, and this coupled with sub-optimal antigen processing leaves their 
responses underdeveloped compared to those seen in later life (Seghaye et al. 
1998, Burchett et al. 1992). 
By contrast, V9V2 T cell expansion in the young is rapid and sees a dynamic 
shift from a “naïve” to a memory/effector-like phenotype (De Rosa et al. 2004).  
This ability to mount early  T cell effector responses has led to the proposition 
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that  T cells are an important cell population in early life before acquired 
immune responses have had time to develop.  It seems that it is not only in 
young humans that  T cells are disproportionately active compared to  T 
cells, as this same pattern seems to be repeated in all vertebrates that have 
been studied to date (Hayday et al. 2000). 
1.4.3 Immunosurveillance of cancer 
 T cells have also been implicated in cancer immunosurveillance in that they 
are capable of sensing “stress/danger” signals on tumour cells.  In addition, 
transformed eukaryote cells often have disrupted metabolic processes and 
often produce high levels of IPP.  Because of this, V9V2 T cells have a 
central role in sensing, as well as mounting cytotoxic responses to, a range of 
cancer cell types (Kabelitz 2008).  As further evidence of an important anti-
tumour role, murine knockout models that lack  T cells often display an 
increased risk of tumour development (Girardi et al. 2001). 
The anti-tumour effector function of V9V2 T cells has initiated a plethora of 
research into developing immunotherapies to boost the V9V2 T cell response 
as a cancer immunotherapy for certain solid tumours (e.g. prostate and breast 
cancer) as well as B cell lymphomas (Dieli et al. 2007, Wilhelm et al. 2003, 
Bennouna et al. 2008).  The success of these clinical trials has been mixed with 
the therapy only effective in a certain “responder” cohort of patients.  The use of 





Although the predominant tissue subset of human  T cells bears the V1 
TCR, it is also evident that V9V2 T cells be found in the tissues during 
disease (McCarthy et al. 2013).  Whilst many have questioned the functional 
significance of these  T cells, it is becoming clear that they may play an 
important role in controlling pathological immune dysregulation by exerting their 
effects on immune cells locally at tissue sites.  As an example of this, a recent 
study considered the effects of complete absence of skin resident  T cell intra-
epithelial lymphocytes (IELs) in a  T cell “knockout” mouse model.  The 
animals in this study showed spontaneous chronic dermatitis (local 
inflammation) in comparison to wild type mice (Girardi et al. 2001).  The authors 
of this study concluded that tissue resident  T cell subsets could have a 
significant role in controlling  T cell mediated inflammation.  Indeed, there are 
now several further pieces of experimental evidence to support the 
immunoregulatory control that  T cells exert on  T cells and the immune 
dysregulation that results in their absence (Mombaerts et al. 1993, D'haese et 
al. 2010, D'Souza et al. 1997, Mukasa et al. 1995).  Clearly the dual properties 
(pro and anti-inflammatory effects) that  T cells possess are key to regulating 
immune responses.  Figure 1.2 illustrates some of the mechanisms by which  
T cells are thought to exert their immunoregulatory effects (Jameson et al. 
2002, Vincent et al. 1996, Tramonti et al. 2006, Kapp et al. 2004, Hsieh et al. 






Figure 1.2   T cell mechanisms can mediate local immunoregulation. 
 T cells can exert immunoregulation by their various effector mechanisms.  An overview of the experimental evidence is summarised above.  
 T cells can encourage wound repair, induce CD4 cell apoptosis, regulate macrophage responses, and control TH1 and cytokine responses as 




1.5 Functional plasticity of V9V2 T cells 
On the whole, the default V9V2 T cell cytokine profile seems to resemble that 
of a TH1 response in  T cells; namely the production of IFN- and TNF-.  
This ability appears to be acquired by the majority of V9V2 T cells quickly 
after birth (De Rosa et al. 2004).  However, it is unclear whether the cytokine 
milieu during initial T cell activation has any bearing on the cytokines produced 
by these same cells in subsequent immune responses (Manetti et al. 1993).  
Despite the prevalence of this TH1-like phenotype of human V9V2 T cells from 
the peripheral blood, it has been shown in vitro that a wide range of phenotypic 
and functional states can be generated following phosphoantigen activation in 
the presence of various priming cytokine conditions (Pang et al. 2012).  This 
functional plasticity is arguably greater than that seen for  T cells.  A 
summary of the conditions required to induce these distinct phenotypes in vitro 
is summarised in Figure 1.3 (Wesch et al. 2001, Caccamo et al. 2011a, Bansal 
et al. 2012, Brandes et al. 2005, Casetti et al. 2009).  Interestingly, this 
remarkable plasticity of human V9V2 T cells is in complete contrast to murine 
 T cells which seem to polarise and commit early in development to a 
particular cytokine profile (Ribot et al. 2009). 
1.6  T cells and memory responses 
One of the traits of the adaptive immune system is the ability to generate 
memory cells that provide faster and better immune responses on re-exposure 
to a particular antigen.  V9V2 T cells have been postulated to show some 







Figure 1.3  Functional plasticity of V9V2 T cells. 
V9V2 T cells exhibit extensive plasticity following phosphoantigen stimulation in the presence of certain combinations of priming cytokines.  
The studies demonstrating this plastic function are indicated for each of the six described effector subsets as well as the characteristic cytokine 
production/extracellular marker expression associated with each phenotypic population. 
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(Abate et al. 2005, Cendron et al. 2007, Ryan-Payseur et al. 2012, Shen et al. 
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Table 1.1  A summary of the primate studies investigating V9V2 T cell 
memory function. 
For each study, the primate model is indicated along with infectious 
agent/vaccine and the memory effector responses measured.  MPV is 
Monkeypox vaccine, BCG is Bacille Calmette-Guérin and TB is Tuberculosis.
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Whilst many of these studies present evidence to demonstrate memory 
properties in terms of a greater magnitude of response on re-exposure, others 
indicate that phosphoantigen priming may actually induce V9V2 T cell anergy 
(Cendron et al. 2007).  Indeed, there is some evidence to suggest that V9V2 
T cells are particularly sensitive to repeated stimulation by phosphoantigen and 
are prone to activation induced cell death (AICD) (Gan et al. 2001). 
However, as V9V2 T cells are not activated in the same manner as 
conventional  T cells the use of the term “memory” to describe certain types 
of V9V2 T cells is perhaps misplaced.  Alternatively, these changes in 
functionality may be short-term and solely based on changes in expression of 
co-receptors/co-stimulatory molecules.  This may render V9V2 T cells more 
responsive on experimental re-challenge for a short period after initial 
stimulation, thus appearing as if a memory response had occurred. 
1.7 Differentiation pathway of V9V2 T cells 
V9V2 T cell differentiation describes the progression of “naïve” V9V2 T cells 
that are generated in the thymus to the more mature phenotypes seen in the 
secondary lymphoid organs and tissues.  There is very little experimental 
evidence for a definitive differentiation pathway.  Nonetheless, it has been 
suggested that V9V2 T cells follow a linear pathway of progression in 
sequential, non-reversible stages that are best defined by the surface 
expression of CD27 and CD45RA; passing through; Naive (TN)
  
[CD27(+)CD45RA(+)] Central memory (TCM) [CD27
(+)CD45RA(-)] Effector 
memory (TEM) [CD27
(-)CD45RA(-)] Effector Memory CD45RA(+) or Terminally 
differentiated Effector Memory (TEMRA) – [CD27




differentiation pathway was presented by Dieli and co-workers (Dieli et al. 
2003b) using a 12-day in vitro experimental cell culture model whereby 
individual sorted TN, TCM, and TEM cell populations were stimulated in culture by 
phosphoantigen (IPP).  This paper showed that TN cells could be differentiated 
into TCM cells and TCM cells into TEM cells, thus suggesting that a linear 
differentiation pathway exists.  The generation of TEMRA was suggested to occur 
in vivo in response to an inflammatory tissue environment.  However, apart from 
this paper there is very little other evidence to show that these cells differentiate 
in a similar way to conventional  T cells which clearly follow a TN TCM TEM 
TEMRA pathway (Hintzen et al. 1993, Hamann et al. 1997, Okada et al. 2008, 
Inokuma et al. 2013).  In summary, the differentiation of V9V2 T cells has 
been poorly studied and has not been conclusively determined. 
1.8  T cell homeostasis 
Although T cell numbers fluctuate following infection and immune challenge, in 
general their numbers are maintained at a relatively constant level throughout 
life (Almeida et al. 2005).  The majority of studies investigating  T cells in 
health and disease have tended to observe percentages and phenotypes on a 
single occasion, making it difficult to follow how these characteristics change 
over time.  However, one study did follow nine healthy volunteers for a period of 
14 years and concluded that on average there was a reduction of 0.1% in the 
proportion of V9V2 T cells (as a proportion of total lymphocytes) every year 
after the age of twenty.  However, this was an average figure with some 
individuals experiencing a slight increase (+0.06%/year) but with others 
experiencing a significant depletion with time (-0.42%/year) (Caccamo et al. 




phenotypic changes as a result of aging.  On the whole, phenotypes remained 
relatively stable throughout life and particularly in females.  However, this same 
study did report age related changes in males with an increase in the            
TCM [CD27
(+)CD45RA(-)] population and a depletion of TEM
 [CD27(-)CD45RA(-)] 
and TEMRA [CD27
(-)CD45RA(+)] cells from the peripheral circulation with 
increasing age.  Importantly, there was no real evidence to support a linear 
differentiation pathway from TN TCM TEM TEMRA over time, as the latter 
subsets did not significantly accumulate over the 14-year period of study. 
1.9 Role of the thymus 
Current thinking suggests that the thymus undergoes involution and reduction in 
size at around the age of 20, and that its functional output after this point is very 
much reduced.  However, a recent study postulated that the thymus continues 
to produce “naïve cells” well into adult life and that females maintain a higher 
proportion of recent thymic emigrants (RTEs) and maintain a better thymic 
function with increasing age compared to males (Pido-Lopez et al. 2001).  It is 
clear from patients thymectomised after birth that the thymus is not absolutely 
essential for a fully functioning immune system and that the early seeding of 
cells from the thymus into the peripheral pool must also provide some “stem-
like” properties especially in the memory pool. 
1.10 Variation in  T cell number 
In general, the percentage of  T cells in the peripheral blood of adults is 
relatively stable between 1 and 5% (Parker et al. 1990).  This level is reached 
early in adult life following earlier dynamic changes due to V9V2 T cell post-




with mean levels rising to as high as 15-20% of total CD3(+) lymphocytes 
(Parker et al. 1990, Caccamo et al. 2006).   Following the dynamic variation 
seen during these early years,  T cell levels then seem to plateau.  The 
factors affecting  T cells levels in the blood have been associated with a 
range of factors including age, sex, ethnicity/race, genetics, place of birth, 
infectious history, environmental exposure and certain diseases (see Table 1.2).  
However it is extremely difficult to elucidate the true reasons for observed 
differences, as these factors are obviously intimately linked. 
1.10.1 Age 
There is a steady increase in the absolute and relative numbers of V9V2       
T cells found in the peripheral blood in the first 10 years of life which seems to 
be independent of thymic V9V2 T cell production (Parker et al. 1990).  This 
expansion results in the V9V2 T cell subset becoming the predominant       
T cell population representing > 75% of all  T cells in adult peripheral blood.  
The extra-thymic expansion is thought to be as a result of repeated 
environmental challenges, but perhaps may instead represent normal 
maturation. 
1.10.2 Gender 
While some reports suggest relative percentages of V9V2 T cells to be higher 
in adult females (Caccamo et al. 2006), others have suggested that the reverse 
is true with higher levels also being reported in males (Michishita et al. 2011).  
Caccamo et al. also suggested that the gender differences were only seen after 
the age of 20 years and reported that aging differences seemed more marked 
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Table 1.2  Variation in V2/CD3(%) in published studies. 
The variation in V2/CD3(%) is shown depending on gender, age, ethnicity and 
country of study population.  The age range (years), gender distribution and 




1.10.3 Ethnicity/race and environmental exposure 
Ethnicity/race and environmental exposure are also factors suggested as 
having an impact on V9V2 T cell number.  Once again, these are difficult 
factors to unravel in terms of determining the causative factor. 
As an example of this, a Swedish study (Esin et al. 1996) found a significantly 
higher percentage of V9V2 T cells in Turkish (9.3%) and Asian (non-
Japanese) (9.2%) healthy volunteers compared to those who were Swedish 
(4.2%) or Japanese (4.5%). The study concluded that these differences could 
be due to either genetic or environmental factors (Esin et al. 1996).  In general, 
 T cell levels seen in the hygiene-conscious Westernised populations are 
lower compared to other parts of the world.  Therefore, the “cleaner” 
environment of the Western world seems to impact on the immunological 
development and probably the phenotype of V9V2 T cells (Romagnani 2004). 
As V9V2 T cells are clearly reactive to environmental challenge, particularly 
early in life, it is possible that early exposure or significant disease exposure 
(e.g. malaria) can affect  T cell number.  This is exemplified in studies of     
T cells in West African populations.  One of these, that compared Ghanaian and 
Danish populations, showed  T cells to be around twice the level in healthy 
individuals from Ghana (9%) compared to the Danish population (3.5-4%) 
(Hviid et al. 2000).  Interestingly however, the predominant population was the 
V1 population and not V9V2 T cells as typically found in white Caucasian 
populations (Esin et al. 1996).  However, it is obviously difficult to tease out the 




unconventional T cells particularly when sampling from a heterogeneous 
population who have a different environmental history and genetic background. 
1.11 V9V2 T cell heterogeneity 
Recent studies have clearly highlighted the remarkable functional plasticity of 
V9V2 T cells at least in vitro.  They have also questioned whether the use of a 
system of identification designed for conventional T cells (i.e. using CD27 and 
CD45RA) is appropriate for  T cells.  For these reasons several groups have 
tried to establish an improved methodology for cataloguing V9V2 T cells 
heterogeneity.  These systems typically use between two and four markers in 
combination to divide the total V9V2 T cell population cells into four or five 
subsets based on whether these extracellular markers are present or absent.  
The increased use of multi-colour flow cytometry now means that 10-12 
extracellular markers are being routinely used to analyse cell phenotypes.  
Whilst this allows the analysis of many different combinations of markers, it 
does make the elucidation of their relationship difficult, particularly when two-
dimensional flow cytometry plots are used.  The use of multiple marker 
combinations potentially leads to a huge number of theoretical subsets that 
increases exponentially with additional markers (Table 1.3).  Thus great care 
needs to be taken when designing new identification strategies. 
1.12 Phenotypic characterisation of V9V2 T cells 
The characterisation of human V9V2 T cells has utilised several combinations 
of markers, that include; CD45RA, CD45RO, CD27, CD28, CD16, CD56, 
CD11a, CCR7 and CD62L.  This has led to different groups characterising 
























Table 1.3  Theoretical number of phenotypic subsets as the number of 
surface markers used increase. 
Theoretically possible number of phenotypic groups based on the number of 
potential combinations of different numbers of extracellular markers.  Phenotypic 
group combinations are based on each marker having only two levels of 
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Table 1.4  Summary of the main published V9V2 T cell phenotypic 
systems. 
The published classification systems used to describe V9V2 T cell subsets with 
a variety of different extracellular markers are shown.  The year and author of 
each study is indicated along with the surface markers used to define each of the 
various sub-populations.  V9V2 T cell subsets are described as; Naïve (TN), 
Central memory (TCM), Central memory CD27
(-) (TCM27-), Effector memory (TEM) 




to reconcile how their subsets correspond to other studies.  Indeed, a definitive 
methodology has yet to emerge. 
1.12.1 CD27/CD45RA 
As mentioned previously, the most common method of characterising V9V2   





CD45RA(-)] and TEMRA [CD27
(-)CD45RA(+)] (Dieli et al. 2003a).  This landmark 
paper described the TN and TCM populations as having lymph node homing 
potential but lacking immediate effector function, whilst the TEM and TEMRA 
populations express markers facilitating homing to inflammatory tissues and 
display immediate effector function.  This paper also implied a sequential linear 
pattern of differentiation [TN TCM TEM TEMRA], with TN (21.4%) cells in the 
lymph nodes, TCM (52.1%) and TEM (26.5%) cells largely “patrolling the blood” 
and TEMRA cells present at inflammatory sites. 
1.12.2 Naïve V9V2 T cells 
A continued area of debate concerns the size and phenotype of a “naïve” 
V9V2 T cell population.  Whilst CD27 and CD45RA are good markers at 
defining “naïve” cells in the  T cell world, many consider that their use in 
describing “naïve” V9V2 T cells grossly overestimates this subset (De Rosa et 
al. 2004).  Whilst the Dieli study estimates the “naïve” subset at about 21% of 
peripheral blood V9V2 T cells (Dieli et al. 2003b), this is in stark contrast to 
other groups who have found only very low levels of “naïve” V9V2 T cells 
when alternative combinations of markers are used (De Rosa et al. 2004, Morita 




CD11a; CD27(Bright) CD11a(Dull) being the phenotype used in combination with 
either CD45RA(+) or CD45RO(-) to identify “naïve” cells.  By contrast, the 
aforementioned Dieli study also found that both TN (75%) and TCM (63%) 
V9V2 T cells express CCR7.  This would suggest that the majority of these 
subsets retain the ability to recirculate through secondary lymphoid organs in a 
similar way to naïve conventional  T cells.  However, these levels of CCR7 
expression were not observed in other studies with a general consensus that 
<25% of V9V2 T cells express CCR7 compared to around 80% of 
conventional  T cells (Morita et al. 2007, Brandes et al. 2003).  If the more 
conservative estimates of CCR7 expression are correct, then it means that far 
less V9V2 T cells retain the ability to recirculate through lymph nodes.  The 
MHC-independent mode of antigen recognition used by V9V2 T cells to 
recognise phosphoantigen also raises the question as to why V9V2 T cells 
would need to recirculate through lymph nodes (Sallusto et al. 1999). Thus, the 
use of CCR7 as a reliable phenotypic marker must be considered with a note of 
caution. 
1.12.3 CD27/CD28 
A further system for the identification of V9V2 T cell subsets uses the co-
stimulatory molecules CD27 and CD28 to divide cells into four subsets; Central 
Memory TCM
 [CD28(+)CD27(+)], Central Memory CD27(-) TCM27- [CD27
(-) CD28(+)], 
Effector Memory TEM [CD28
(+)CD27(-)], and Terminally differentiated Effector 
Memory TEMRA [CD28
(-)CD27(-)] (Puan et al. 2009).  The same terms i.e. TNaïve, 
TCM, TEM and TEMRA are used to describe the four subsets, which becomes 
slightly confusing as it is not clear how these populations relate to subsets 




surface markers (i.e. CD27 and CD45RA).  In particular, whilst Dieli describes a 
TEM population as CD27
(-)CD45RA(-), Puan uses CD27(+)CD28(-), which is clearly 
inconsistent with regard to CD27 expression (Puan et al. 2009, Dieli et al. 
2003b).  In addition, the use of TEMRA to describe the [CD28
(-)CD27(-)] subset by 
Puan et al is odd, as it makes no reference to CD45RA expression despite the 
“RA” of TEMRA referring to CD45RA, and thus seems to assume that this 
population will be CD45RA(+). 
1.12.4 CD27/CD45RA/CD62L/CD16 
A final system of identification for V9V2 T cells uses four markers (CD27, 
CD45RA, CD62L and CD16) (Angelini et al. 2004). This system is really a 
modification of Dieli’s original methodology as it uses CD62L and CD16 in 
combination with the markers CD27 and CD45RA to describe four subsets; 
Naïve TN [CD27
(+) CD45RA(+) CD62L(+) CD16(-)]; Central Memory TCM [CD27
(+) 
CD45RA(-)CD62L(+)CD16(-)]; Effector Memory TEM [CD27
(-) CD45RA(-) CD62L(-) 
CD16(-)] and Terminally differentiated Effector Memory RA(+) TEMRA [CD27
(-) 
CD45RA(+) CD62L(+) CD16(+)].  The additional use of markers here does give 
some indication as to how multiple markers are related, but clearly ignores the 
CD27(+) CD62L(-) population (which is clearly visible in the paper) as well as the 
CD27(-)CD62L(-)CD16(-)CD45RA(+) population in the analysis.  Therefore, this 
phenotyping system does not characterise all V9V2 T cells and demonstrates 
how the addition of further markers often leads to small subsets and an 




1.13 Human  T cells – A summary 
Human  T cells are an enigmatic and under-studied component of the 
immune system.  They demonstrate rapid innate-like responses without the 
need for prior priming in secondary lymphoid organs, yet possess a rearranged 
TCR and possible memory characteristics which are hallmarks of adaptive cells.  
They display a range of functions from direct anti-microbial activity through to 
immunoregulation, and appear to be important at certain times (i.e. in young 
animals) and in some locations (i.e. epithelial tissues).  Recent work has 
highlighted the considerable heterogeneity of both V1(+) and V9V2 T cell 
populations, and particularly for V9V2 T cells has demonstrated remarkable 
plasticity of function in vitro.  Finally, there is ever-increasing interest in utilising 
and boosting  T cell function in the clinic, and a growing appreciation that 
these cells may have a central role in several immunopathologies.  This 
introduction will now consider these roles, in particular the hypothesis that 
V9V2 T cells may be a key component of the chronic disease known as 




1.14 Bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) 
A central hypothesis to this work is the view that V9V2 T cells are a central 
component of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).  
This next section will review the disease and outline reasons for implicating 
V9V2 T cells as a possible disease component. 
1.14.1 BRONJ - An undesirable side-effect 
Bisphosphonates were first licensed for therapeutic use in the early 1990s for 
treatment of hypercalcaemia and in the mid-1990s for osteoporosis (Agency 
2011).  In addition, bisphosphonates were also licensed for use in the 
prevention of adverse skeletal events, a recognised side effect of some 
malignancies, in particular multiple myeloma and breast cancer (Terpos et al. 
2009).  Despite their clear beneficial therapeutic role in preventing bone loss, an 
inadvertent side-effect of the drug was first described in a case series in 2003 
(Marx 2003).  This initial publication highlighted an apparent association 
between patients taking bisphosphonates and osteonecrosis of the jaw.  It also 
led to the FDA issuing a patient safety notice for the drug the following year 
(2004) as more cases of BRONJ were diagnosed in patients taking 
bisphosphonate medication.  Indeed, since this initial description there have 
been numerous case reports and case series describing the condition 
(Ruggiero et al. 2004, Sarathy et al. 2005, Merigo et al. 2005, Ficarra et al. 
2005, Bonacina et al. 2011, Nicolatou-Galitis et al. 2011).  Several theories 
have been proposed to explain the condition but to date there is no consensus 




1.14.2 Phossy Jaw and BRONJ – A resurgence of an historical disease? 
There have been parallels drawn between BRONJ and an historical disease 
known as “Phossy jaw” observed in match-making factory workers in the 19th 
century.  These workers were exposed to white/yellow phosphorus as part of 
the “strike anywhere” match-making process.  Workers directly involved in 
match production at this time developed necrotic jaw lesions similar to those 
since observed in BRONJ (Hellstein and Marek 2004).  It is now thought that 
phosphorous match-making compounds with similarities to therapeutic 
bisphosphonates were inhaled into the lungs of factory workers and were 
subsequently incorporated into bone.  These observations have led many in the 
field to conclude that the pathophysiology of the historical disease, phossy jaw 
is likely to be the same as BRONJ (Marx 2008). 
1.14.3 BRONJ Classification and nomenclature 
A number of different terms are used to describe the disease driven mainly by 
semantic preferences by leaders in the field. These include; 
 Bisphosphonate-related osteonecrosis of the Jaw (BRONJ)  
 Bisphosphonate osteonecrosis of the Jaw (BON/BONJ) 
 Bisphosphonate-associated osteonecrosis of the Jaw (BAONJ).  
 Antiresorptive agent-induced osteonecrosis of the jaw (ARONJ)  
 Medication-related osteonecrosis of the jaw (MRONJ) 
The latter term (MRONJ) has arisen as a cover-all to describe osteonecrosis 
arising in patients on different forms of medication including bisphosphonates, 
RANKL inhibitors, as well as Vascular Endothelial Growth Factor (VEGF) 




pathologies caused by different treatments are similar.  For the purposes of 
consistency in this thesis, BRONJ will be used throughout to refer to patients 
who have osteonecrosis with a history of bisphosphonate intake. 
1.14.4 Prevalence and Incidence 
Prevalence and incidence of new diseases can be difficult to determine 
particularly when pathogenesis is poorly understood.  Risk of osteonecrosis 
appears to be related to cumulative exposure to bisphosphonates with a 
median range of exposure from 4-120 months (Zervas et al. 2006), but typically 
occurring between 18 and 39 months (Durie et al. 2005, Bamias et al. 2005).  
The incidence of osteonecrosis in patients on intravenous bisphosphonate 
therapy ranges from 0.9%-18.3% (Stumpe et al. 2009, Zervas et al. 2006, 
Aragon-Ching et al. 2009) with generally higher incidence in multiple myeloma 
patients compared to breast cancer and prostate cancer patients (Wang et al. 
2007).  A recent meta-analysis has suggested that the mean cumulative 
incidence is 6.1% (Migliorati et al. 2010) but this may represent an over 
estimation of the true incidence, with the majority of studies suggesting the true 
figure to be in the range of 1-3% (Wang et al. 2007, Badros et al. 2006, Hoff et 
al. 2008, Stumpe et al. 2009, Tosi et al. 2006, Pozzi et al. 2007).  By contrast, 
the incidence of osteonecrosis in patients on oral bisphosphonates is extremely 




1.14.5 Clinical features of BRONJ 
Bisphosphonate-related osteonecrosis of the jaw is characterised by the 
following features; 
 Current or previous exposure to bisphosphonate medication. 
 Exposed necrotic bone in the maxillofacial region persisting for at least 
eight weeks. 
 No previous exposure to head and neck radiotherapy. 
These essential disease characteristics were identified by an expert committee 
of The American Association of Oral Maxillofacial Surgery (AAOMS) in a paper 
in 2007 (AAOMS 2007).  The committee also highlighted the potential for mis-
diagnosis, with similar diseases in this group of patients including; alveolar 
osteitis (dry-socket), osteomyelitis, osteoradionecrosis, caries, periodontitis and 
sinusitis. 
1.14.6 Unexposed BRONJ 
More recently, exposure of necrotic bone has been questioned as a necessary 
clinical sign in BRONJ diagnosis with reports of pain, bone enlargement, and 
gingival swelling in the absence of evidence of oral mucosal breach (Patel et al. 
2012, Junquera and Gallego 2008, Fedele et al. 2010).  This suggests that 
bisphosphonates may cause osteonecrosis without the need for a mucosal 
breach in the form of an extraction socket or through a periodontal pocket.  It 
also raises doubt as to the importance of oral bacteria in initiating the disease 
(Marx 1983).  These observations give further credence to theories of 





1.14.7 Histological features 
Whilst the clinical presentation of BRONJ is similar to osteomyelitis and 
osteoradionecrosis (ORN), the histological descriptions of BRONJ differ subtly 
but significantly from these similar conditions (Hansen et al. 2006b).  In 
osteoradionecrosis, the necrotic areas of bone are avascular, which is in line 
with the proposed pathogenesis of the condition in which the jaw vasculature is 
obliterated by direct radiotherapeutic damage (Chrcanovic et al. 2010).  
Interestingly, there are some reports of increased osteoclast numbers in 
osteonecrotic lesions of BRONJ patients (Kuroshima et al. 2012, Hansen et al. 
2006a).  This observation is slightly counter-intuitive as bisphosphonates are 
thought to work by causing osteoclast apoptosis.  Another histological feature of 
BRONJ is the colonisation of lesions with the Actinomyces species of bacteria 
(Biasotto et al. 2006, Bisdas et al. 2008, Hansen et al. 2007, Hansen et al. 
2006b, Lazarovici et al. 2009, Lugassy et al. 2004).  The presence of 
Actinomyces species in chronically exposed lesions may however be a result of 
colonisation of normal host oral bacteria.  It is therefore unclear whether these 
bacterial species are causative agents or simply innocent bystanders in the 
disease process.  Finally, the dominant cell types in the mixed inflammatory cell 
infiltrate in BRONJ lesions are neutrophils and plasma cells (Hansen et al. 
2007).  However, a recent research abstract has also highlighted an increased 
mononuclear cell infiltrate in BRONJ specimens and 4-5 fold higher levels of  
T cells localised to the gingival tissue of BRONJ specimens (Mawardi H (2013)).  
Indeed,  T cells have also been previously found in chronically infected oral 





1.15 Clinical management of BRONJ 
There is no consensus as to the best methods to treat the condition although 
most emphasis today is on prevention and ensuring good oral health and oral 
hygiene practices prior to starting the medication.  There is also an increased 
dental awareness of the potential of osteonecrosis development in patients on 
bisphosphonates and the risks posed by extraction and/or oral surgery.  It is 
hoped that this heightened understanding may lead to a reduction in the 
number of BRONJ cases over time (Saldanha et al. 2012).  The broad 
treatment strategies of BRONJ are explored below.   
1.15.1 Prevention 
Patients are encouraged to undergo pre-dental screening to ensure optimal oral 
health before embarking upon bisphosphonate medication particularly in those 
on the intravenous and more potent forms of the drug.  Caries and periodontitis 
are the two most common causes of oral infection and are the two principle 
diseases of tooth loss.  Promoting dental disease prevention through oral health 
advice, oral hygiene instruction, fluoride delivery and encouraging regular 
dental maintenance has clear benefits in terms of reducing the requirement for 
interventional dentistry and need for extraction (Krimmel et al. 2013). 
1.15.2 Antimicrobials 
The control of infection is one of the most important management principles in 
patients with BRONJ with antimicrobial preparations available as local mouth 
rinses or as a systemic medication.  The choice of antimicrobial preparation is 
dependent on disease stage, with systemic antibiotics reserved for use where 




treatment of all patients with exposed lesions.  Indeed it is considered that 
antimicrobials are important in managing infections resulting secondarily as a 
result of mucosal exposure that occurs in BRONJ and not as a primary 
treatment agent.  However the efficacy of antimicrobials in changing the 
bacterial profile has been questioned by one recent study that found little 
change in the microbial profile in BRONJ patients treated with antimicrobials 
compared to those who had not received this therapy (Ji et al. 2012). 
1.15.3 Surgery 
Surgical resection has been reported in some maxillofacial units to be a highly 
effective modality of BRONJ treatment with low recurrence rates of 3.1% and 
9.4% at 3 and 6 months respectively (Bedogni et al. 2011).  However, 
aggressive resection and curettage has also been shown to lead to further 
osteonecrosis, which has led to a move away from interventional surgical 
treatment of BRONJ lesions (Khan et al. 2008, McLeod et al. 2011).  However, 
particularly when there are large regions of necrotic jawbone, there is a need to 
surgically remove sequestrae in order to manage infection and improve quality 
of life.  Nonetheless, the consensus now favours a more conservative approach 
to BRONJ lesion management (McLeod et al. 2011, Khan et al. 2008).  
1.16 The therapeutic use of bisphosphonates 
1.16.1 Chemistry 
Bisphosphonates are synthetic pyrophosphate analogues that exist in two main 
structural forms based on the presence or absence of nitrogen within the 
compound.  Nitrogen-containing bisphosphonates are the group most highly 




compared with non-nitrogen containing bisphosphonates (Rogers et al. 2000). 
Non-nitrogen containing bisphosphonates function by inducing osteoclast 
apoptosis by interfering with normal ATP metabolism (Roelofs et al. 2010).  By 
contrast, nitrogen-containing bisphosphonates work by inhibiting farnesyl 
pyrophosphate synthase (FPPS), an enzyme critical to the mevalonate pathway 
of isoprenoid synthesis.  The inhibition of this key enzyme subsequently leads 
to the inhibition of several downstream proteins and ultimately to the apoptosis 
of osteoclasts (Roelofs et al. 2010). 
1.16.2 Medical Indications for use 
The first clinical use of bisphosphonates was described in the late 1960s and 
early 1970s with the first use of etidronate to treat myositis ossificans and 
Paget’s disease (Bassett et al. 1969, Smith et al. 1973, Altman et al. 1973).  
Etidronate and clodronate continued to be used in the 1970s and into the 1980s 
at which time more bisphosphonate compounds were developed, and in 
particular the more potent anti-resorptive nitrogen-containing bisphosphonates.  
Over the past 20 years nitrogen-containing bisphosphonates have been 
approved for medical use with FDA approvals granted for Pamidronate in 1991, 
Alendronate in 1995 and Zoledronate in 2002.  These drugs were licensed as a 
medical therapy to treat a variety of conditions including osteoporosis, Paget’s 
disease, multiple myeloma and the osteolytic skeletal effects of malignancy. 
1.16.3 Dose and route of drug administration 
For osteoporosis, alendronate is the first line treatment either prescribed at an 
oral dose of 10mg/day or 70mg/week.  Alternatively risedronate is an alternative 
oral preparation prescribed at 5mg/day or 35mg/week. The intravenous dose for 




hypercalcaemia of malignancy, Paget’s disease and the osteolytic effects of 
malignancy, zoledronate is prescribed as a dose of 4mg and pamidronate at 60-
90mg every 3-4 weeks by slow intravenous infusion.  The drug is also available 
as a once yearly 5mg intravenous dose as an alternative to oral preparations for 
osteoporosis. 
A single intravenous dose of the nitrogen containing bisphosphonate, 
zoledronate does not persist in the circulation for very long following a single 
administration.  The pharmacokinetics of zoledronate shows that by 24 hours, 
40% of the drug has been excreted in the urine and that the plasma 
concentration is only 1% of the post-administrative peak concentration. The 
remainder is sequestered into the bone around the whole skeleton (Reid et al. 
2002).  Zoledronate is then slowly leached back into the circulation over time 
although the dynamics of release is poorly understood.  The half-life of 
zoledronate in plasma is thought to be around 167 hours (Reid et al. 2002). 
1.16.4 Post-menopausal osteoporosis 
Post-menopausal changes in oestrogen and progesterone levels are linked to a 
reduction in bone mineral density in females (Worley 1981).  Bisphosphonates 
have clear benefits in terms of reducing adverse skeletal-related events in the 
elderly and have been shown to significantly improve morbidity without 
significantly affecting mortality rates (Mhaskar et al. 2010).  Bisphosphonates 
are generally prescribed orally at a low dose for treatment of osteoporosis.  
However, intravenous bisphosphonates (typically zoledronate and pamidronate) 
are now also licensed and prescribed in once/twice yearly doses to patients 




1.16.5 Adverse skeletal events in cancer patients 
Multiple myeloma, prostate, breast and lung cancers are among the malignant 
diseases characterised by diffuse or more generalised bone resorption due to 
increased osteoclast activity.  Reduced bone mass can lead to increased rates 
of fractures in this patient group which can have significant effects on quality of 
life and on morbidity and mortality rates (Diamond et al. 2011).  There is a clear 
beneficial effect of bisphosphonates in reducing skeletal related-events in 
cancer.  In contrast to osteoporotic doses, these drugs are typically delivered 
intravenously on a monthly basis at higher cumulative doses. 
1.16.6 Other Indications 
Less commonly, bisphosphonates are used to treat other osteolytic conditions 
where a reduction in bone remodelling is of benefit.  These conditions include 
Paget’s disease, giant cell lesions of the jaw, osteogenesis imperfecta, fibrous 
dysplasia, Gaucher’s disease and osteomyelitis (Landesberg et al. 2009). 
1.17 BRONJ - Aetiology and Theories of Pathogenesis 
The cause of BRONJ remains poorly understood with numerous proposed 
theories of pathogenesis, none of which fully explain the clinical and 
histopathological manifestations of the condition. 
1.17.1 Anti-angiogenesis 
The two major clinical forms of osteonecrosis are avascular necrosis of the hip 
and osteoradionecrosis (Allen and Burr 2009, Malizos et al. 2007, Chrcanovic et 
al. 2010).  It would therefore follow that disruption of the vascular supply might 
also be important in the pathogenesis of BRONJ.  Bisphosphonates have been 




growth factor (VEGF) (Wood et al. 2002, Wypij et al. 2008).  However, one 
interesting study into the effect of bisphosphonates in a dog model failed to 
show a disruption of the bone vasculature despite the observation of loss of 
osteocytes within their lacunae (Allen and Burr 2008). 
1.17.2 Dysregulation of normal bone turnover 
As normal bone turnover in healthy adults sees the tight coupling of bone 
resorption with bone deposition, a drug that causes osteoclast 
inhibition/apoptosis would be expected to affect this process.  However, 
although the uncoupling of this system and the resultant bone remodelling 
suppression might explain the osteonecrosis, it does not obviously explain why 
the condition is localised to the jaw.  One proposed explanation for this may be 
due to the high turnover rate of jawbone in comparison to other extra-oral sites 
(Han et al. 1997, Garetto et al. 1995).  As an example of this, the turnover rate 
in the jawbone is twenty-times faster compared to iliac crest bone.  In further 
support of this theory, patients who were prescribed parathyroid hormone (a 
medication that simulates bone remodelling) in small clinical studies showed 
evidence of BRONJ healing (Harper and Fung 2007).  However as these 
patients received this therapy alongside surgical and antimicrobial therapy it is 
difficult to be certain that the beneficial effects were directly due to the 
parathyroid hormone therapy. 
1.17.3 Actinomyces / Bacterial cause 
The search to explain the localisation of osteonecrosis to the jaws of patients 
who take bisphosphonates has led many to suggest a bacterial cause.  The oral 
cavity is colonised by a huge number of bacteria with over 700 species 




means that the identification of a causative species/strain is difficult as bacterial 
colonisation is present in both health and disease.  However, one particular 
species of Actinomyces bacteria (Actinomyces israelii) has been described in a 
large number of BRONJ lesions (Hansen et al. 2007).   These bacteria have 
also been identified as causing necrotic lesions in the head and neck region of 
humans (Actinomycosis) and a similar condition (lumpy-jaw) affecting cattle 
(Antiabong et al. 2013).  Interestingly, these bacteria also have the ability to 
cause periodontal bone resorption as evident in monoinfection of the bacteria in 
a rat model (Garant 1976).  Importantly, the Actinomyces species of bacteria 
produce HMB-PP bacteria and so have potential to also activate V9V2 T cells 
locally in jaw-associated tissues. 
1.17.4 Direct toxic effect on oral epithelial cells 
Bisphosphonates are rapidly sequestered by bone following therapeutic 
administration of the drug with much of the drug being taken up and stored in 
the bone matrix reservoir (Khan et al. 1997, Kimmel 2007).  It is postulated that 
bisphosphonates are retained in the bone matrix and are released into the local 
microenvironment during periods of bone remodelling.  This might suggest that 
the local release of bisphosphonates, perhaps following extraction and/or 
surgery may have toxic effects on oral epithelial cells in the jaw and may explain 
the exposed necrotic bone found in BRONJ.  Studies have shown that a range 
of bisphosphonates affect proliferation of oral, renal, gastro-intestinal and 
cervical cells in a dose dependent manner (Landesberg et al. 2011).  Indeed, 
mouse oral epithelial cells (Landesberg et al. 2008) and primary human 
osteoblasts (Marolt et al. 2011) showed dose-dependent inhibitory effects on 




1.17.5 Mucosal breach / Tooth extraction 
Dental tooth extraction or oral surgery is thought to precipitate osteonecrosis in 
patients taking bisphosphonates with evidence that supports this as a 
significant risk factor (Odds ratio=16.4) (Kyrgidis et al. 2008).  However, it is 
also apparent that previous dental extraction or oral surgery is not an absolute 
pre-requisite for the development of BRONJ (Patel et al. 2012, Kyrgidis et al. 
2008).  Indeed, denture wear has also been shown to increase risk of 
development of BRONJ with an odds ratio of 4.9 in breast cancer patients 
(Kyrgidis et al. 2008). 
1.17.6 Evidence for V9V2 T cell involvement in BRONJ 
There is only limited published evidence (Kalyan et al. 2013, Mawardi H 2013) 
to suggest a role for V9V2 T cells in the pathogenesis of BRONJ, despite the 
well-established effects that bisphosphonate medications have on the activation 
of these unconventional T cells (Thiébaud et al. 1997).  However, one recent 
study showed a correlation between intake of nitrogen-containing 
bisphosphonates (n-BP) (these patients included some with BRONJ) and low 
levels of V9V2 T cells in the peripheral blood.  This observation was in 
contrast to age-matched osteoporotic patients that had not yet started 
bisphosphonate therapy and who showed no evidence of V9V2 T cell 
depletion (Kalyan et al. 2013). 
The mechanistic implications of this study are several.  These data could simply 
imply that long-term bisphosphonate use leads to an activation induced 
depletion of V9V2 T cells that may or may not recover after withdrawal of 




bisphosphonates plus interleukin-2 are a promising approach to treat several 
cancers in early stage clinical trials.  In terms of BRONJ pathogenesis, a 
scenario could be envisaged in which depletion of V9V2 T cells may lead to a 
disruption of immunoregulation resulting in active immune-driven disease 
(Hypothesis #1, Figure 1.4).  V9V2 T cells are thought to display certain 
immunoregulatory function in certain circumstances, which could fit with this 
hypothesis.  This may also explain the delay observed between starting 
bisphosphonate therapy and the onset of the clinical manifestations of disease, 
and the association of BRONJ with dental surgery, in which post-extraction 
mucosal healing may be affected by the absence of V9V2 T cells. 
An alternative interpretation of a bisphosphonate-induced depletion of V9V2  
T cells from the peripheral blood could be that these cells have left the blood 
and entered the tissues.  Indeed, a recent research abstract suggested that 
these are increased numbers of  T cells in the mononuclear cell infiltrates 
from BRONJ lesions when compared with similar lesion infiltrates from non-
bisphosphonate associated necrosis (Mawardi H 2013).  This abstract further 
suggested that a combination of oral bacteria, bisphosphonates and local 
cytokine could activate  T cells to display direct cytotoxic effector function 
against gingival fibroblasts (Hypothesis #2, Figure 1.4).  Extending this idea 
further, it is conceivable that the bisphosphonate-mediated activation of V9V2 
T cells in jaw tissue could be affected in a range of ways by the presence or 
absence of various cytokines, and importantly, specific species of oral bacteria.  
For example, V9V2 T cells that are specifically activated to secrete certain 
cytokines such as interleukin-17, may affect the on-going differentiation of 







Figure 1.4  Hypothesised role for V9V2 T cells in the pathogenesis of Bisphosphonate-related osteonecrosis of the jaw. 
Activation of V9V2 T cells by bisphosphonates in the presence of inflammation and oral bacteria in the jaws is proposed to cause BRONJ by 
a number of potential mechanisms including; (1) loss of immunoregulation through depletion of V9V2 T cells in the local tissues (Hypothesis 
#1), (2) direct cytotoxicity to fibroblasts and endothelial cells (Hypothesis #2) and (3) regulating osteoclast activity through local cytokine release 
(Hypothesis #3).  Cell abbreviations are PMNs – Polymorphonuclear Neutrophils, M - Macrophages and DCs – Dendritic cells.  (+) symbolises 




alternative fates, such as osteoclasts.  This may disrupt the balance of bone 
remodelling in the jaw leading to osteonecrosis (Hypothesis #3, Figure 1.4). 
1.18 Study Hypothesis 
The general hypothesis that underpins this study is that; Bisphosphonate-
mediated activation of V9V2 T cells, in combination with oral bacteria, and 
located in the jaw tissue, is a central component of the pathogenesis that 
underpins Bisphosphonate-related osteonecrosis of the jaw.  The key ideas 
incorporated in this hypothesis are illustrated in Figure 1.4. 
1.19 Working hypothesis 
As detailed in the thesis overview section of the introduction, there were several 
logistical issues that significantly delayed the recruitment of patients into the 
study.  While these issues were being dealt with, it was decided that an initial 
characterisation of V9V2 T cells from the peripheral blood of healthy 
individuals would be an important step to establish a suitable baseline for the 
study.  However, as described in the initial sections of this first chapter, these 
initial investigations revealed some surprising findings.  These observations led 
us to quickly establish some further working hypotheses, which are as follows; 
1. That healthy individuals are heterogeneous for V9V2 T cell phenotype 
and function, that has direct implications for V9V2 T cells cell based-
therapies. 
2. That an individual’s V9V2 T cells profile is stable over time with 
minimal differentiation between V9V2 T cell subsets. 
3. That the definition of “naïve” and memory subsets needs to be re-




1.20 Aim and objectives of thesis 
The aims and objectives of the thesis, as described in the following results 
sections, are as follows; 
1. To extensively characterise the degree of heterogeneity in the 
phenotype of V9V2 T cells in a large sample of healthy individuals. 
2. To assess the functional potential of V9V2 T cells from individuals 
with significantly different V9V2 T cell profiles. 
3. To compare and contrast V9V2 T cells with V1(+)  T cells, using 
information generated in aim-1 and aim-2. 
4. To initially characterise the phenotype of V9V2 T cells from fresh 
human neonatal thymus, to establish the phenotype of a “naïve” 
V9V2 T cell subset. 
5. To use information generated in aims 1-4 to make initial observations 













Chapter 2 Materials and methods 
2.1 Ethical approval 
Four separate research ethical approvals cover the tissue sample use in this 
study:  
 Immunoregulation at the mucosal barrier (P/03/122) –East London and 
City REC - Healthy Blood samples (Existing ethical approval in place for 
recruitment of healthy volunteers). 
 Inflammation and Immunity in diseases involving the digestive system in 
children and adults (P/01/023) - East London and City REC – Healthy 
blood samples. (Existing ethical approval in place for recruitment of 
youngest healthy volunteers). 
 Thymus Transplantation for Complete DiGeorge Syndrome (06-MI-13(B)) 
Thymus Study ethics – Paediatric thymic organs were obtained under an 
existing ethical approval. 
 BRONJ and the Immune System (13/LO/0548) – East London and City 
REC - Healthy Blood samples, BRONJ Blood samples and Osteoporotic 
patient samples are covered in this ethic approval. 
Details of the process of applying for ethical approval (BRONJ and the Immune 
System) are outlined in the flow chart below (Figure 2.1).  The Health Research 
Authority (HRA) oversees clinical research within the NHS. This body ensures 
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Figure 2.1  Schematic of the ethical approval process. 
Overview of the stages involved in obtaining ethical approval for research 
involving healthy volunteers and NHS patients.  Initially the research 
methodology and study design were formulated with justification for patient 
involvement in the research study.  Following internal peer review, all documents 
(shown above) were sent for approval by the City and East research ethics 
committee (REC). A favourable opinion for the study at Barts Health NHS Trust 
and the Blizard Institute (QMUL) was then granted.  A subsequent amendment 
was then added to the application by addition of another research site to facilitate 
sample collection at a second site (University College London Hospitals NHS 
Foundation Trust). 
Therefore the process of obtaining ethical approval required an application to 
this regulatory body for permissions to work with clinical samples and data 
relating to patients.  While this was an essential process it also provided 




research project.  In particular, it involved considering how patients are 
approached and recruited, the necessary clinical samples/patient information 
required, planning the laboratory experiments and ensuring overall that the 
project was carried out ethically (Appendices 10.1-10.3). 
2.2 Collaborative unit 
A collaborative agreement was reached with the Eastman Dental Hospital for 
recruitment of BRONJ patients. A further amendment to the ethics application 
was obtained to add Eastman Dental Institute as a secondary research site to 
the project ethics approval (University College London Hospitals Foundation 
Trust). 
2.3 Recruitment of study subjects 
2.3.1 Healthy volunteers 
A total of 63 healthy volunteers were predominantly recruited from staff and 
postgraduate students at the Blizard Institute (Queen Mary University of 
London) and from the Dental Institute (Barts Health NHS Trust).  Two of the 
youngest individuals in the study were recruited as patients from Barts Health 
NHS Trust.  Healthy volunteers ranged in age from 3-69 years with a median 
age of 33 years (31 males, 32 females).  Informed consent was obtained from 
each subject and peripheral venous blood (up to 50ml) was collected along with 





2.3.2 Infants undergoing corrective cardiac surgery 
A total of 8 children who were undergoing surgery for correction of congenital 
heart defects at Great Ormond Street Hospital were enrolled in the study.  
Parents of children undergoing these operations were asked for permission to 
analyse thymic tissue removed during the normal course of corrective cardiac 
operations.  Children’s ages ranged from 4 days–35 months (Males=4, Females 
= 4) with a median age of 11.5 months. 
2.3.3 Bisphosphonate treated control patients 
Osteoporotic patients were recruited from patients attending the outpatient 
Rheumatology Clinic at Mile End Hospital (Barts Health NHS Trust).  A total of 
10 patients treated with either oral or intravenous bisphosphonates were 
recruited as a BRONJ control group.  This group was subdivided into; 
 5 patients on intravenous bisphosphonates (Zoledronate and 
Pamidronate), aged from 44-81 years with a median age of 76.5 years. (4 
females and 1 male). 
 5 patients on oral bisphosphonates (Aledronic acid), aged from 56-79 with 
a median age of 72 years (4 females, 1 male). 
Informed consent was obtained from each patient and peripheral venous blood 
(up to 50ml) was collected along with relevant demographic and health 
information (see data collection sheets - Appendix 10.3). 
2.3.4 BRONJ patients 
BRONJ patients were recruited from patients attending Oral and Maxillofacial 
Surgery and Oral Medicine clinics at both The Royal London Dental Institute 




London Hospitals NHS Foundation Trust).  Patients ranged from 46-88 years 
with a median age of 58.5 years (6 females and 2 males).  Informed consent 
was obtained from each patient and peripheral venous blood (up to 50ml) was 
collected from each patient along with relevant demographic and clinical/health 
information (see data collection sheets Appendix 10.3). 
2.4 Tissue Preparation 
2.4.1 Blood donor cones 
Six 15ml blood samples were obtained initially in the form of anonymised 
“leukocyte cone” samples from the National Blood Transfusion Service.  Cones 
are provided as a concentrated cell sample from an original 600ml blood 
sample.  The contents of the leukocyte cone were initially transferred to a 50ml 
centrifuge tube and 40mls of sterile PBS was used to wash the cone and 
maximise the cell yield into the collecting tube.  Following this, peripheral blood 
mononuclear cells (PBMCs) were extracted in the same way as subsequently 
described for fresh blood samples. 
2.4.2 Blood 
Peripheral venous blood was collected from volunteers and patients following 
informed consent in accordance with the ethical approvals outlined above.  
Blood samples were collected in 10ml BD Vacutainer sodium heparin tubes 
(Becton Dickinson (BD), UK) ready for PBMC extraction.  All samples were 
processed on the same day of venepuncture and were analysed and used 




2.4.3 Separation of PBMCs from peripheral venous blood 
Peripheral blood was diluted 1:1 in sterile Phosphate Buffered Saline (PBS) and 
then gently layered on Ficoll-Paque (GE Healthcare, Amersham, UK).  Up to 
20ml of diluted blood was layered onto 15ml Ficoll-Paque at room temperature 
(18C) in 50ml tubes.  PBMCs were separated by density gradient 
centrifugation at 1500rpm (400xg) for 35 minutes (brake off) (Thermo 
Scientific, USA) at room temperature (18C).  The plasma layer was removed 
before carefully pipetting off the buffy coat interface containing mononuclear 
cells.  This layer was then washed in FACS buffer (2% FBS (Gibco, Life 
Technologies, UK) in Sterile PBS and 1mM EDTA (Life Technologies) and 
pelleted by centrifugation (400xg – 10 minutes) prior to counting. 
2.4.4 Thymus 
Human thymic organs were obtained from The Institute of Child Health (Great 
Ormond Street Hospital for Children NHS Foundation Trust), and stored in 
complete media containing; RPMI 1640 (Invitrogen, Life Technologies, UK), 
10% Heat-inactivated FBS (Gibco, Life Technologies), 10mM HEPES buffer, 
50g/ml Streptomycin (Life Technologies), 50U/ml Penicillin (Life 
Technologies).  Samples were then transferred cold with the aid of an ice pack 
in an organ transport cool bag to The Blizard Institute (Queen Mary University of 
London). 
2.4.5 Isolation of thymocytes from the neonatal thymus 
The thymic organs were then weighed, re-immersed in complete media and 
whole organs were left overnight at 4C before processing the following day.  




tissue moist with complete media wherever possible throughout all stages of 
preparation.  The fat and connective tissue were removed from the thymus 
using sterile forceps and scissors and cut into small cubes in a sterile petri dish.  
The tissue and complete culture media was then transferred to a 200ml beaker 
and placed on a stirrer at room temperature for 30 minutes.  The supernatant 
(thymocyte fraction 1) was filtered using a 100m cell strainer and then stored 
on ice.  The remaining tissue was then placed on a sterile steel mesh and 
mechanically disrupted with the use of a sterile syringe plunger over a beaker 
using complete media.  This second supernatant (thymocyte fraction 2) was 
then pooled with thymocyte fraction 1 making up the total extracted thymocyte 
sample ready for flow cytometric analysis. 
2.4.6 Cell counting and viability assessment 
PBMCs and thymocytes were enumerated using Trypan Blue exclusion. 
Samples were diluted in 0.4% Trypan Blue (Sigma-Aldrich, Poole, UK) and 
counted using an improved Neubauer haemocytometer.  Mononuclear live cells 
were counted and blue dead cells excluded to determine cell number.  Typical 
yields were approximately 1 x 106cells per 1ml of peripheral venous blood. 
2.4.7 Storage of leukocyte cone samples 
Due to the large number of cells obtained in each leukocyte cone sample, cells 
were initially frozen down in 10% DMSO (Sigma-Aldrich) and 90% Human AB 
serum (Sigma-Aldrich). Cells were aliquotted in 2ml cryovials (Fisher Scientific, 
UK) at a 25 million cells/ml concentration and frozen slowly at -80C a rate of -
1°C per minute in an isopropyl alcohol gradient freezing device.  Samples were 
subsequently used as required by rapid thawing of individual samples in a 37C 




cryopreserving DMSO.  Cells were then recounted and viability assessed by 
Trypan blue (Sigma-Aldrich) cell exclusion, which was previously described 
(Section 2.4.6). 
2.5 Cell Culture 
PBMCs were cultured in complete media in 96-well round-bottomed plates 
(VWR) at a final concentration of 2x106/ml at 37C and 5% CO2. 
 HMB-PP 1nM (Sigma-Aldrich) + recombinant human Interleukin-2 (rhIL-2) 
100U/ml (PeproTech, Rocky Hill, NJ, USA) – Proliferation assays (5 days). 
 Zoledronate 1M (Novartis pharma, Basel, Switzerland) + IL-2 (rhIL-2) 
100U/ml (PeproTech) (7 days). 
2.5.1 Proliferation assay 
A single cell suspension of PBMCs was prepared and washed twice in sterile 
PBS (warmed to room temperature) to remove any serum.  PBMCs were then 
resuspended at 4x106/ml (twice the final culture concentration).  A 10M 
solution of cell proliferation dye eFluor® 670 (eBioscience, UK) in PBS (pre-
warmed to room temperature) was mixed 1:1 with the cell suspension whilst 
vortexing (i.e. cells were labelled at a final concentration of 5M).  The cells 
were incubated for 10 minutes at 37°C in the dark.  After incubation the labelling 
was stopped by the addition of 5 volumes of complete media (RPMI 1640 + 
10%FBS (Gibco, Life Technologies) + Pen.Strep (Life Technologies).) and 
incubated on ice for a further 5 minutes.  The cells were then washed three 
times in complete media before culturing for 5 days in the presence of 1nM 




Baseline flow cytometry data (at day 0) was obtained by acquiring PBMCs on 
the flow cytometer BD FACSCanto™ II (Becton Dickinson-BD) to ensure even 
loading of cells and a fluorescent intensity reference to compare cultured cells 
at 5 days.  After 5 days, the cultured cells were extracellular stained and 
analysed on the flow cytometer BD FACSCanto™ II.  Percentage of 
proliferating cells at 5 days was calculated as the percentage of cells below the 
fluorescent loading peak using FlowJo (Version 8.8.7)(Tree Star). 
2.5.2 Extracellular staining 
Peripheral blood mononuclear cells (Typically 5x106) were stained and 
incubated in 100l total FACS buffer (Sterile PBS containing 2% FBS (Gibco, 
Life Technologies) / 1mM EDTA) in 5ml polystyrene Falcon Tubes (Becton 
Dickinson) using directly conjugated monoclonal antibodies (mAbs) to 
extracellular markers (Tables 2.1).  The antibody panels used in experiments 
are summarised in Table 2.2 with isotype and FMO staining controls used when 
appropriate.  Staining was carried out for 30 minutes at 4C (on ice) in the dark 
using manufacturers suggested dilutions of monoclonal antibodies (mAbs).  
Cells were subsequently washed in FACS Buffer and pelleted by centrifugation 
at 350xg and resuspended in a final volume 500l of FACS buffer.  Cells were 
then acquired on the flow cytometer (BD FACSCanto™ II). In order to detect the 
maximum number of V9V2 T cells within a mixed PBMC population it was 




Supplier Marker Antigen Clone Fluorophore Cat. No. 
BioLegend Variant of TCR  chain V2 B6 FITC 331406 
Thermo 
Scientific 
Variant of TCR  chain V1 TS8.2 FITC TCR2730 
BioLegend A chain of the CD3/TCR CD3ε HIT3a APC 300312 
BioLegend Co-stimulatory receptor CD27 O323 Pacific Blue 302822 
BioLegend Type I transmembrane protein CD45RA HI100 APC-Cy7 304128 




CD11a HI111 PE 301208 
BD 
Bioscience 
Fc-receptor CD16 3G8 V500 561394 
BioLegend Transmembrane glycoprotein CD56 HCD56 PerCPCy5.5 318322 
BioLegend Lymph node homing receptor  CCR7 G043H7 APC 357203 
BioLegend Lymph node homing marker CD62L DREG-56 PerCP/Cy-5.5 304823 
BioLegend Chemokine Receptor CCR2 K036C2 PerCP/Cy-5.5 357203 
BioLegend Chemokine Receptor CCR9 L053E8 APC 358907 
BioLegend Chemokine Receptor CCR5 HEK/1/85a PerCP/Cy-5.5 313715 
BioLegend Chemokine Receptor CXCR5 J252D4 APC 356907 
BioLegend Chemokine Receptor CX3CR1 K0124E1 PE 355703 
BioLegend Chemokine Receptor CCR6 G034E3 PerCP/Cy-5.5 353405 
eBioscience Serine protease Granzyme B GB11 PE 12-8899-41 
eBioscience Serine protease Granzyme K G3H69 PerCP-eFluor 710 46-8897-41 
BioLegend Skin/mucosa-homing receptor CLA HECA-452 APC 130-098-573 
BioLegend Ig superfamily of receptors 7-Integrin FIB-27 PerCP/Cy-5.5 121008 
BioLegend Pro-inflammatory cytokine IFN- 4S.B3 APC 502512 
eBioscience Pro-inflammatory cytokine TNF- MAb11 PerCP/Cy-5.5 45-7349-41 
BioLegend Pro-inflammatory cytokine IL-17 BL168 PerCP/Cy-5.5 512314 
eBioscience Cytotoxic protein Perforin dG9 APC 17-9994-41 




MOPC-21 APC 400119 




MOPC-21 PerCPCy5.5 400149 




11F2 Biotin 130-050-701 




Table 2.1 Table of antibodies used in thesis. 
Antibody type, clone, fluorophore and supplier details are shown for each 
antibody.  Antibodies used were all anti-human and were used as indicated in 
manufacturer’s guidelines. Fluorophores are as follows; APC is Allophycocyanin, 
APC-Cy7 is allophycocyanin+cyanine dye Cy7, FITC is Fluorescein 
isothiocyanate, PE is Phycoerythrin, PECy7 is Phycoerythrin and Cyanine dye 
(Cy7), PerCP is Peridinin Chlorophyll protein, PerCPCy5,5 is Peridinin 
























































































































































































V2 Standard panel                
V1 Standard panel                
V2 IC panel 1                
V2 IC panel 2                























































































































































































     
  
         
V2 Chemokine 
panel 2 
     
  
         
V2 Chemokine 
panel 3 
     
  
         
V2 Chemokine 
panel 4 
                
V1 Chemokine 
panel 1 
     
  
         
V1 Chemokine 
panel 2 
     
  
         
V1 Chemokine 
panel 3 
     
  




Table 2.2  Antibody panels used in thesis. 
Table A and B show the combinations of directly conjugated markers used in flow 
cytometry staining of V1 and V2 T cells.  Table A shows the standard 
extracellular and intracellular panels used with chemokine panels shown in B. 
Full fluorophore descriptions are as follows; Fluorophores are as follows;  APC is 
Allophycocyanin, APC-Cy7 is allophycocyanin+cyanine dye(Cy7) , FITC is 
Fluorescein isothiocyanate, PE is Phycoerythrin, PECy7 is Phycoerythrin + 
Cyanine dye (Cy7), PerCPCy5,5 is Peridinin Chlorophyll protein+Cyanine 
dye(5.5) and V500 is Violet excitable dye 500, PerCP-eFluor 710 is Peridinin 




2.5.3 Intracellular staining 
Cell stimulation, surface staining, permeablisation and intracellular staining 
were carried using protocols currently in use in the Blizard Institute and 
recommended by manufacturers of the reagents (BioLegend, UK) and 
eBioscience, Hatfield, UK). 
PBMCs (5 x 106 cells) were re-suspended in 1ml of complete media stimulated 
with PMA (50ng/ml) and Ionomycin (1µg/ml) in a 5ml polystyrene Falcon Tube 
(Becton Dickinson - BD) for 4 hours in an incubator (37C and 5% CO2).  Cells 
were vortexed every 30 minutes throughout this 4-hour period to prevent 
settling of cells. After 2 hours incubation, 10g/ml Brefeldin A (eBioscience) and 
2m Monensin (GolgiStop: Becton Dickinson) were added to the mixture and 
left for a further 2 hours.  Cell were then washed in 2ml FACS buffer containing 
3g/ml Brefeldin A (eBioscience) and 2M Monensin (eBioscience) (FBM).  
Extracellular staining was then carried out at 4C (on ice) for 30 minutes in FBM 
as per protocol outlined in section 2.3.3.  Following extracellular staining, cells 
were again washed in FBM and centrifugation at 400xg.  Following removal of 
supernatant, the pellet was vortexed to dissociate the pellet and then fixed for 
20 minutes in the dark with 250l of Fixation-Permeabilisation solution 
containing 4% Paraformaldehyde (BD).  Vortexing was carried out throughout 
the addition of the fixating solution to avoid clumping.  Cells were then washed 
twice in 250l Wash/Perm Buffer™ (BD).  The fixed and permeabilised cells 
were then resuspended in 100l of Perm/Wash™ (BD) containing intracellular 
fluorochrome-cojugated anti-cytokine antibody (IFN-, IL-17A, TNF- and 
Perforin) as well as appropriate isotype controls.  Antibodies were incubated on 




Wash/Perm Buffer™ (BD) and pelleted before finally being resuspended in 
FACS buffer and analysed on a BD FACSCanto™ II. 
2.6 Flow Cytometry: Machine set up and calibration 
Analysis of the staining of cell surface markers and intracellular molecules was 
carried out using the BD FACSCanto™ II flow cytometer.  Measurement 
parameters and spectral overlap between adjacent fluorphores were set up 
using single stained compensation beads as recommended by the 
manufacturer (BD CompBeads Anti-Mouse Ig, microparticles and BDComp 
Beads Negative control) for each antibody used in the experiments.  PBMCs 
from each sample were used to set appropriate voltages for forward scatter 
(FSC) and side scatter (SSC) to determine the gating of the lymphocyte 
population according to size and granularity.  Compensation was performed 
prior to running the samples by use of the automated compensation matrix on 
the BD FACS Diva software and checked and corrected manually as necessary. 
2.6.1 Cell sorting 
Cell sorting was carried out on the BD FACSAria™ II (Becton Dickinson – BD).  
The machine was set up as described for the BD FACSCanto™ II and cell 
populations sorted into 12 x 75mm falcon polypropylene collection tubes 
containing 1ml of RPMI 1640 (Invitrogen, Life Technologies) culture media and 
20% FBS (Life Technologies) were used to collect the sorted cell populations.  
Media containing Fetal Bovine Serum (FBS) was used to increase overall cell 




2.6.2 Conventional Flow Cytometry analysis 
FlowJo (Version 8.8.7)(Tree Star) software was used to analyse all flow 
cytometry data with conventional 2-dimensional plots.  Pre-compensated .fcs 
data files were imported into the FlowJo programme from the flow cytometer BD 
FACSCanto™ II. 
2.6.3 Gating Strategy 
Lymphocytes were first gated based on FSC-A/SSC-A plots by size (FSC-A) 
size and granularity (SSC-A).  Doublet discrimination was carried out to ensure 
only analysis of single cells was carried out by gating out doublets on Forward 
Scatter-Height vs. Area as well as Side Scatter-Height vs. Area plots i.e. (FSC-
H v FSC-A) and (SSC-H v SSC-A).  Subsequently CD3 v V2 plots were 
generated to allow gating of V2(+)CD3(+) cells as well as V2(-)CD3(+) and TCR 

(-)CD3(-) populations.  Following this, a range of extracellular and chemokine 
markers were assessed on V2(+)CD3(+) T cells.  Where appropriate, relevant 
isotype controls, fluorescence minus one (FMO) controls or reference 
population controls were used to determine gating of populations. 
2.6.4 Gating strategy applied for cell sort 
In order to sort the four populations, lymphocytes were first identified and gated 
based on size (FSC-A) and granularity (SSC-A) as previously described.  
Following elimination of doublet cells (doublet discrimination), V2(+)CD3(+)        
T cells were identified and subsequently gated using CD27 and CD28 
extracellular markers.  CD27(-)CD28(-) cells were then further divided into 





2.6.5 Analysis of differentiation pathways using Probability State 
Modelling (PSM) (GemStonesoftware) 
Probability state modelling (PSM) using GemStone software was applied to 
V9V2 T cells using a range of different extracellular markers in an attempt to 
model the differentiation pathway and identify the major population subsets.  
PSM was used as an unbiased system of displaying correlated multi-colour flow 
cytometric markers and modelling the cell differentiation pathway.  This 
modelling system (PSM) was used alongside conventional 2-dimensional 
analysis plots as it removed subjective user-defined gating to identify key cell 
subsets and their likely differentiation pathway.  PSM was used to integrate 
extracellular marker parameters on a common “progression” axis (i.e. a single 
plot) and the strength of the model was determined by use of a goodness of fit 
reduced chi-square (RCS) test.  The GemStone™ programme allowed 
visualisation assessing the relationship and transition of markers. 
Cell differentiation was modelled using a set of known rules/assumptions about 
directional change in marker expression as cells differentiate from a presumed 
early “naïve” phenotype along a pathway to a final terminally differentiated 
population.  PSM involved generating and integrating single parameter 
progression plots also known as Q functions and modelling these correlated 
measurements along a cumulative probability axis.  The cumulative probability 
(x-axis) was used as a surrogate measure of time/differentiation and a proposed 





2.7 Microarray of V9V2 T cell subsets 
2.7.1 Enrichment of V9V2 T cells 
 Preparation of PBMCs 
V9V2 T cells were enriched by magnetic bead column separation (Miltenyi 
Biotec, Germany) in order to facilitate more time efficient cell sorting.  PBMCs 
were extracted from peripheral venous blood and counted to determine cell 
number and viability using trypan blue exclusion as described (section 2.4.6).  
Baseline phenotyping of whole PBMCs was carried out using the standard V2 
panel (Table 2.2) of extracellular markers so that subsequent magnetic 
enrichment efficiency could be established. 
A biotin conjugated TCR  antibody (Miltenyi) was then added to the PBMCs at 
10l/10x106 cells in 100l of MACs buffer (Miltenyi) at 4C for 10 minutes in the 
dark.  Frequent vortexing of cells was carried out to ensure maximal antibody 
binding.  Following cell washing in MACS buffer (Miltenyi) and pelleting at 
300xg for 5 minutes, anti-biotin microbeads (Miltenyi) were added at 
(20l/10x106 cells) for a further 15 minutes at 4C.  The cells were then washed 
and pelleted (300xg/5 minutes) before resuspension of up to 10x106 cells in 
500l of MACS buffer (Miltenyi). 
2.7.2 Magnetic column cell separation 
A cell separation column (LS Column – MACS Miltenyi Biotec) was placed in a 
VarioMACS™ Separator (MACS Miltenyi Biotec) to create a high-gradient 
magnetic field within the separation column.  The column was first prepared by 
pre-rinsing with 3ml of MACS buffer (Miltenyi) before transferring the previously 




The unlabelled flow through containing the non-T cell component was 
collected in a falcon collection tube.  Three further washes were carried out with 
the column within the magnetic field by adding 1ml of MACS buffer through the 
column to ensure all non-T cells were washed through and to increase the 
purity of the enrichment process.  The unlabelled fraction containing non-      
T cells was discarded and the column subsequently removed from the magnetic 
field and placed on a fresh falcon collection tube. 
The positively selected  T cell fraction retained within the column was then 
flushed into the new collection tube by plunging 5mls of MACS buffer through 
the column outside the magnetic field.  Cells were then pelleted by 
centrifugation at 300xg for 5 minutes. The supernatant was discarded and 
FACS buffer added to concentrate cells at approximately 50x106/ml in 
preparation for cell sorting. 
2.7.3 Extracellular staining 
The enriched  T cell fraction was stained with the following antibody cocktail 
in preparation for cell sorting (see antibody Table 2.1) for details of directly 
conjugated antibodies. 
 CD3 - APC 
 V2 - FITC 
 CD27 - Pacific Blue 
 CD28 - PeCy7 
 CD16 - V500 
 CD56 - PerCPCy5.5 




Enriched  T cells were stained for 30 minutes as described previously.  
Following staining, the cells were washed and the cells were resuspended in 
FACS buffer to a final concentration of approximately 50x106/ml in preparation 
for cell sorting.  Enriched and stained  T cells were kept on ice on transfer to 
the cell sorter. 
2.7.4 Cell sorting of V9V2 T cells 
Enriched  T cells were sorted using the BD FACSAria™ II cell sorter (Becton 
Dickinson) in order to collect the following four V9V2 T population subsets: 
 Subset 1.  (28+) [CD28(+)CD27(+)] 
 Subset 2.  (28-) [CD28(-)CD27(+)] 
 Subset 3.  (16-) [CD28(-)CD27(-)CD16(-)] 
 Subset 4. (16+) [CD28(-)CD27(-)CD16(+)] 
The enriched  T cell fraction was first vortexed to re-suspend the settled cells 
and then loaded onto the sorter by inserting the falcon tube into the tube holder.  
Four 12 x 75 mm falcon polypropylene collection tubes containing 1ml of RPMI 
1640 culture media and 20% FBS (Life Technologies) were used to collect the 
sorted cell populations.  Media containing FBS was used to increase overall cell 
viability of sorted cells. 
2.7.5 RNA stabilisation post-sorting 
Following sorting, cells were first re-suspended in their polypropylene collection 
tubes and transferred to polystyrene tubes in order to pellet cells by 




was added to pelleted cells in 1ml RNAse free Eppendorf tubes in order to 
stabilise RNA prior to storage at -80C.   
2.7.6 RNA extraction 
The RNA was then extracted according to recommended protocols using the 
RNeasy Micro Kit (Qiagen) which are briefly outlined.  Stored frozen sorted 
populations were thawed and centrifuged at 5000xg for 5 minutes.  After careful 
removal of the supernatant, the pellets were loosened, by flicking the 1ml 
eppendorff tubes and 350l of lysis Buffer RLT containing 1% -
mercaptoethanol (-ME) was added to each sample.  -mercaptoethanol was 
added to reduce and prevent RNA degradation during the process). 
Briefly, the pellet was rigorously resuspended by vortexing for one minute to 
facilitate homogenization of the sample.  Following this, 350l of 70% ethanol 
was added to the homogenized sample and mixed well by pipetting.  Each 
sample was then transferred to an RNeasy MinElute spin column and 
centrifuged for 15 seconds at 8000xg.  The flow through was discarded. 350l 
of Buffer RW1 was then added to the RNeasy MinElute spin column and again 
centrifuged for 15 seconds at 8000xg to wash the spin column membrane. The 
flow-through was again discarded.  Next, 10l of DNase I stock solution was 
added to 70l of incubation mix and mixed by gentle inversion.  This mixture 
was added directly onto the RNeasy MinElute spin column membrane and left 
for 15 minutes at room temperature (20 degrees).  Once again the spin column 
was washed by adding 350l of Buffer RW1 and again centrifuged for 15 
seconds at 8000xg.  The flow through was once again discarded.  The RNeasy 
Min Elute spin column was then placed on a new collection tube and 500l of 
100 
ethanol diluted Buffer RPE was added to the spin column.  This was centrifuged 
at 8000xg for 15s to wash the spin column. 500l of 80% ethanol was added to 
the column and centrifuged for 2 minutes and the supernatant discarded. The 
column was then transferred to a new collection tube and centrifuged at full 
speed with cap off to evaporate the column.  Finally, 14l of RNase-free water 
was added to the centre of the spin column and placed over a fresh collection 
tube.  After centrifugation for one minute the RNA was eluted in the collection 
tube and the RNA samples were stored at -80C until quality and quantity 
assessments of the samples were made.  RNA samples were then transferred 
on ice to the genome centre for microarray analysis.  The final stages of the 
microarray process of cell subsets is outlined in 2.7.8-2.7.11 and was carried 
out by staff at the Genome Centre core facility in Charterhouse Square, London 
(QMUL). 
2.7.7 RNA Concentration and RNA Integrity Quality Control 
The NanoDrop TM8000 Spectrophotometer was used to measure the 
absorbance of the sample to determine the following ratios: 
 260nm/280nm (measure of the purity of RNA).
 260nm/230nm (secondary measure of RNA purity and is usually in the
range of 2.0-2.2). 
2.7.8 RNA Integrity Number (RIN) Scores 
The quality of the RNA was further monitored using the RIN score, an objective 
measurement obtained to assess RNA quality and is independent of the actual 
quantity of RNA in the sample. RIN scores were determined using a 




determined to be of good quality/integrity.  Briefly the RNA sample was 
deposited into an RNA Nano LabChip before inserting the chip into the 
Bioanalyser (Agilent).  The bioanalyser then created an electrophoretic trace of 
the sample, which is converted to a numeric score based on RNA quality. 
2.7.9 Ambion Total Prep Kit 
The Ambion WT expression kit® (Life Technologies) was used to generate 
cRNA from a starting RNA sample.  The technique involved firstly the 
production and purification of cDNA from RNA by reverse transcription.  This 
was then followed by in vitro transcription to generate multiple copies of cRNA 
from cDNA ready for array hybridisation. 
2.7.10 Production and purification of cDNA from RNA 
RNA samples were made up to 11l with RNAse free water and 9l of Reverse 
Transcription Master Mix was added and incubated at 42ºC for 3 hours.  
Following this the second complimentary strand of cDNA was generated by 
adding 80l of Second Strand Master mix and incubated for a further 2 hours at 
16ºC.  The cDNA was then purified by adding cDNA binding buffer and then 
running the mixture through a cDNA filter cartridge. The cartridge was washed 
to remove primers, RNA, enzymes and salts within each sample to prevent 
interference in the later process of in vitro transcription. The cDNA was finally 
obtained in 20L Nuclease-free Water at 55°C. 
2.7.11 Transcription of purified cRNA from purified cDNA 
Firstly, 7.5l of In Vitro Transcription reaction Master Mix (IVT Master Mix) was 
added to each cDNA sample and mixed at 37°C for 6 hours to construct the 




Purification of the cRNA was carried out by pipetting a mixture of 350l cRNA of 
binding buffer and 250μl of 100% ethanol to the initial cRNA samples.  This was 
then filtered through a cRNA Filter cartridge and washed again with 650l of 
each buffer. The final purified cRNA sample was then eluted at 55°C in 200l of 
nuclease-free water. 
2.7.12 Human expression array of V9V2 T cell subsets 
The human expression array HumanHT-12 v4 Expression BeadChip array) 
(Illumina) was used to carry out the gene microarray, analysing each of the four 
subsets in triplicate.  This allowed determination of the transcriptome of over 
47,000 characterised genes and splice variant probes in the analysed 
populations. 
2.7.13 Gene Array analysis 
The data from the array was exported into Genome Studio (Illumina) to allow 
analysis of differential gene expression between populations. In general the 
differential expression threshold was assessed using a fold difference of >2 and 
p < 0.05 (Bonferroni corrected).  Each of the four V9V2 T cell subsets was 
compared against the others in a systematic way to highlight transcriptome 
differences between populations.  Validation of the sorted populations analysed 
in the transcriptome array was confirmed by flow cytometry. 
2.7.14 Statistical analysis 
All graphs and statistical data were generated using GraphPad Prism and 
individual tests and statistics are described in individual results sections.  




expression. Threshold for differential gene expression was set at a fold 
difference of > 2 and a p-value < 0.05 (Bonferroni corrected). 
2.7.15 Validation of gene array 
Initial validation of the sorted populations involved comparing the level of gene 
expression determined by the microarray to the surface markers used to initially 
sort the V9V2 T cell subsets (i.e. CD27, CD28 and CD16).  Following this, 
validation of four further differentially expressed genes (CX3CR1, CCR6, 
Granzyme B and Granzyme K) determined by the microarray (at least 2-fold 
different and p < 0.05 between V9V2 T cell subsets) was carried out by flow 









Investigating V9V2 T cell 






Chapter 3 Investigating V9V2 T cell heterogeneity 
in healthy human volunteers 
3.1 Introduction 
The first results chapter describes the process of surface marker re-evaluation 
in the initial characterisation of V9V2 T cells in human healthy volunteers.  
The initial experiments detail some of the challenges encountered when V9V2 
T cells were analysed using the most popular method of phenotyping with CD27 
and CD45RA, as well as issues surrounding the source of blood sample used 
for the investigations.  The process of surface marker evaluation is then 
described leading to a conclusion as to an improved set of surface markers that 
best characterise V9V2 T cell populations.  This in turn revealed V9V2        
T cell “person-profiles” at the level of the individual.  Finally, the effect of age, 
gender, infection history, ethnicity, and region of birth is considered in terms of 
V9V2 T cell number and phenotype in the peripheral blood. 
3.2 Leukocyte cone-derived PBMCs show wide variability in 
V9V2 T cell percentage, phenotype and expansion 
potential 
In order to investigate a potential role for  T cells, and in particular the V9V2 
T cell subtype, in BRONJ, it was important to establish baseline characteristics 
for these cells in a number of healthy individuals.  In the first instance, it was 
decided to characterise the percentage, phenotype and expansion potential of 
V9V2 T cells in six PBMC samples obtained from anonymised blood bank 




source of large blood volumes from healthy individuals and therefore allowed 
for analysis of a large number of cells. 
Analysis of six healthy cone samples revealed there to be a significant variation 
in percentage of V9V2 T cells relative to the total number of CD3(+) 
lymphocytes, ranging from 0.5% to 12.8% (Figure 3.1A).  In addition, there was 
a wide variation in V9V2 T cell proliferative capacity when PBMCs were 
stimulated with zoledronate (1M) and IL-2 (100U/ml) over seven days.  Whilst 
certain samples showed high V9V2 T cell expansion relative to total CD3(+) 
cells after 7-day culture (up to 17.7-fold), by contrast others seemed to show 
much lower expansion; as low as 1.4-fold (Figures 3.1B and 3.1C). 
The initial CD27/CD45RA phenotypic characterisation of these cells also 
seemed to be challenging as the use of these particular cell surface markers did 
not seem to divide V9V2 T cells into distinct populations (Figure 3.1D).  There 
was additionally a concern regarding the lack of information as to the identity 
and details of the blood donor samples.  There was no information on the age 
of the sample, as well as no indication regarding the transport time and 
conditions, which could potentially be long and varied.  Finally, the use of frozen 
aliquots of banked samples added another variable to the analysis, as it is well 
established that expression of surface markers can be significantly affected by 
freeze/thaw cycles.  In summary, we concluded that the use of fresh healthy 













































































Figure 3.1  Variation in V9V2 T cell number, phenotype and functional potential in blood cones. 
Blood cones from six anonymous human individuals show variation in; (A) Baseline V2/CD3(%); (A-left panel) shows typical baseline PBMC 
staining with V2 and CD3. (A-right panel) shows the variation in baseline V2/CD3(%) for each of the six blood cone samples (1-6). (B) Example 
of typical flow cytometry dot plot at baseline (T=0) and at 7 days (T=7) following in vitro PBMC culture with zoledronate (ZOL) (1μM) + interleukin-2 
(IL-2).  (C) Variation in V2/CD3(%) from (T=0) to (T=7) (relative expansion) in six different cone samples following 7-day ZOL + IL-2 culture.  (D) 
Flow cytometry profiles (dot plots) of V9V2 T cells from the six cone samples stained with antibodies to the surface markers CD27 and CD45RA. 
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3.3 Fresh peripheral blood samples also show variability in 
V9V2 T cell percentage, phenotype and expansion 
potential 
The analysis of fresh peripheral blood from the first six healthy volunteers also 
showed a great degree of variation in both the V2/CD3(%) (range 1.1%-21.6%) 
and expansion capacity (range 2.2-60.9-fold change) following 7-day culture 
with zoledronate (1M) and IL-2 (100U/ml) (Figure 3.2 A,B and C).  In addition, 
a range of CD27/CD45RA phenotypes was again seen with fresh samples, 
including individuals with a predominantly CD27(+) phenotype (mainly 
CD27(+)CD45RA(-)) (individual #1) to others who seemed to have a 
predominance of CD27(-) effector populations and express a terminally 
differentiated effector phenotype [CD27(-)CD45RA(+)] (individuals #5 and #6) 
(Figure 3.2D). 
These initial results from both frozen blood cone samples, and a small number 
of fresh blood samples suggested that a considerable amount of V9V2 T cell 
heterogeneity existed in the normal healthy population that was related to 
neither experimental technique nor sample processing.  In addition, there was 
clearly a spectrum of normal healthy phenotypes in the peripheral blood that 
warranted further investigation and characterisation. 
Having observed significant variability in these twelve initial blood samples, it 
was apparent that there was a need to describe this phenotypic variability in a 
greater number of healthy volunteers.  Therefore a total of 63 fresh healthy 
volunteer samples were phenotyped in order to better understand this observed 
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Figure 3.2  V9V2 T cell variability in healthy human volunteer peripheral blood samples. 
Six freshly processed healthy volunteer peripheral blood samples show variation in (A) Baseline V2/CD3(%); (A-left panel) shows example of 
typical baseline PBMC staining with V2 and CD3 surface antibody markers.  (A-right panel) shows variation in baseline V2/CD3(%) for each 
of the six blood samples (1-6).  (B) Example of typical flow cytometry dot plot at baseline (T=0) and at 7 days (T=7) following in vitro PBMC 
culture with zoledronate (ZOL) (1μM) + interleukin-2 (IL-2).  (C) Variation in V2/CD3(%) from (T=0) to (T=7) (relative expansion) following 
7-day ZOL + IL-2 culture in six fresh healthy peripheral blood volunteer samples.  (D) Flow cytometry profiles (dot plots) of V9V2 cells from six 
different individuals stained with antibodies to the surface markers CD27 and CD45RA. 
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3.4 CD45RA fails to define distinct phenotypic populations 
of V9V2 T cells when used in combination with CD27 
Having evaluated fresh peripheral blood samples from 63 healthy human 
volunteers (see later sections for details of these volunteers), it became 
apparent that CD45RA surface expression on V9V2 T cells ranged widely 
(from 5.2% to 84.5%) and this was particularly obvious on CD27(+) cells.  This 
consistently made the determination of TN
 [CD27(+)CD45RA(+)] and TCM
 [CD27(+)
CD45RA(-)] populations difficult (Figure 3.3).  The use of CD27 and CD45RA 
consistently failed to divide V9V2 T cells into the four conventionally-
described phenotypic populations; TN
 [CD27(+)CD45RA(+)], TCM
[CD27(+)CD45RA(-)], TEM






















































Figure 3.3  CD45RA is a poor discriminator of distinct V9V2 T cell 
subsets. 
A representative set of flow cytometry profiles (dot plots and density plots) from a 
single healthy individual peripheral blood sample showing gating strategy and 
expression of surface markers CD27 and CD45RA on V9V2 T cell subsets 
(Top) and V2(-)CD3(+) populations (predominantly  T cells) (Bottom). Density 
plots are used to demonstrate the predominant cell populations.  The percentage 








This was in direct contrast to the expression of these markers on CD3(+) non-
V9V2 T cells (most of which would be  T cells) (Figure 3.3).  The fact that 
both V9V2(+) and non-V9V2(+) T cells could be stained within the same 
PBMC sample indicated that the difference in CD45RA expression was a real 
effect and not related to differences in flow cytometry staining procedure.  In 
moving forward, it was decided that phenotypic characterisation of V9V2 
T cells with CD45RA was not robust, and that an alternative method of 
identifying these cells was required. 
3.5 The use of different combinations of surface markers 
reveal significant confusion when phenotyping V9V2 
T cells. 
Figure 3.4 shows a single V9V2 T cell peripheral blood sample stained for 
multiple surface markers (CD27, CD45RA, CD28, CD11a, CD16, CCR7 and 
CD62L).  This allowed us to display V9V2 T cells using methods described in 
the literature.  This figure highlights the confusion that exists within the literature 
(Dieli et al. 2003b, De Rosa et al. 2004, Angelini et al. 2004, Puan et al. 2009, 
Yokobori et al. 2009) in both the use of different marker combinations and the 
nomenclature used to describe populations.  For example, when defining the 
“naïve” population (TN) as [CD27
(+)CD45RA(+)] (Dieli et al. 2003b), it
represented 27.3% of total V9V2 T cells, whilst if [CD27(Hi) and CD11a(Lo)] (De 
Rosa et al. 2004) was used, it was only 4.6%.  Similarly, the TEM was 3.7% 
when defined as [CD27(-)CD45RA(-)] but much higher (18.7%) when 
[CD27(+)CD28(-)] was used (Table 3.1). 
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III - Angelini et al. 2004 
II - DeRosa et al. 2004 
I - Dieli et al. 2003 
IV - Puan et al. 2009 
V - Yokobori et al. 2009 
V9V2 T cells 















































































































































































Figure 3.4  Use of different V9V2 T cell phenotypic strategies leads to a 
range of estimates for each population subset. 
Flow cytometry dot plots showing differences in published V9V2 T cell 
phenotypic subsets depending on phenotyping strategy.  Surface marker staining 
of V9V2 T cells from a single PBMC healthy volunteer sample is shown and is 
phenotyped using various extracellular marker combinations; (I) CD27 v 
CD45RA, (II) CD27 v CD11a, (III) CD27 v CD62L (CD16 v CD45RA) (IV) CD27 v 
CD28 (V) CCR7 v CD45RA.  The year and lead author of each phenotypic 
strategy is indicated. Subsets are described as; TN
 (Naïve), TCM (Central 
Memory), TCM27(-) (Central Memory CD27
(-)) TEM
 (Effector Memory) and TEMRA
(Terminally differentiated Effector Memory CD45RA(+)).  Summary table showing 
the percentage of different V9V2 T cell subsets using the various phenotypic 
strategies is shown in Table 3.1. 
113 
Phenotypic description 
TN TCM TCM (CD27-) TEM TEMRA 
Dieli (CD27 v CD45RA) 27.3 30.9 NA 3.7 38.0 
DeRosa (CD27 v CD11a) 4.6 93.4 
Angelini (CD27 v CD62L CD16 v CD45RA) 21.6 17.9 NA 3.4 25.7 
Puan (CD27 v CD28) NA 38.8 2.3 18.7 40.3 
Yokobori (CCR7 v CD45RA) 5.2 3.0 - 33.4 58.4 
Table 3.1  Summary table of V9V2 T cell subset size as defined by 
different phenotypic strategies.  
V9V2 T cell subset percentages from Figure 3.4 are compared.  Subsets are 
termed; TN (“Naïve”), TCM (Central Memory), TCM27- (Central Memory CD27
(-)), TEM 
(Effector Memory) and TEMRA (Terminally differentiated Effector Memory 
CD45RA(+)).   These results highlight the problem that exists in describing V9V2 
T cells with different marker combinations particularly when similar terms of 
nomenclature are used by different groups. 
These results highlight the problem that exists in describing V9V2 T cells with 
different marker combinations particularly when similar terms of nomenclature 
are used by different groups, using different combinations of surface markers. 
3.6 V9V2 T cells showed no significant variation with 
respect to age, gender, ethnicity, or place of birth. 
Having characterised 63 healthy individuals using conventional methods, it was 
apparent that there was no obvious gender differences in V9V2 T cell 
percentage within the lymphocyte population with a median V2/CD3(%) of 
2.1% in 31 males (range 0.4-21.4%) and 2.2% in 32 females (range 0.3-21.9%) 
(Figure 3.5).  In addition, although there did not seem no be any statistically 
significant differences due to ageing (p = 0.06), the overall trend showed a slow 
downward decline in V9V2 T cell percentage with age, which approached 
significance when the youngest and oldest groupings were compared 
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Figure 3.5  Effect of age and gender on V2/CD3(%) in peripheral blood. 
Peripheral V9V2 T cells are expressed as a percentage of total CD3(+) lymphocytes comparing; (A) Males (M) vs. Females (F) (M=31, F=32, 
N=63) with age range 3-69 years. (B) Peripheral V2/CD3(%) in all healthy individuals aged 3-69 years showing linear regression lines with 
95% confidence interval bands indicated as dashed lines for males (blue) and females (red) respectively. V2/CD3(%) is also shown by age 
sub-groups (C) 0-29 years (Male=10, Female=16), 30-49 years (Male=9, Female=12) and 50-69 years (Male=12, Female=4) comparing 
differences in V2/CD3(%) in age groups. All data points are shown with red lines representing median V2/CD3(%).  Statistical differences 
were assessed using the Mann–Whitney U test with p-values indicated in (A and C) and Kruskal-Wallis one-way ANOVA with multiple 
comparison post-hoc testing (Bonferroni corrected) in B. 
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Although this summarises the general trend, it must be noted that two 50 year 
old healthy volunteers had a V2/CD3(%) of > 20% and highlighted that high 
percentages of V9V2 T cells can be found in the peripheral blood well into 
adulthood. 
Finally, healthy volunteers were then grouped by ethnicity, and region of birth to 
investigate whether these factors had any influence on V2/CD3(%).  However, 
no significant differences were observed (Figure 3.6).  Similarly, no significant 
differences were found if the developmental index of country of birth was 
considered in relation to V2/CD3(%) (p = 0.18). 
3.7 Re-assessment of the “naïve” V9V2 T cell population 
In general, it was apparent that in moving away from the use of CD45RA as a 
marker, a “naïve” population of V9V2 T cells appeared to be very small 
(consistently < 5%) when other combinations of typical “naïve” markers were 
used i.e. CD11a, CCR7 and CD62L (Figure 3.7). 
For example when [CD27(Hi)CD11a(Lo)] was used to describe “naïve” cells the 
median percentage was 0.8% (range 0.1-14.0%).  Other combinations of typical 
“naïve” markers including [CCR7(+) CD62L(+)] as well as a combination of 
[CD27(Hi)CCR7(+)CD62L(+)CD11a(Lo)] also seemed to confirm the small size of a 
“naïve” population, with median estimates of 1.9% and 0.6% respectively.  It 
was therefore clear that the “naïve” population of V9V2 T cells makes up a 
very small proportion of total V9V2 T cells in the peripheral blood, when 
methods that do not use CD45RA are considered.  A method using CD45RA 
gives a TN cell estimate of 23.4% (range 1.2-52.6%). 
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Figure 3.6  Variation in V2/CD3(%) in peripheral blood shown by ethnicity, 
region of birth and by country of birth development status. 
V2/CD3(%) is shown in all sampled healthy individuals (N=63) by (A) Ethnic 
group (B) Geographic sub-region of birth (C) Continent of birth and (D) Human 
Development Index (HDI).  Ethnic groupings in A are based on Office for National 
Statistics (ONS) ethnic groupings used for UK census data.  Regions stated in B 
are as per scheme derived from the United Nations Statistics Division (UNSD) of 
sub-regions of the world. Human Development index (HDI) is a United Nations 
composite index of life expectancy, education and income HDI score (Low 0.4-
0.6), Medium (0.6-08) and High (0.8-1.0).  Red bars represent median 
V2/CD3(%) with statistical differences assessed using Kruskal-Wallis test 
(ANOVA) and multiple comparison post-hoc testing (A-D) with Bonferroni 


































Figure 3.7  “Naïve” V9V2 T cell subset estimates show large variation 
depending on phenotyping strategy. 
(A) Scatter plot showing the range of estimates of the “naïve” subset by use of 
four different marker combinations.  CD27(+)CD45RA(+) (N=63), CD27(Hi)CD11a(Lo) 
(N=63), CCR7(+)CD62L(+) (N=31) and a combination of all markers CD27(Hi)
CD11a(Lo)CD62L(+)CCR7(+) (N=31).  Red lines represent median V2/CD3(%) with 
statistical differences assessed using Kruskal-Wallis test (ANOVA) and multiple 
comparison post-hoc testing with Bonferroni correction.  p-values are indicated, 
with p < 0.05 considered significant. 
3.8 CCR7 expression is dependent on clone and staining 
conditions. 
CCR7 seemed to show a great variation in expression on V9V2 T cells and 
this appeared to depend on the clone of antibody used as well as the staining 
conditions.  Figure 3.8 shows an example of this variation in a single healthy 



























































Figure 3.8  CCR7 expression on V9V2 and  T cells varies depending on clone and staining conditions. 
V9V2 and  T cells from a single representative peripheral blood sample showing the variation in CCR7 expression depending on clone of 
antibody and staining conditions.  Two different antibody clones (BioLegend (clone G04H37) and eBioscience (clone 3D12)) are shown under 
three different staining conditions; ice, room temperature (RT) and at 37°C.  Flow cytometry contour plots are shown with the percentage of 
cells in each gate indicated. Median fluorescent intensity (MFI) of CCR7(+) events is indicated for each clone under the three staining conditions. 
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Similarly, the median fluorescent intensity of CCR7 positive events seemed to 
be greater when staining at 37C (MFI=807) compared to on ice (MFI=576).  
The clone of antibody used also seemed to effect the detection of CCR7 
expression on V9V2 T cells with much higher levels found using G04H37 
(BioLegend) compared to the 3D12 clone (eBioscience).  As an example of this, 
at 37C the percentage of CCR7(+) cells was 19.2% with G04H37 (BioLegend) 
compared to only 0.8% with 3D12 (eBioscience).  The variation of CCR7 
expression on V9V2 T cells therefore led to concerns in the use of this marker 
for characterising the “naïve” cell population.  In addition the reported instability 
of CD62L also suggested this to be an unsuitable marker for predictable 
characterisation (De Rosa et al. 2004).  Consequently CD27 and CD11a were 
considered to be the most reliable markers to use in the characterising of the 
small “naïve” V9V2 T cell population. 
3.9 CD27, CD28 and CD16 are more consistent markers for 
defining distinct V9V2 T cell populations 
In order to establish the most appropriate markers to phenotype V9V2 T cells, 
all 63 healthy individuals were stained with a range of commonly used markers 
including CD27, CD45RA, CD28, CD11a, CD16 and CD56 (Dieli et al. 2003b, 
De Rosa et al. 2004, Angelini et al. 2004, Puan et al. 2009, Yokobori et al. 
2009).  Following extensive analysis, it was apparent that the combined use of 
CD27 and CD28 consistently divided non-naïve V9V2 T cells into three clear 
distinct populations; [CD28(+)CD27(+)], [CD28(-)CD27(+)] and [CD28(-)CD27(-)]
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Figure 3.9  Phenotypic analysis of V9V2 T cells showing distinct phenotypic subsets 
Flow cytometry density plots showing the predominant V9V2 T cell subsets in the peripheral blood of a single healthy human donor using; 
CD27, CD11a, CCR7, CD28, CD62L and CD16.  The figure shows an individual with all the major V9V2 T cell phenotypic populations. 
Populations are initially subdivided into “Naïve” and “Non-naïve” V9V2 T cell populations.  Naïve V9V2 T cells are characterised as; 
[CCR7(+), CD27(Hi), CD28(+), CD11a(Lo) and CD62L(+)].  “Non-naïve cells” are subsequently subdivided into four groups based on CD27, CD28 and 
CD16 expression to give four further phenotypic populations; (28+) [CD28(+)CD27(+)] (red box), (28-) [CD28(-)CD27(+)] (yellow box), (16-) [CD28(-
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Figure 3.10  Proposed V9V2 T cell phenotypic characterisation as defined by CD11a, CD28, CD27, and CD16. 
Phenotypically distinct V9V2 T cell subsets as identified using CD11a, CD28, CD27 and CD16. A small naïve cell subset is defined as 
CD27(Hi)CD11a(Lo) with the majority of V9V2 T cells being non-naïve (CD11aHi).  This non-naïve subset can then be divided into four major 
phenotypic subsets and will be subsequently referred to as; (28+) [CD28(+)CD27(+)] (red box), and (28-) [CD28(-)CD27(+)] (yellow box), (16-)
[CD28(-)CD27(-) CD16(-)] (blue box) and (16+) [CD28(-)CD27(-)CD16(+)] (green box). 
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A [CD28(+)CD27(-)] population was rarely seen, and when present seemed to 
form part of a “tail” from the [CD28(+)CD27(+)] population, and so was not 
thought to represent a significant V9V2 T cell population.  It also appeared 
that V9V2 T cells appeared to be transitioning from the [CD28(+)CD27(+)] to 
the [CD28(-)CD27(-)] population via a [CD28(-)CD27(+)] intermediate. 
Thus, having concluded that CD27 and CD28 were useful markers to use, it 
was then decided to also use CD16 as a late effector marker to further sub-
divide the [CD28(-)CD27(-)] population into two further sub-populations, as CD16 
expression seemed to increase in expression across the [CD28(-)CD27(+)] to 
[CD28(-)CD27(-)] subsets (Figure 3.9). 
3.10 The four non-naïve V9V2 subsets vary markedly in 
percentage between healthy individuals. 
In looking at the percentage of each of our newly-defined V9V2 T cell subsets 
in healthy volunteers, it was apparent that there was huge variability in the 
proportions of these non-naïve subsets across the 63 individuals (Figure 3.11).  
The (28+) population ranged from (0.6-89.6%) with a median percentage of 
55.9%, the (28-) population ranged from (0.5-51.1%) with a median percentage 
of 20.8%, the (16-) population ranged from (0.4-44.6%) with a median 
percentage of 4.5% and finally the (16+) population ranged from (0.1-88.7%) 
with a median percentage of 3.8%.  Clearly there is not a typical “normal” 
healthy phenotype and individuals ranged from those with an almost complete 
predominance of the (28+) subset to those with a predominance of the (16+) 
population with a spectrum of profiles in between. 
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Figure 3.11  V9V2 T cell phenotypic subset distribution showing the four 
major non-naïve subsets. 
Peripheral blood mononuclear cells (PBMCs) were stained with CD28, CD27 and 
CD16 and the relative percentage of each of the newly-defined non-naïve 
V9V2 T cell subsets determined.  Individual data points for all 63 healthy 
volunteers are shown with median values indicated. V9V2 subsets; (28+)
[CD28(+) CD27(+)], (28-) [CD28(-)CD27(+)], (16-) [CD28(-)CD27(-)CD16(-)] and (16+) 
[CD28(-)CD27(-) CD16(+)]. 
3.11 V9V2 T cell subset distribution does not appear to be 
related to age 
In observing the spectrum of V9V2 T cell phenotypes in healthy volunteers, it 
might be reasonably postulated that a certain subset might accumulate in the 
peripheral blood as a consequence of ageing and cumulative increase in 
antigen and infection experience.  Thus, the distribution of the main V9V2 
T cell subsets was assessed across three different age ranges (0-29 years), 
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(30-49 years) and (50-69 years) to determine whether there were any significant 
changes due to ageing (Figure 3.12).  No significant changes were observed in 
the (N), (28+), (16-) or (16+) subsets across the three age ranges with the 
only exception being decrease in the (28-) subset between the youngest age 
group (0-29 years) and the oldest group (50-69 years) (p= 0.005).  Thus, there 
was little evidence to support the hypothesis that a certain V9V2 T cell subset 
accumulated with increasing age. 
3.12 Individual V9V2 T cell profiles can be clustered into six 
phenotypic “signature” groups 
Previous literature has mainly described V9V2 T cells from a single 
“representative” individual with little consideration of how this phenotype varied 
between individuals.  Having observed considerable variability in the expression 
of each our newly-defined V9V2 T cell subsets, it became apparent that 
individuals could be grouped into distinct clusters based on the relative 
proportions of each V9V2 T cell subset in their peripheral blood. 
The apparent spectrum of V9V2 T cell “phenotypic signatures” seen across 
the normal healthy population ranged from those with a (28+) biased phenotype 
to those with an almost exclusive (16+) phenotype.  It was therefore possible to 
group the 63 individuals into six “phenotypic signature” clusters, which were 
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Figure 3.12  V9V2 T cell subsets show little evidence of accumulating with 
increasing age. 
Healthy volunteers were grouped into three age groups; 0-29 years (Male=10, 
Female=16), 30-49 years (Male=9, Female=12,) 50-69 years (Male=12, 
Female=4) and examined for changes in V9V2 T cell subsets over time. 
V9V2 T cell subsets are defined as (A) N [CD27(Hi)CD11a(Lo)], (B) (28+) 
[CD28(+)CD27(+)], (C) (28-) [CD28(-) CD27(+)], (D) (16-) [CD28(-)CD27(-)CD16(-)] and 
(E) (16+) [CD28(-)CD27(-) CD16(+)].  Red bars represent median values with 
statistical differences assessed using Kruskal-Wallis one-way ANOVA and 
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Figure 3.13  Criteria for phenotypic signature groupings of V9V2 T cells. 
Graphs show the relative proportions of the four newly-defined V9V2 T cell subsets based on CD28, CD27 and CD16 expression in each of 
six phenotypic signature groups (#1-6).  V9V2 T cell subsets are defined as (28+) [CD28(+)CD27(+)], (28-) [CD28(-)CD27(+)], (16-) [CD28(-) 
CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)].  Graphs show the range of each V9V2 T cell subsets in each signature group with the 
dotted red line bisecting these proposed ranges and showing a pictorial representation of each phenotypic signature (1-6).  The approximate 
percentage of each V9V2 T cell subset in each phenotypic signature group is shown in the table below (B).  Grouping criteria were 
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Figure 3.14  V9V2 T cell subsets cluster into six “ henot     signatures”. 
(A) Representative dot plots show the relative percentage of each subset based on CD28, CD27 and CD16 in each phenotypic signature (1-6). 
(B) Six phenotypic signatures were established based on clustering of similar phenotypic profiles and based on the relative proportions of each 
V9V2 T cell subset. Criteria for groupings are outlined in Figure 3.13. 
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The most commonly observed phenotypic signature in 44.4% of individuals 
(28/63) was signature #2, characterised by a predominance of both (28+) and 

(28-) cells (Figure 3.14/3.15A).  Individuals in this profile group had 50-75% of 
the (28+) subset and 10-35% in the (28-) subset with < 20% of (16-) and (16+)
cells.  The next most commonly seen cluster was phenotypic signature #1, 
observed in 17.5% (11/63) of healthy volunteers and characterised by a 
predominance of (28+) cells (> 75%). Signatures #3 and #4 were observed in 
10-15% of the healthy volunteer group with signatures #5 and #6 being the 
least commonly observed at around 5% of the cohort (Figure 3.14/3.15A). 
3.13 V9V2 T cell phenotypic “s gnat res” are w de   s read 
across all age groups. 
The correlation between the six newly-defined phenotypic signatures and the 
age of individuals in the cohort was next examined to see whether there was 
evidence that certain signatures were gained with increasing age.  The graph in 
Figure 3.15B plots the six signatures against age and shows that there are no 
obvious correlations for age distribution and any of the signature groups 
(p>0.05).  This supports the previous observation that a certain V9V2 T cell 
phenotype is not gained as individuals get older.  This in turn suggests that 
increasing cumulative infectious exposure is also not a factor defining V9V2 T 
cell phenotype.  Indeed, in looking at the signature groups (indicated in 
parentheses) of the five oldest volunteers aged 63-69 years (1,2,1,3,6) and the 
five youngest volunteers aged 3-24 years (2,2,2,2,3) there were no obvious 
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NS p > 0.05 for all multiple comparisons 
Figure 3.15  Distribution of phenotypic signatures in healthy volunteers. 
(A) Distribution of phenotypic signatures of all 63 healthy volunteers (B) Distribution of age (years) for the six phenotypic signatures with median 
values indicated (red).  Statistical differences were assessed using ANOVA Kruskal-Wallis non-parametric testing and multiple-comparison 
post-hoc testing using Bonferroni correction p < 0.05.  (C) Phenotypic signatures of five youngest and the five oldest healthy volunteers with 
phenotypic signature group (1-6) indicated for each individual. 
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3.14 V9V2 T cell phenotypic “signatures” do not appear to 
correlate with ethnicity, region of birth or the 
development status of country of birth 
Having assigned each individual to a particular phenotypic signature, the 
correlation between these signatures and ethnicity, sub-region/continent of 
birth, and the developmental status of country of birth, was then assessed.  
There was no phenotypic signature that predominated in individuals of a 
particular ethnicity, sub-region or continent of birth (Figure 3.16).  Nor did these 
signature groupings seem to relate to the developmental status of country of 
birth.  However one interesting observation was that all three of the most 
extreme phenotypes (signature #6) were born and spent their early life in the 
continent of Africa, raising the question whether a particular early environmental 
exposure to specific antigen or infections might have a permanent effect on an 
individual’s V9V2 T cell phenotype. 
3.15 Malaria has no significant effect on V2/CD3(%) but may 
lead to extreme V9V2 T cell phenotypic signatures 
In five of the healthy volunteer cohort, a history of malaria exposure was 
reported in early life (< 5 years old in all cases).  Therefore, in order to examine 
the influence of this specific infection, the V2/CD3(%) and the phenotypic 
signature were examined in each of these individuals to investigate whether 
there could be an association between exposure to malaria and changes in 
V9V2 T cells in the peripheral blood.  Figure 3.17 shows that V2/CD3(%) did 
not seem to be significantly affected by previous malaria infection with a median 
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Figure 3.16  Distribution of V9V2 T cell phenotypic signatures by 
ethnicity, region of birth and by developmental status of country of birth. 
Phenotypic signatures shown by (A) Ethnic group (B) Geographical sub-
region/place of birth (C) Continent of birth and (D) Human Development index 
(HDI). Ethnic groupings in A are based on Office for National Statistics (ONS) 
ethnic groupings used for UK census data.  Regions stated in B are as per 
scheme derived from the United Nations Statistics Division (UNSD) of sub-
regions of the world. The Human Development index (HDI) shown in D is a 
United Nations composite index of life expectancy, education and income 
available by individual country.  HDI scores are grouped by country development 
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Figure 3.17  Effect of previous malaria infection on V9V2 T cell percentage and phenotypic signature. 
A comparison of healthy volunteers, with and without a previous history of malaria infection.  (A) Graph comparing V2/CD3(%) in healthy 
volunteers with and without a previous history of malaria exposure is shown. Statistical differences were assessed using the Mann–Whitney U 
test with p-values indicated (Y=Yes, N=No). (B) Phenotypic profiles of the 5 healthy volunteers with a previous history of malaria infection are 
shown, with phenotypic signature groups indicated above each of these 5 individuals. 
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percentage of 2.0% in the malaria sub-group compared to 2.2% in unaffected 
healthy controls (p = 0.70).  However the phenotypic signatures of the group 
with a past history of malaria infection seemed to contain a number of the more 
extreme phenotypes (2,4,4,4 and 5) and perhaps suggested that this specific 
infection might permanently increase the percentage of certain V9V2 T cell 
subsets in the peripheral blood over a longer period of time. 
3.16 Summary; What is the nature of V9V2 T cell 
differentiation? 
The data described in this chapter have argued that the commonly-used 
methods of phenotyping V9V2 T cells are sub-optimal.  Furthermore, the 
literature has under-represented the degree to which the phenotype of V9V2 
T cells differs between individuals.  Here, we re-assess the phenotype of these 
cells using CD28, CD27 and CD16, proposing a method of identification which 
recognises four subsets; (28+) [CD28(+)CD27(+)], (28-) [CD28(-)CD27(+)], (16-) 
[CD28(-)CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)].  Interestingly, the 
relative proportions of these subsets allow individuals to be placed in a number 
of clusters or phenotypic signatures.  These signatures differ significantly from 
one another, and importantly do not correlate with age, gender, ethnicity, or 
country of birth.  Finally, the data pose interesting questions as to the nature of 
V9V2 T cell differentiation; Do V9V2 T cells move through the various 
CD28/CD27/CD16-defined subsets in a linear manner, or are the phenotypic 
signatures that they define stable over time, or even determined by genetic 
inheritance and or developmental history.  These ideas are summarised in 
Figure 3.18. 
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Figure 3.18  Proposed models of V9V2 T cell differentiation. 
Model A shows a linear pattern of differentiation where cells move along a 
sequential pathway from “Naïve” to other phenotypes.  Model B describes an 
alternative model that implies that each individual subset arises from a common 
naïve progenitor or stem-like cell.  Homeostatic mechanisms from a stem-like 
progenitor subset may be involved in replenishing depleted subsets after 
infectious challenge, or alternatively the thymus may have a continued role in 
topping up subsets despite gradual age-related involution.
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Chapter 4 Phenotypic and functional 
characterisation of newly defined V9V2 T cell subsets 
4.1 Introduction 
Having proposed a revised system of V9V2 T cell classification based on 
CD11a, CD28, CD27 and CD16, it was important to further characterise the five 
distinct V9V2 T cell subsets; [(N); (28+); (28-); (16-) and (16+)] in order to 
establish their properties and functional potential.  This chapter describes this 
analysis, which assesses the expression of a range of common extracellular 
markers, cytokine secretion and proliferative potential. Finally a gene 
microarray was performed on four of the five subsets to reveal further 
differences between these populations. 
4.2 Surface marker expression on V9V2 T cell subsets 
4.2.1 The (N) subset is characterised by high levels of CCR7 and 
CD62L expression 
The small “naïve” V9V2 T cell subset (N), defined as [CD27(Hi)CD11a(Lo)] was 
characterised using a number of other common markers.  Figure 4.1 shows that 
the (N) population also commonly expresses CCR7 (median percentage of 
subset positive for CCR7 being 69.1%) and CD62L (median percentage of 
subset positive for CD62L being 85.7%).  By contrast, the percentage of the 
non-naïve V9V2 T cell populations expressing CCR7 was low (typically 
<10%), with CCR7 being surprisingly poorly expressed by (28+) and (28-) 
subsets (Figure 4.1A). 
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Figure 4.1  Expression levels of various surface markers on V9V2 T cell 
subsets. 
Extracellular surface marker expression is shown for (A) CCR7, (B) CD62L, (C) 
CD45RA and (D) CD56 on V9V2 T cell subsets.  For each marker, individual 
data points are shown indicating percentage of positive cells in each subset with 
median values indicated as a red bar.  V9V2 T cell subsets are defined as; (N) 
[CD27(Hi)CD11a(Lo)], (28+) [CD28(+)CD27(+)], (28-) [CD28(-)CD27(+)], (16-) [CD28(-) 
CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)]. 
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The percentage of cells positive for CD62L expression decreased across the 
populations from high levels in the (N) subset to low levels in the (16+)
population (Figure 4.1B).  The (N) population also commonly expresses 
CD45RA (median percentage of subset positive for CD45RA being 59.4%) 
although the range of expression of this marker is large (4-100%), and similar in 
magnitude and distribution to the (28-) and (16-) populations (Figure 4.1C).  
The wide range of expression of CD45RA on the (N) population adds further 
weight to the argument that CD45RA is a variable and unreliable naïve cell 
marker for V9V2 T cells (Figure 4.1C). 
The cytotoxic marker CD56 was expressed by the vast majority of non-naïve 
subsets (typically > 80%) but was only expressed by around 50% of the (N) 
population.  This suggests that perhaps all of the non-naïve cell populations 
have cytotoxic potential in contrast to the memory and effector populations 
observed for conventional  T cells. 
4.2.2 The (28+) subset is characterised by high CCR2 and CCR5 
expression 
The (28+) population appears to be the most different non-naïve V9V2 T cell 
subset in terms of surface markers.  (28+) cells showed a significantly lower 
median percentage of CD45RA expression (18.5%) compared to (28-) cells 
(61.1%), (16-) cells (59.6%) and (16+) cells (77.4%) (p < 0.05) (Figure 4.1).  In 
addition, (28+) cells also displayed a high median percentage expression of 
both CCR2 (66.9%) and CCR5 (94.2%) with significantly higher levels 




Figure 4.2  Expression levels of various chemokine receptors and homing markers on V9V2 T cell subsets. 
Surface marker staining is shown for (A) CCR5, (B) β7-Integrin, (C) CXCR5, (D) CCR2, (E) Cutaneous lymphocyte antigen (CLA) and (F) CCR9 
on V9V2 subsets. For each marker, individual data points are shown indicating percentage of positive cells in each subset with median values 
indicated as a red bar.  V9V2 subsets are defined as; (N) [CD27(Hi)CD11a(Lo)], (28+) [CD28(+)CD27(+)], (28-) [CD28(-)CD27(+)], (16-) [CD28(-
)CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)]. 
CCR2
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This same population also expressed the highest median percentage of the 7-
integrin marker (67.8%).  In summary, it appears that (28+) cells represents a 
particularly distinct population with many different surface markers in 
comparison to the other V9V2 T cell subsets. 
4.2.3 CXCR5, CCR9 and CLA are expressed at low levels on V9V2 T 
cells 
Characterisation of V9V2 T cells with CXCR5, CCR9 and CLA showed there 
to be low levels of surface expression of these markers and with no obvious 
differences between subsets (p > 0.05) (Figure 4.2). 
4.3 Assessment of cytokine secreting potential by V9V2 T 
cell subsets 
Having characterised some common surface markers on the newly-defined 
V9V2 T cell subsets, the cytokine-secreting potential of these populations was 
then established by investigating the production of IFN-, TNF-, and IL-17A 
following 4-hour stimulation with PMA and ionomycin.  In addition, the potential 
of subsets to produce the cytotoxic protein, Perforin was also determined using 
the same method.  The small number of cells in the (N) population meant that 
it was not possible to characterise the secreting-potential of this subset, and 
therefore this subset (that also has a CD28(+)CD27(+) expression pattern) was 
included together with the (28+) subset.  A typical example from a single 
individual healthy volunteer is shown in Figure 4.3 showing the cytokine 



































































































































































Figure 4.3  Cytokine potential of V9V2 T cell subsets. 
Representative plots from a single healthy individual are shown.  PBMCs were 
stimulated with PMA and Ionomycin for 3 hours, blocked with Brefeldin/Monensin 
and then fixed and permeabilised before staining for intracellular cytokines; 
Interferon- (IFN-), Tumour Necrosis Factor- (TNF-) and Interleukin-17A 
(IL-17A).  Cell secreting potential for the intracellular cytotoxic protein, perforin is 
also shown (far right).  Flow cytometry dot-plots show percentage of cells positive 
and negative for each cytokine in total V9V2 cells and in constitutive subsets. 
V9V2 subsets are defined as; (28+) [CD28(+)CD27(+)] (red box), (28-) [CD28(-) 
CD27(+)] (yellow box), (16-) [CD28(-)CD27(-)CD16(-)] (blue box) and (16+)[CD28(-) 
CD27(-)CD16(+)] (green box). 
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4.3.1 All V9V2 T cell populations can secrete IFN- and TNF- with low 
levels of IL-17A 
Intracellular cytokine staining revealed that the majority of the V9V2 T cell 
subsets showed the capacity to secrete IFN- upon stimulation, with a high 
median percentage expression in all four non-naïve subsets (typically between 
60-80%) (see Figure 4.4).  Similarly, TNF- was also readily produced by a high 
percentage of cells in all V9V2 T cell subsets.  However, the percentage of 
TNF- secreting cells in the (16+) subset was significantly lower    
(median = 38.4%) in comparison to the (28+) subset, which had a median 
expression percentage of 91.9% (p = 0.002).  In addition, whilst not significantly 
different, (28-) and (16-) subsets also appeared to express TNF- at much 
higher levels than the (16+) subset.  IL-17A was expressed at very low levels  
(< 5%) in all V9V2 T cell populations with no obvious differences between 
subsets (p = 0.35). 
4.3.2 Perforin is produced at higher levels in (16-) and (16+) subsets 
The ability of each V9V2 T cell subsets to make the cytotoxic protein Perforin 
was also assessed following PBMC stimulation.   Results indicated in Figure 4.4 
show a significantly higher percentage of cells expressing Perforin in the (16-)
and (16+) V9V2 subsets (p < 0.05) with median percentage expression levels 
of 39.3% and 47.4% respectively compared to the (28+) population (3.7%).  
This suggests that CD27(-) populations [(16-) and (16+) subsets] have 
increased cytotoxic potential. 
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Figure 4.4  Cytokine and Perforin-secreting potential in non-naïve V9V2 T 
cell subsets. 
Percentage of cells with cytokine-secreting potential (IFN-, IL-17A and TNF-) is 
shown for each V9V2 T cell subset from six healthy peripheral blood PBMC 
samples.  Cell-secreting potential for the intracellular cytotoxic protein, perforin is 
also shown (bottom right).  V9V2 subsets are (28+) [CD28(+)CD27(+)], (28-) 
[CD28(-)CD27(+)], (16-) [CD28(-)CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)]. 
Red lines represent median values with statistical differences assessed using the 
Kruskal-Wallis one-way ANOVA test and multiple comparison post-hoc testing 
with Bonferroni correction (p-values < 0.05 were considered significant). 
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4.4 Proliferative potential 
4.4.1 Increased phosphoantigen-induced proliferation is observed in 
CD27(+) subsets compared to CD27(-) populations 
Proliferative potential was assessed in each of the four main V9V2 T cell 
subsets after 5 days of culture in vitro with HMB-PP (1nM) and IL-2 (100U/ml).  
Figure 4.5 shows a V9V2 T cell proliferation assay from a single 
representative individual.  Histograms showing membrane incorporation of the 
eFluor 670 proliferation dye (eBioscience) in V9V2 T cells, as well as for the 
individual V9V2 subsets are shown at day-0 and subsequently at day-5.  On 
day-5, 77.3% of the total V9V2 T cell population had proliferated in response 
to HMB-PP and IL-2, unlike the IL-2 only control, in which only 0.5% of the cells 
had divided.  On further analysis of the proliferating populations, it was apparent 
that the CD27(+) populations [(28+) and (28-) subsets] seemed to show a much 
higher proliferative capacity in comparison to those subsets not expressing 
CD27, with the percentage of cells with reduced levels of proliferative dye being 
81.7% for the (28+) subset, 82.1% for (28-) cells, 15.8% for (16-) cells, and 
51.6% for the (16+) population (Figure 4.5). 
Having repeated the assay three times for two different healthy volunteers who 
had all four of the main V9V2 T cell subsets, a similar proliferation pattern 
seemed to emerge (Figure 4.6).  Cells in the (16-) subset at day-5 showed 
significantly less proliferation when compared to the (28+) and (28-) subsets 
(all p < 0.05).  The (16+) population also showed significantly less proliferation 
in healthy volunteer 2 compared to (28+) and the (28-) subsets (p=0.003 and 
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Figure 4.5  CD27(+) V9V2 T cell subsets show high proliferative potential. 
Representative plots are shown from a single healthy volunteer.  PBMCs were 
initially loaded with eFluor 670 (eBioscience) and run to ensure even loading of 
cells at baseline.  PBMCs were then cultured with HMB-PP (1nM) + IL-2 
(100U/ml) over 5 days and then surface stained for V2, CD3, CD27, CD28 and 
CD16 at the end of this period.  Flow cytometry density plots show the gating of 
V9V2 subsets and histograms show eFluor670 expression and the percentage 
of non-proliferated and proliferated cells in each gated subset.  V9V2 subsets 
are defined as; (28+) [CD28(+)CD27(+)], (28-) [CD28(-)CD27(+)], (16-) [CD28(-) 
CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)]. 
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Figure 4.6  CD27(+) cells show the highest proliferation following 
phosphoantigen stimulation 
Graphs show percentage of proliferating cells in each V9V2 subset at 5-days 
following stimulation of PBMCs with HMB-PP (1nM) and IL-2 (100U/ml).  Scatter 
graphs of two different healthy individuals performed in triplicate are shown (all 
data points are shown). Mean percentage of proliferating subsets are shown for 
each V9V2 subset. Significant differences were assessed using one-way 
ANOVA with Tukey’s multiple comparison correction (p-values are stated). V2 
subsets are defined as; (28+) [CD28(+)CD27(+)] (red), (28-) [CD28(-)CD27(+)] 
(yellow), (16-) [CD28(-)CD27(-)CD16(-)] (blue) and (16+) [CD28(-)CD27(-)CD16(+)]
(green). 
In both volunteers the (16+) subsets showed a higher median percentage 
expression compared to the (16-) subset but this difference was not significant 
(p > 0.05).  The results from these proliferation assays therefore suggests that 
the CD27 co-stimulatory molecule seems to be a key marker in identification of 
V9V2 cells capable of proliferation in response to HMB-PP and IL-2. 
147 
4.5 Gene microarray on newly-defined V9V2 subsets 
At this point, having characterised the newly-defined V9V2 T cell subsets 
using a range of basic functional read-outs, it was decided to use a gene 
expression microarray to further assess these  T cell populations.  The four 
main subsets; (28+), (28-), (16-) and (16+) cells, were sorted to >90% purity.  
Due to its small size, the (N) subset was included as part of the (28+) subset. 
Figure 4.7 gives a summary overview of the sorting and processing of each 
V9V2 subset for gene microarray analysis. 
Seven healthy individuals were used to purify three subset replicates for each of 
the four main V9V2 T cell subsets.  In order to generate sufficient RNA for 
microarray analysis, a certain number of sorted cells (106) needed to be 
collected for each subset.  Thus, it was necessary to use several different 
individuals from a range of phenotypic signatures to provide adequate yields.  In 
addition, individuals with a high V2/CD3(%) were chosen in order to maximise 
the number of sorted events to be collected for each subset (Figure 4.8). 
Therefore having generated 12 RNA samples (each of the four subsets in 
triplicate) of sufficient quantity.  RNA integrity was then determined using a 
bioanalyser and all samples had a RIN score of > 7.5 and were assessed to be 
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37.4 58.2 19.1 26.4
Figure 4.7  Enrichment, sorting and processing of V9V2 subsets for gene microarray. 
Isolation of four subsets of V9V2 T cells by (A) Initial enriching PBMCs for V9V2 T cells by Magnetic Activated Cell Sorting (MACS) followed 
by (B) Fluorescence-activated cell sorting (FACS) using CD28, CD27 and CD16 extracellular markers to isolate four subsets; (28+) 
[CD28(+)CD27(+)], (28-) [CD28(-)CD27(+)], (16-) [CD28(-)CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)]. (C) Preparation of cRNA was carried out 
by RNA extraction followed by reverse transcription to generate cDNA samples. Finally the production of biotinylated cRNA samples for array 





























1 28 M Arabic 2 12.3 
2 24 F 
White 
British/Irish 
3 21.9  
3 27 F 
White 
European 
3 8.4   
4 50 F 
White 
British/Irish 
5 19.0   




6 27 F Chinese 4 10.3 




























































































Figure 4.8  Summary of healthy volunteer samples used for V9V2 T cell subset 
purification. 
Details of the healthy donors used to generate V9V2 T cell subsets for gene 
microarray analysis.  Three separate sorted subsets were obtained for each V9V2 T 
cell subset.  A range of donors with different phenotypic signatures was required in 
order to generate sufficient RNA for the array.  Age, gender and ethnicity is shown 
along with V2/CD3(%) and  V9V2 T cell phenotypic signature (1-6).  The subsets 
obtained from each individual are indicated along with their CD28/CD27 profile. 
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Following production of cDNA from RNA by reverse transcription, and 
subsequent production of cRNA as previously described in the material and 
methods, RNA was hybridised to the array overnight and finally stained with 
streptavidin Cy5 before being read on the illumina iScan (microarray scanner).  
Unfortunately, two of the (16-) subsets failed to generate data for unknown 
experimental reasons and so the results presented for the (16-) subset are from 
only a single sample. 
4.5.1 Initial microarray validation 
To initially validate the array data, the average expression signal was assessed 
for the three genes that were used to identify and sort the four V9V2 subsets; 
CD28, CD27 and CD16.  Figure 4.9 shows that both CD28 and CD27 show 
gene expression levels from the array that directly correlate with the surface 
expression used to identify the subsets.  Interestingly, CD16 gene expression, 
whilst increasing across the four subsets and being highest in the (16+) subset 
was not statistically significantly higher in the (16+) subset than the (28+), (28-) 
or (16-) subsets.  However, taken together, the expression of CD28, CD27 and 
CD16 seemed to validate the microarray data. 
4.5.2 Gene microarray analysis 
Figure 4.10 shows a schematic outlining the approach to the gene microarray 
analysis for the 47,231 gene probes for each of the subsets.  As shown in the 
figure, the initial analysis determined the number of differentially expressed 
genes (> 2 fold different and p < 0.05) between the four subsets, which is 
shown in Figure 4.11. 
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Figure 4.9 Initial validation of microarray 
Assessment of mRNA expression levels for CD28, CD27 and CD16 determined 
by microarray analysis. Bar charts show the Average Signal Intensities  
(fluorescence units on linear scale) of analysed subsets relative to each other. 
Background levels are indicated by the red line (Average Signal Intensity = 100 
fluorescence units). The heat-map shown below each graph indicate the relative 
difference in expression across all four subsets see log10 scale (bottom) showing 
gene expression levels ranging from background level=2 (Log10100) fluorescent 




Figure 4.10 Schematic summary of gene microarray analysis strategy for V9V2 T cell subsets. 
The gene microarray carried out analysed the transcriptome expression of the sorted RNA samples extracted from the four main V9V2 T cell 
subsets using 47,231 known gene probes.  V9V2 T cell subsets were characterise as follows; (28+) [CD28(+)CD27(+)] (red box), (28-) 














Figure 4.11 Total number of differentially expressed genes between V9V2 
T cell subsets. 
Schematic shows the total number of differentially expressed gene probes when 
different V9V2 T cell T cell subsets are compared.  Differentially expressed 
genes are > 2 fold different in expression levels (p < 0.05) (Bonferroni corrected). 
4.5.3 The (28+) and (16+) V9V2 T cell subsets show most distinct 
expression profiles 
The most different subsets in terms of expression profile were the (28+) and 

(16+) populations (359 differences).  This supports the view that they are 
located at either end of a differentiation pathway.  Interestingly, if the four 
subsets are ordered by placing the most similar together and the most different 
apart, in terms of the number of differentially expressed genes between the 
subsets, this also support the hypothesis that V9V2 T cells differentiate 
sequentially from (28+) to (28-) to (16-) and finally to (16+).  Following this line 
of reasoning, the most similar populations appear to be the (28-) and (16-) 
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subsets.  This could suggest that these are transitional populations that 
represent a bridge between the more distinct populations that are the (28+) and 

(16+) subsets. 
This proposed sequence of differentiation is also supported when an alternative 
approach to differential analysis is taken i.e. when individual V9V2 T cell 
subsets are compared to remaining subsets grouped together as shown in 
Figure 4.12.  This alternative method of differential analysis also supports the 
observation that (28+) and (16+) are the most distinct V9V2 T cell population 
subsets, with 81 differentially expressed genes in the (28+) subset and 142 in 
the (16+) subset compared to remaining grouped subsets.  Again, the (28-) and 

(16-) subsets showed the least number of differentially expressed genes (0 and 
6 differentially expressed genes respectively) compared to all other subsets 
grouped together, further supporting the proposition that they are transitional 
populations. 
4.5.4 Further microarray analysis 
Having identified the total number of differentially expressed genes between the 
four subsets, the list of genes was narrowed down to select those with obvious 
immune function.  The full lists of immune-related differentially expressed genes 
are shown in figures 4.13 - 4.15 showing gene name/symbol, fold difference, 
p-value, heat-maps and gene function.  No differentially expressed genes were 
observed when (28-) cells were compared to other grouped subsets (Figure 
4.12) and so differentially expressed immune-related gene comparisons are 
only shown for the (28+), (16-) and (28-) subsets compared to the other 
grouped subsets. 
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Figure 4.12  Total number of differentially expressed genes between individual 
V9V2 T cell subsets and the other populations grouped together.  
Schematic shows the total number of differentially expressed gene probes when 
different V9V2 T cell subsets are compared against all other grouped V9V2 
subsets.  Differentially expressed genes are >2 fold different in expression levels 
(p<0.05 – Bonferroni corrected).  Genes with obvious immune function/links are 






(28+) subset vs. [(28-), (16-) and (16+)] grouped subsets. 
Log10 Avg.  
Signal 
V9V2 T cell subset 












1 GZMK granzyme K 5.9 <0.0001 Serine protease involved in cytotoxicity. 
2 CCR6 chemokine receptor 6 4.0 <0.0001 
Chemokine receptor regulating T cell migration during inflammation. Skin homing 
marker associated with IL-17 production. 
3 LTB lymphotoxin-beta 4.0 <0.0001 
Type II membrane protein involved lymphoid tissue development and a direct 
inducer of inflammatory responses. 
4 PDE4B phosphodiesterase 4B 3.6 <0.0001 Regulatory second messenger enzyme involved in TCR signaling. 
5 MYC 
v-myca avian myelocytomatosis viral 
oncogene homolog 
3.2 <0.0001 Transcription factor induced during T cell activation. 
6 CD28 Cluster of differentiation 28 2.8 <0.0001 Co-stimulatory receptor involved in assisting TCR signaling. 
7 RORC RAR-related orphan receptor gamma C 2.6 <0.0001 
Transcription factor expressed by Th17 cells. Involved in thymopoiesis and 2 
lymphoid tissue formation. 
8 IL23R interleukin 23 receptor 2.4 <0.0001 Type I cytokine receptor that binds IL-23 and associated with Th17 phenotype 
9 FAM46C 
family with sequence similarity 46, 
member C 
2.2 <0.0001 Involved in type I interferon responses. 
10 GPR56 G-protein coupled receptor 56 7.4 <0.0001 
G-protein coupled receptor protein involved in cell guidance and adhesion on 
cytotoxic lymphocytes. 
11 CX3CR1 chemokine (C-X3-C motif) receptor 1 7.3 <0.0001 
Transmembrane chemokine receptor involved in cell adhesion and migration of 
activated lymphocytes. 
12 GZMB granzyme B 5.4 <0.0001 Cytolytic serine protease enzyme found in cytotoxic T cell granules. 
13 GNLY granulysin 4.2 <0.0001 
 
Cytolytic molecule in lymphocytes and chemoattractant for inflammatory cells. 
14 GZMH granzyme H 4.1 <0.0001 
 
Cytotoxic serine protease found in cytotoxic T cell granules involved in cell lysis. 
15 LAIR2 
leukocyte-associated immunoglobulin-
like receptor 2 
3.4 <0.0001 
 
Leukocyte-associated immunoglobulin-like receptor 2 and member of Ig superfamily. 
16 ITGB1) integrin beta 1 (CD29) 2.8 <0.0001 
 
Integrin involved in cell adhesion and extravasation of T cells. 
17 PRF1 perforin 1 2.6 <0.001 Cytolytic protein found in cytotoxic granules of cytotoxic lymphocytes. 
18 ITGAM integrin, alpha M (CD11b) 2.2 <0.0001 
Integrin adhesion molecule regulating adhesion/migration in phagocytosis. Involved 
in cell-mediated cytotoxicity. 
19 HSPA6 heat shock protein 6 2.1 <0.0001 
Chaperone protein stabilising proteins against aggregation. Induces cytotoxic 
responses in lymphocytes. 
20 MYO1G myosin IG 2.1 <0.0001 Plasma cell membrane myosin – Immunogenic peptide involved in T cell activation. 
Figure 4.13  Differentially expressed genes with immune function in 
(28+) T cells compared to the other three subsets grouped together
Table of genes indicates immune-related genes differentially expressed at > 2 fold difference (p < 0.05) in (28+) cells compared to all non-(28+) 
T cell subsets assessed as a group (others).  The gene name, fold change, p-value, description of the gene, and heat map are indicated for 
each differentially expressed gene.  The heat-maps indicate the relative difference in expression across populations showing gene expression 
levels ranging from background levels (black) to highest gene expression (red).  Heat map scale values are log10 transformed average signal 
intensities (fluorescence units).  Gene symbols indicated in red are highest in the (28+) subset with genes in black indicating genes significantly 





(16-) subset vs. [(28+), (28-) and (16+)] grouped subsets. 
 Log10 Avg. Signal 
V9V2 T cell subset 










cluster of differentiation 
8A 
2.7 <0.0001 
Cell surface glycoprotein on surface of cytotoxic lymphocytes. Co-receptor 
along with TCR recognises antigen on MHC Class I. Possible role in T-cell 
mediated killing. 
Figure 4.14  Differentially expressed genes in CD28(-)CD27(-)CD16(-) V2 T cells.
Table indicates the single immune-related gene differentially expressed at >2 fold difference (p < 0.05) in (16-) cells compared to all non-(16-) T 
cell subsets assessed as a group (others).  The gene name, fold change, p-value, description of the gene, and heat map are indicated for the 
only immune-related differentially expressed gene.  The heat-map indicates the relative difference in expression across populations showing 
gene expression levels ranging from background levels (black) to highest gene expression (red).  Heat map scale values are log10 transformed 





(16+) subset vs. [(28+), (28-),(16-)] grouped 
Log10 Avg.  Signal 













1 CD3E CD3 epsilon chain 4.0 <0.0001 
Forms part of TCR. Involved in antigen recognition, T cell development and 
signalling. 
2 LSP1 lymphocyte specific protein-1 2.6 <0.0001 Intracellular F-actin binding protein. Involved in trans-endothelial migration. 
3 KIR2DL3 
killer cell Ig-like receptor, two 
domains, long cytoplasmic tail, 3 
2.6 <0.0001 
Transmembrane regulatory glycoprotein and inhibitory receptor on the surface 
of cytotoxic lymphocytes preventing cell lysis. 
4 PACS1 
phosphofurin acidic cluster sorting 
protein 1 
2.5 <0.0001 
Coats proteins and controls localisation of trans-golgi network membrane 
proteins. 
5 KIR2DL4 
killer cell Ig-like receptor, two 
domains, long cytoplasmic tail, 4 
2.4 0.0058 
Intracellularly expressed regulatory glycoprotein inside endosomes in cytotoxic 




Rho guanine nucleotide exchange 
factor (GEF) 1 
2.4 0.001 
Intracellular signalling molecule involved in cell mobility and migration and TH2
cytokine responses and T cell signalling. 
7 FCAR Fc fragment of IgA receptor (CD89) 2.4 <0.0001 
Transmembrane glycoprotein on T cell surface involved in phagocytosis, cell-
mediated cytotoxicity, and inflammatory mediator release. 
8 LY6E 
lymphocyte antigen 6 complex locus 
E 
2.4 <0.0001 Involved in signal transduction. 
9 BCL9L B-Cell CLL/lymphoma 9-like 2.3 <0.0001 Transcriptional regulator. 
10 SMAD7 SMAD family member 7 2.2 0.0025 TGFB Type I receptor antagonist. Inhibits TGFB signaling. 
11 STXBP2 syntaxin binding protein 2 2.1 <0.0001 
Protein involved in intracellular trafficking. Release of cytotoxic granules from 
cytotoxic cells. 
12 ITGB1 integrin, beta 1 (CD29) 2.0 0.0185 
Integrin involved in cell adhesion, recognition and facilitating extravasation of   
T cells. 
13 ABI3 ABI gene family member 3 2.0 <0.0001 Adaptor protein that inhibits tumour metastasis and reduces cell motility. 
14 CD27 cluster of differentiation 27 12.4 0.0004 
TNF-receptor (Co-stimulatory molecule) involved in TCR signalling and co-
stimulation. 
15 CD160 cluster of differentiation 160 3.4 0.0006 




associated protein 1 
2.4 <0.0001 
Involved in cell mobility and migration. Perinuculear mitogen induced GTPase 
activating protein (GAP). Reduces T cell adhesion to ICAM. 
17 HMHA1 histocompatibility (minor) HA-1 2.2 <0.0001 Histocompatibility antigen involved in cytotoxic responses. 
18 SIRPG 
signal-regulatory protein gamma 
(CD172G) 
2.1 <0.0001 
Transmembrane glycoprotein and negative regulator of tyrosine kinase 
signalling processes 
19 IRF1 interferon regulatory factor 1 2.1 <0.0001 Regulatory transcription factor, induces cytotoxic function in T cells 
Figure 4.15  Differentially expressed genes with immune function in (16+) T cells compared to the other three subsets grouped together 
Table of genes indicates immune-related genes differentially expressed at > 2 fold difference (p < 0.05) in (16+) cells compared to all non-(16+) 
T cell subsets assessed as a group (others).  The gene name, fold change, p-value, description of the gene, and heat map are indicated for 
each differentially expressed gene.  The heat-maps indicate the relative difference in expression across populations showing gene expression 
levels ranging from background levels (black) to highest gene expression (red).  Heat map scale values are log10 transformed average signal 
intensities (fluorescence units).  Gene symbols indicated in red are highest in the (16+) subset with gene symbols in black indicating genes 
significantly higher in the grouped non-(16+) subsets. 
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4.5.5 Transition from (28+) to (28-) subsets coincides with 
transcriptional regulation of cytotoxic proteins. 
The expression of a number of cytotoxic proteins showed a significant 
upregulation in the three grouped CD28(-) populations (the (28-), (16-) and 

(16+) subsets), relative to the (28+) subset (p < 0.05).   These upregulated 
genes included; GZMB - Granzyme B (5.4-fold increased), GZMH - 
Granzyme H (4.1-fold increased) GNLY - Granulysin (4.2-fold increased), 
GPR56 - G-protein coupled receptor 56 (7.4-fold increased) and PRF1 - perforin 
(2.6-fold increased) (Figure 4.13).  Thus, the transition from the (28+) subset to 
the (28-) i.e. the downregulation of CD28, appears to be the point at which 
many important cytotoxic genes increase their expression levels in V9V2 T 
cells.  This may indicate a significant point in V9V2 T cell differentiation in 
which cells switch to a more cytotoxic phenotype. 
One exception to this pattern of cytotoxic protein expression was seen in 
Granzyme K, which was significantly higher in (28+) cells compared to CD28(-) 
populations (p < 0.0001).  Validation of the expression of Granzyme B and 
Granzyme K were carried out using flow cytometry (Figure 4.16 and 4.17).  This 
showed an opposing pattern of expression in which a higher percentage of 
Granzyme B was observed in the CD28(-) populations compared to (28+) cells, 
which reached statistical significance when the (28+) and (16-) subsets were 
compared (p=0.003).  By contrast, expression of Granzyme K was 
predominantly seen in the (28+) subset, with significantly higher percentage of 
Granzyme K(+) cells compared to the CD27(-) subsets ((16-) (p=0.04) and (16+) 






























































































Figure 4.16  Granzyme B and Granzyme K expression for V9V2 T cell subsets. 
Flow cytometry dot plots showing expression of Granzyme K and Granzyme B for V9V2 T cell subsets in a single representative sample.  
V9V2 T cell subsets are defined as; (28+) [CD28(+)CD27(+)](red box), (28-) [CD28(-)CD27(+)] (yellow box), (16-) [CD28(-)CD27(-)CD16(-)] (blue 
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*p < 0. 1 
*p < 0. 1 
*p = 01 
*p < . 001 
*p < 0.0001 
*p < .0001 
*p = 002 
*p = .0 3 
*p = .0005 
*p = 0.037 
*p  0.012 
*NS – p > 0.05 multiple comparisons 
Figure 4.17  Summary of expression levels of granzyme B and granzyme K on V9V2 T cell subsets. 
Microarray data for granzyme B and granzyme K are shown for V9V2 T cell subsets (A and C), with transcript intensities (fluorescence units) 
shown for each subset replicate. Flow cytometry data from five healthy individuals showing percentage of V9V2 T cell subset that express 
granzyme B or granzyme (B and D) and the median fluorescent intensities (MFIs) for positive cells.  V9V2 T cell subsets are defined as; (28+) 
[CD28(+)CD27(+)], (28-) [CD28(-)CD27(+)], (16-) [CD28(-)CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)]. Median values are indicated in red. 
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4.5.6 Genes associated with an IL-17 secreting phenotype are 
expressed in the (28+) subset 
Chemokine (C-C Motif) Receptor 6 (CCR6), Interleukin-23 Receptor (IL-23R) 
and RAR-Related Orphan Receptor C (RORC) are associated with an IL-17 
producing phenotype.  Interestingly, the array data revealed that these genes 
are expressed at significantly higher levels in the (28+) subset compared to the 
CD28(-) populations (p <0.0001) (Figure 4.13).  Following the downregulation of 
CD28, these IL17-associated genes demonstrated a complete loss of 
expression in the subsequent (28-), (16-) and (16+) subsets, suggesting that 
the (28+) population is the only subset with the transcriptional machinery to 
potentially produce IL17. 
However, although the expression of these IL-17-associated genes might be 
necessary to produce this pro-inflammatory cytokine, they are clearly not 
sufficient, as there was little or no production of IL-17 in any of the V9V2 T 
cell subsets when intracellular cytokine production was assessed (Figure 4.4).  
Nonetheless, future work will attempt to differentially generate IL-17-secreting 
 T cells (something that heretofore has proved problematic), using this new 
valuable insight into which  T cells may be capable of secreting this cytokine. 
4.5.7 CCR6 and CX3CR1 show opposing patterns of gene expression in 
V9V2 T cell subsets 
The microarray data indicated that chemokine receptors CCR6 and CX3CR1 
showed opposing patterns of expression when (28+) cells were compared with 
the other CD28(-) populations (Figure 4.13).  Whilst CCR6 seemed to be 
exclusively expressed in the (28+) subset, CX3CR1 seems to be low in the 
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
(28+) subset and increase significantly in the CD28(-) subsets (p < 0.0001).  
Once again, the downregulation of CD28 seemed to represent a significant 
point in the transition of expression for these chemokine receptors.  Thus, to 
validate the array data, flow cytometry was used to investigate the expression of 
CCR6 and CX3CR1 on the cell surface of all V9V2 T cell subsets in 5 
different healthy individuals (Figure 4.18 and Figure 4.19).  As suggested by the 
array, CCR6 was exclusively expressed on a significant proportion (30-40%) of 
the (28+) population and was absent from the three CD28(-) subsets.  By 
contrast, CX3CR1 was expressed predominantly in the CD28(-) subsets, but 
was also expressed by a significant proportion of the (28+) subset 
(median=42.5%).  Quite strikingly, the expression of CCR6 and CX3CR1 in the 

(28+) subset was mutually exclusive, seeming to neatly divide the (28+) subset 
into two distinct further subsets i.e. a CCR6(+)CX3CR1(-) and a CCR6(-)
CX3CR1(+) subset.  This suggests that within the (28+) subset, there are two 
distinct subsets with a potentially important further transition between the two. 
4.5.8 Adhesion and migration associated proteins increase across the 
four V9V2 T cell subsets 
Genes associated with a number of adhesion and migratory proteins also seem 
to show a consistent pattern of change across the four V9V2 T cell subsets. 
G-protein coupled receptor 56 (GPR56), integrin alpha M (ITGAM), and integrin, 
beta 1 (ITGB1) all show significantly increased expression in the three CD28(-) 









































































































Figure 4.18  CCR6 and CX3CR1 expression subdivides (28+) V9V2 T cells into two further distinct subsets.
Flow cytometry dot plots showing expression of CCR6 and CX3CR1 on V9V2 T cell subsets.  CCR6/CX3CR1 bi-variate plots are also shown 
to show the relationship of both markers relative to each other on each V9V2 subset. V9V2 subsets are defined as; (28+) [CD28(+)CD27(+)] 







































































































































































































































*p < . 01 
*p < 0.0001 





*p  .0 01 
*p < 0.0001 
*p < 0.0001 
*p  0.0004 
*p < .0001 
Figure 4.19  Summary of expression levels of CCR6 and CX3CR1 on V9V2 T cell subsets. 
Microarray data for CCR6 and CX3CR1 are shown for V9V2 T cell subsets (A and C), with transcript intensities (fluorescence units) shown for 
each subset replicate. Flow cytometry data from five healthy individuals showing the percentage of each V9V2 T cell subset that express 
CCR6 or CX3CR1 (B and D) and the median fluorescent intensities (MFIs) for positive cells are shown.  V9V2 T cell subsets are defined as; 

(28+) [CD28(+)CD27(+)], (28-) [CD28(-)CD27(+)], (16-) [CD28(-)CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)]. Median values are indicated in 
red. 
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Rho guanine nucleotide exchange factor 1 (ARHGEF1) and lymphocyte-specific 
protein 1 (LSP1) also demonstrate this same increase across the subsets, but 
are expressed significantly higher in the (16+) subset compared to the three 
CD16(-) subsets (Figure 4.15).  Overall there seems to be an increase in the 
expression of genes associated with adhesion and migration in (16+) subsets 
compared to the (28+) cells, suggesting an increased ability to home to tissues 
and sites of inflammation/infection. 
4.5.9 Increase in KIR regulatory proteins in the (16+) subset 
Two of the Killer cell Ig-like Receptor regulatory genes (KIR2DL3 and KIR2DL4) 
were both significantly differentially expressed in the (16+) subset compared to 
all the three CD16(-) populations with respective fold difference and p-values of 
(fold change 2.6, p < 0.001) and (2.4 fold change, p = 0.006) (Figure 4.15).  The 
surface expressed receptor KIR2DL3 is as an inhibitory receptor thought to 
regulate cytotoxic T cell responses, with the related KIR2DL4 receptor only 
expressed inside endosomes and conversely thought to be mildly pro-
inflammatory in regulating pro-inflammatory cytokine release from cells (e.g. 
IFN-, TNF- and IL-1) (Rajagopalan and Long 2012). 
4.6 Summary 
In general, all V9V2 T cell subsets produce IFN- and TNF-, but not IL-17. 
The (28+) and (28-) subsets (i.e. the CD27(+) populations) demonstrated the 
highest proliferative potential.  The (N) subset, identified as [CD27(Hi)CD11a(Lo)] 
expressed high levels of CCR7 and CD62L but displayed a wide range of 
CD45RA expression.  The (28+) subset seemed to be the most distinct of all 
the populations, containing two further non-overlapping subsets, defined by 
167 
mutually exclusive expression of CCR6 and CX3CR1 (i.e. CCR6(+)CX3CR1(-) 
and CCR6(-)CX3CR1(+) subsets).  (28+) cells was also characterised by high 
levels of CCR2 and CCR5 surface expression, low CD45RA expression and 
interestingly high levels of RORC, IL-23R and CCR6, three genes associated 
with the secretion of IL-17.  (16+) cells also appeared to represent a distinct 
cytotoxic subset, expressing the highest levels of CD45RA, the lowest levels of 
CCR2 and CCR5 and the highest level of Perforin.  (16+) cells additionally 
showed the highest transcriptional levels of a number of cytotoxicity-associated 
genes including perforin, granzyme B, granzyme H and granulysin.  (28-) and 

(16-) subsets appear to be much less distinct in terms of surface marker and 
gene expression, possibly representing transitional cell populations, with 
intermediate levels of gene expression between the predominant and more 
distinct (28+) and (16+) subsets. 
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Chapter 5 Probability state modelling of  T cell 
differentiation 
5.1 Introduction 
One of the main problems with multi-parameter flow cytometry data is the 
difficulty in understanding how multiple parameters relate to each other within a 
single sample.  Whilst the identification of subsets is straightforward when using 
just two markers, it becomes extremely challenging when multiple markers are 
used. 
Furthermore, there is a high degree of user subjectivity when setting gates and 
deciding which cells to investigate further.  Thus, there exists a pressing need to 
remove these biases, and return to a more objective method of analysis.  In 
relation to the work of this thesis, the hypothesis that V9V2 T cells 
differentiated through a series of stages, for example from (28+) to (28-) to 

(16-) to (16+), was difficult to test using conventional manual methods of FACS 
analysis, due to the multiple markers used, and the widely differing phenotypes 
of our cohort of healthy volunteers.  Thus we used a relatively new analysis tool 
called Probability State Modelling (PSM), using the GemStone software from 
Verity Software House to assess our multiple datasets in as unbiased a manner 
as possible.  This software allows all parameters to be visualised on a single 
plot, removing the subjectivity of user-defined gating, and allowing possible 
pathways of differentiation to be modelled objectively. 
170 
5.2 Generating a probability state model (PSM) for human 
V9V2 T cells 
To generate a probability state model (PSM) for any system of cell 
differentiation a number of assumptions need to be made.  First, it should be 
assumed that the various phenotypes that can be identified by flow cytometry 
represent stages along a pathway of differentiation.  For V9V2 T cells based 
on the literature (Dieli et al. 2003b, Puan et al. 2009, De Rosa et al. 2004, 
Yokobori et al. 2009, Angelini et al. 2004) and our aforementioned studies, we 
would propose a differentiation pathway that started with the (28+) subset and 
ended with the (16+) subset with the (28-) and (16-) subsets placed tentatively 
in the middle.  Additionally, for each of the markers considered in the model (i.e. 
V2, CD3, CD28, CD27, CD16, CD45RA and CD11a.) a likely progression (e.g. 
start high, end low, or constant throughout etc.) should be inputted to guide 
generation of the model.  The software then uses these assumptions to 
generate a model that represents the real expression values of the various cells 
in the samples run on the flow cytometer. 
Figure 5.1 shows some of the expression level assumptions used to generate a 
model for V9V2 T cell differentiation.  These include; CD27- 3-step down; 
CD28- 2-step down; CD16- 2-step up; CD45RA- 3-step, down followed by step-
up; and CD11a- 2-step up.  To generate an average PSM for V9V2 T cell 
differentiation we used 15 healthy volunteer samples.  It was important to select 
individuals with all four subsets so that any relationships between these 
populations could be modelled.  Thus, fifteen individuals with phenotypic 
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Figure 5.1  Expression level assumptions for various markers used to 
generate a probability state model (PSM) for V9V2 T cell differentiation. 
(A) Shows the assumed changes in surface marker expression intensity used to 
generate a PSM for V9V2 T cell differentiation.  (B) Shows an example of the 
surface marker intensity of sequential markers input into GemStone to generate 
the PSM model from the assumed changes indicated in (A). 
Using the 15 samples, the GemStone software was able to generate an 
average PSM for V9V2 T cell differentiation.  Essentially, the software uses 
the basic assumptions for the expression of the various markers to try to order 
the cells in a differentiation pathway.  As an example, we used a simple “step-
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down” rule for CD28 i.e. CD28 expression starts high and then at some point is 
downregulated.  The software uses this rule to place cells with high CD28 at the 
start, with those with low CD28 placed at the end.  It then sees whether the next 
rule for the next marker is compatible with the suggested order of cells, and so 
on.  A model will only be generated if the cells can be ordered in a way that 
satisfies all the rules.  Figure 5.2 shows the average PSM for the 15 selected 
samples.  The relative intensity of each marker expression as cells progress 
along a proposed differentiation pathway is shown.  “Control Definition Points” 
(CDPs) indicated by white diamonds show the average point at which a surface 
marker changes, with “d” indicating the distance (%) along the cumulative 
progression (i.e. % of events between the start and end of the transitional 
change on the cumulative progression axis) and r indicating the correlation 
coefficient for each statistically significant transitional change (p < 0.01).  The 
thickness of each line represents the 95% confidence limits of relative intensity 
of each marker. 
5.3 The PSM suggests that the (28-) and (16-) subsets are 
not distinct, but instead represent transitional 
populations 
According to the PSM created for V9V2 T cell differentiation (Figure 5.2) the 
initial (N) subset is characterised as [CD27(Hi), CD11a(Lo), CD45RA(+), CD28(+), 
CD16(-)] and is only a small population making up 2% of the total V9V2 T cell 
pool.  This population is followed by the (28+) subset, representing over 50% of 
V9V2 T cells and characterised as [CD28(+)CD27(+)CD45RA(-)CD16(-)]. 
Figure 5.2  Average probability state model for V9V2 T cell differentiation. 
An average probability state model derived from 15 healthy volunteers is shown for the markers (CD28, CD27, CD11a, CD16, and CD45RA) on 
V2(+)CD3(+) T cells.  The relative intensity (%) of surface marker expression (y-axis) is indicated along a cumulative progression axis (x-axis), 
which acts as a surrogate measure of time.  White diamonds indicate Control Definition Points (CDPs), which show the average position along 
the cumulative progression axis at which each marker expression changes.  Dotted lines indicate the distance along the cumulative progression 
axis (d) between CDPs at the start and end of transitional change.  Correlation coefficients (r-values) are indicated for each statistically 





The next transition involves the downregulation of CD28 which consistently 
occurs before CD27, and gives rise to the (28-) subset [CD28(-)CD27(+)]. 
However, following downregulation of CD28 there is a period of dynamic marker 
change that involves upregulation of CD16 and CD45RA and downregulation of 
CD27.  This somewhat blurs a boundary between the (28-) and (16-) subsets 
and suggests that cells with these features are undergoing a transitional phase 
in which 3 markers may change at about the same time.  Finally, a stable end 
population emerges, the (16+) subset [CD27(-) CD28(-)CD16(+)CD45RA(+)]. 
5.4 V9V2 T cells do not share the same differentiation 
pathway as  T cells. 
Having constructed a PSM for V9V2 T cells that suggested a (28+) (28-)
/(16-)  (16+) differentiation sequence, we next compared this model to one 
for  T cells from the same individual.  Figure 5.3 shows a comparison of 
PSMs from a single person for both V9V2 T cells and TCR (-) CD3(+) T cells
(predominantly  T cells). 
This demonstrates that V9V2 T cells do not follow a similar differentiation 
pathway to conventional  T cells.  For example, for  T cells, four distinct 
subsets are seen on a CD27/CD45RA plot with the PSM clearly predicting a 
CD27(+)CD45RA(+)CD27(+)CD45RA(-)CD27(-)CD45RA(-)CD27(-)CD45RA(+) 
differentiation pathway, as suggested by numerous studies (Okada et al. 2008, 
Libri et al. 2011, Di Mitri et al. 2011).  However, despite a similar pathway being 
suggested in the literature for V9V2 T cells (Dieli et al. 2003b), the PSM 
predicts something quite different (Figure 5.3), confirming our initial view that 




Figure 5.3  Probability state model for V9V2(+) and V9V2(-) T cells suggest a different sequence of differentiation. 
(A) Probability State Modelling (PSM) progression plots are shown for V9V2(+) and V9V2(-) T cells (predominantly  T cells), for a single 
healthy volunteer PBMC sample using surface markers (CD27, CD45RA, CD28, CD11a and CD16) on V2(+)CD3(+) T cells.  White diamonds 
indicate control definition points (CDPs) at which each surface marker expression changes. The thickness of each band is proportional to the 
95% confidence limits. Colour key for surface marker lines; Pink=V2, Orange=CD3, Red=CD28, Yellow=CD45RA, Green=CD27, Light 
blue=CD11a, Dark blue=CD16, Light green =SSC-A and Light red FSC-A.  Major subsets (I-IV/V) are indicated on top of each progression plot 
as modelled by PSM with percentage in each subset indicated below.  (B)  Two parameter density plot histograms (CD27 v CD45RA) and 
(CD27 v CD28) are shown for V9V2(+) and V9V2(-) T cells from the same individual with arrows indicating the proposed differentiation 
pathway. 
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This difference in proposed differentiation is also clearly evident.  From the 
PSMs translated onto CD27/CD28 plots.  A major difference here is the order of 
CD28 and CD27 downregulation, with CD28 preceding CD27 for V9V2 T 
cells, but CD27 preceding CD28 for  T cells (Figure 5.3). 
5.5 Summary 
The use of probability state modelling allowed the relationship of multiple 
markers to be determined in V9V2 T cells.  Overall, PSM confirmed the 
existence of two major V9V2 T cell populations; (28+) and (16+), at the 
possible start and end of a proposed differentiation process, with intermediate 
transitional populations (28-) and (16-) that perhaps should be considered as a 
single population, in between.  Importantly, whilst PSM modelling confirms the 
much-published differentiation pathway of conventional  T cells i.e. 
CD27(+)CD45RA(+)CD27(+)CD45RA(-)CD27(-)CD45RA(-)CD27(-)CD45RA(+), 
it suggests that this is not appropriate for V9V2 T cells. 
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Chapter 6 A comparison of V9V2 T cells with 
V1
(+)
 T cells 
6.1 Introduction 
For V9V2 T cells, CD28, CD27 and CD16 were more appropriate markers for 
identifying distinct subsets compared to the much-used CD27 and CD45RA 
method.  However, it was not clear whether this could also be applied to the 
less extensively studied V1(+) T cells.  Indeed, relatively little is known 
(published) about the surface phenotype of these cells.  Therefore, this chapter 
will investigate the surface markers on these cells and determine whether the 
newly-proposed system of V9V2 T cell identification is also appropriate for 
V1(+) T cells. 
6.2 The CD27(Hi) CD11a(Lo) “naïve” subset is significantly 
higher for V1(+) T cells compared to V9V2 T cells 
As was shown in Figure 3.9, the “naïve” subset for V9V2 T cells as defined as 
[CD27(Hi) CD11a(Lo)] is a very small population that is often absent or difficult to 
detect.  However, it seems to constitute a significantly larger proportion of V1 T 
cells with a median percentage of 35.9% (range 0.9-73.5%) compared to only 
0.8% (0.1-14.0%) for V9V2 T cells (Figure 6.1).  The majority of these “naïve” 
cells are CD45RA(+) and overall CD45RA expression is significantly higher in 
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*p < 0.
Figure 6.1  “ aïve” [CD27(Hi) CD11a(Lo)] V1(+) T cells are significantly more 
abundant than “naïve” V9V2 T cells. 
(A) Representative dot plots comparing [CD27(Hi)CD11a(Lo)] naïve and CD11a(Hi) 
non-naïve subsets of V9V2 T cells and V1(+) T cells in a single healthy 
individual.  Percentage of each gated population is indicated.  (B) Summary 
scatter plot comparing the percentage of total  T cells expressing the naïve 
phenotype [CD27(Hi)CD11a(Lo)] in V9V2 T cells (N=63) and V1(+) T cells (N=30) 
from healthy volunteer peripheral blood samples.  Median values are indicated as 
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*p < 0.0001
Figure 6.2  CD45RA expression is significantly increased on V1(+) T cells. 
Summary scatter plot comparing the percentage of CD45RA expression in 
V9V2 (N=63) and V1(+) (N=30) T cells in healthy volunteer peripheral blood 
samples.  Median values are indicated as a red bar with statistical differences 
compared using Mann-Whitney U test with p-value indicated. 
6.3 CD27/CD45RA identifies distinct subsets of V1(+) T cells. 
Figure 6.3 shows a comparison of V9V2 T cells, V1(+) and (-) CD3(+) T cells 
stained with CD27 and CD45RA from a single healthy peripheral blood sample.  
This again highlights the difficulty of using CD27/CD45RA to identify distinct 
V9V2 T cell populations.  However, as for  T cells, CD27/CD45RA does 
identify distinct subsets of V1(+) T cells.  Indeed, CD45RA expression appears 
to dominate the V1 subset, with CD27(+)CD45RA(+) and CD27(-)CD45RA(+) cells 
comprising the two major populations (Figure 6.3) in contrast to V9V2 T cells 
in which cells with a CD27(+)CD45RA(-) phenotype often are the majority. 
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Figure 6.3  V9V2 and V1(+) T cells show different CD27/CD45RA profiles. 
(Dot plots show different CD27/CD45RA expression profiles for V9V2, V1(+) 
and non- T cells from a single representative individual. 
6.4 CD28/CD27/CD16 also identify distinct V1(+) T cell 
subsets. 
Figure 6.4 and 6.5 illustrates the use of CD28, CD27 and CD16 to phenotype 
V1(+) T cells, in comparison with V9V2 T cells and TCR (-)CD3(+) () T 
cells.  This methodology identifies distinct subsets for all T cell subtypes (V1(+), 
V9V2 and (-)CD3(+) T cells).  This is a clear advantage over the 
CD27/CD45RA system as it allows comparison of populations in terms of the 
same surface markers.  Three major non-naïve subsets are clearly 
distinguishable for both V1(+) and V9V2 T cells, these being; (28+) cells 
[CD27(+)CD28(+)]; (28-) cells [CD28(-)CD27(+)] and (27-28-) cells [CD28(-)CD27(-)].  
By contrast, the (-)CD3(+) () T cells, whilst having similar [CD27(+)CD28(+)] 
and [CD27(-)CD28(-)] populations have a predominance of [CD27(-) CD28(+)] cells 





















































































Figure 6.4  V1(+) and V9V2 T cells show different CD27/CD28/CD16 
profiles. 
Flow cytometry dot plots show CD27/CD11a/CD28/CD16 expression profiles on 
V1(+), V9V2 and non- T cells in a single representative individual. 
CD27/CD28 plots are shown for non-naïve CD11a(Hi) cells with CD16 expression 
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Figure 6.5  V1(+) and V9V2 T cells show different CD27/CD28/CD16 subset distribution. 
Summary scatter plots show the percentage of each  subset in V1(+) (n=30) and in V9V2 T cells (n=63) in healthy volunteer peripheral 
blood samples.  Population median values are indicated as a red bar.  V9V2 subsets are defined as; (N) [CD27(Hi)CD11a(Lo)], (28+) [CD28(+) 
CD27(+)], (28-) [CD28(-)CD27(+)], (16-) [CD28(-)CD27(-)CD16(-)] and (16+) [CD28(-)CD27(-)CD16(+)]. 
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6.5 Preliminary surface marker analysis of V1(+) T cells 
With it now clear that the CD28/CD27/CD16 methodology could also be used to 
identify distinct subsets of V1(+) T cells, this method was utilised to further 
characterise the surface phenotype of these cells, with reference and 
comparison to the previously analysed V9V2 T cells.  Interestingly, surface 
CCR7, CD62L and 7-Integrin levels were very similar on both the V1(+) and 
V9V2 T cell subsets (Figure 6.6).  Indeed, none of the non-naïve subsets for 
either  cell subtype expressed CCR7, with steadily decreasing levels of both 
CD62L and 7-Integrin in a subset order (28+) (28-) (16-) (16+).  This 
suggests that for both V1 and V2 cells that homing to the secondary lymphoid 
organs is not an obvious priority. 
The surface expression of CCR2 and CCR5 was also assessed on V1(+) 
T cells.  Interestingly, V1(+) T cells did not express CCR2 on any of the non-
naïve subsets (Figure 6.7).  This was in stark contrast to V9V2 T cells, 
especially (28+) V2 T cells, in which 60% of the cells expressed high CCR2 
levels.  CCR5 was also expressed at increased levels on V9V2 T cells in 
comparison to V1(+) T cells although the difference was not as dramatic as for 
CCR2 (Figure 6.7). 
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Figure 6.6  CCR7, CD62L and 7-Integrin expression levels in V1
(+)
 T cells.
Scatter plots showing percentage of expression of CCR7, CD62L and 7-Integrin 
on V1(+) and V9V2 T cell subsets in healthy volunteer peripheral blood 
samples.  T cell subsets are defined as; (N) [CD27(Hi)CD11a(Lo)], (28+) 
[CD27(+)CD28(+)], (27+) [CD27(+)CD28(-)], (16-) [CD27(-)CD28(-)CD16(-)] and (16+) 
[CD27(-)CD28(-) CD16(+)].  Median values are indicated as a red bar.   Statistical 
differences were assessed using ANOVA Kruskal-Wallis test with multiple 
comparison post-hoc testing with Bonferroni correction.  p-values < 0.05 were 
considered significant. 
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Figure 6.7 CCR2 and CCR5 expression levels on V1(+) T cells 
Scatter plots showing percentage of expression of CCR2 and CCR5 on V1(+) 
and V9V2 T cell subsets in healthy volunteer peripheral blood samples.  T 
cell subsets are defined as; (N) [CD27(Hi)CD11a(Lo)], (28+) [CD27(+)CD28(+)], 

(27+) [CD27(+)CD28(-)], (16-) [CD27(-)CD28(-)CD16(-)] and (16+) [CD27(-)CD28(-)
CD16(+)].  Median values are indicated as a red bar.   Statistical differences were 
assessed using ANOVA Kruskal-Wallis test with multiple comparison post-hoc 
testing with Bonferroni correction (p-values < 0.05 were considered significant). 
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6.6 Summary 
This chapter outlined preliminary analysis of V1(+) T cells, with comparison to 
the previous investigations on V9V2 T cells.  Unlike for V9V2 T cells 
CD27/CD45RA does identify clear subsets for V1(+) T cells, in a manner 
reminiscent of  T cells.  However, the proposed system of phenotyping cells 
using CD27/CD28 and CD16 does seem to offer an advantage in identifying 
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Chapter 7 Preliminary analysis of  T cells in the 
human neonatal thymus 
7.1 Introduction 
In phenotyping V9V2 T cells from the adult peripheral blood it was apparent 
that defining a “naïve” population was problematic. Indeed, different 
phenotyping strategies lead to a wide range of estimates for the “naïve” V9V2 
T cell subset (Figure 3.7).  In addition, there is much confusion in the literature 
as to the combination of markers to use to best describe the “naïve” V9V2 
T cell phenotype, with a range of different marker combinations used including 
combinations of; CD27, CD45RA, CD28, CD11a, CD62L and CCR7. 
Therefore, in order to provide insight into the true nature of a “naïve” V9V2 
T cell phenotype, thymocytes were extracted from eight human neonatal 
thymus samples (see Figure 7.1A for details) and phenotyped using a panel of 
common “naïve” surface markers.  Our rationale argued that the “naïve” 
phenotype would predominate in the thymus and would help inform us of the 
phenotype of these cells prior to antigen exposure. 
7.2 V1(+) T cells are more prevalent in the neonatal thymus 
than V9V2 T cells. 
Initially, the percentage of V9V2 and V1(+) T cells as a proportion of total 
CD3(+) T cells, was determined in the thymus samples and compared to the 






Sex (M/F) V2/CD3(%) V1/CD3(%) 
1 4d M 0.03 0.51 
2 20d M 0.08 0.30 
3 3m F 0.06 0.33 
4 7m F 0.05 0.72 
5 16m M 0.12 0.62 
6 17m F 0.06 0.25 
7 28m F 0.12 0.75 
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Figure 7.1  V1(+) T cells are found at higher proportions in the neonatal 
thymus than V9V2 T cells. 
(A) Summary table of the eight thymuses analysed is shown indicating; age, 
gender, V2/CD3(%) and V1/CD3(%) for each sample.  A comparison of  
T cell populations (V2 vs.V1(+)) expressed as a percentage of total CD3(+) cells 
in (B) thymocytes obtained from neo-natal thymuses and (C) PBMCs from 
peripheral blood (Healthy volunteers).  Median values are indicated in red. Data 
from thymocytes from neo-natal thymuses (n=8) is shown in comparison to levels 
in peripheral blood samples; V2 (n=63) and V1 (n=30). 
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Figure 7.1B shows that in the eight thymus samples, the median V1/CD3(%) 
was 0.42% which was significantly higher compared to the median V2/CD3(%) 
of 0.07% (p = 0.001).  This relationship was reversed in peripheral blood 
samples where the median V2/CD3(%) of 2.2% was significantly higher than 
the median V1/CD3(%) of 0.8% (p < 0.001) (Figure 7.1C).  This relationship 
was in accordance with the idea that V9V2 T cells increase due to post-
thymic expansion following antigen exposure. 
7.3 CD27/CD45RA expression on V2(+) T cells in the 
neonatal thymus 
After staining the eight thymus samples with a combination of markers (CD28, 
CD27, CD45RA, CD11a, CCR7, CD62L and CD16), we first assessed V9V2 
T cells for CD27/CD45RA expression.  This method of analysis is commonly 
used in the literature (see previous chapters), and identifies “naïve” cells as 
[CD27(+)CD45RA(+)].  If this staining combination represents a true “naïve” 
population, we would expect it to predominate in the thymus.  However, figure 
7.2A shows that in 6/8 thymus samples the CD27(+)CD45RA(+) subset was not 
the major population, with a median percentage of 27.4%.  This value is 
somewhat similar to that observed for CD27(+)CD45RA(+) V9V2 T cells in the 
peripheral blood; 23.4% (Figure 7.2B), suggesting that it is not enriched in the 
thymus samples.  Indeed, the CD27(+)CD45RA(-) subset is generally the 
dominating population (in 6/8 samples).  Interestingly, two of the three youngest 
samples (Age = 4 days and Age = 3 months) did show higher expression of 




























NS p = 0.56  
Youngest Oldest 
4 days 20 days 3 months 7 months 16 months 17 months 28 months 35 months 





































Figure 7.2  CD27/CD45RA expression on V2(+) T cells in the thymus. 
(A)  CD27/CD45RA flow cytometry density plots of V2(+) T cells from all eight thymic samples are shown and ranked by increasing age (left to 
right).  Age is indicated above the associated plot. Percentage in each quadrant is indicated.  A typical peripheral blood CD27/CD45RA profile is 
shown for comparison (far left). (B) The percentage of “naïve” cells (as defined by CD27(+)CD45RA(+)) for thymic V2 T cells from thymus and 
peripheral blood.  Red lines indicate median values. Statistical differences were assessed using the Mann–Whitney U test with p-values 
indicated. 
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7.4 CD28/CD27 analysis of V9V2 T cells in the neonatal 
thymus 
The eight thymus samples were next assessed for expression of CD28 and 
CD27 (as previously described).  The microarray data and PSM analysis had 
tentatively suggested that a [CD27(+)CD28(+)] phenotype (28+) could be at one 
end (possibly at the start) of a pathway of V9V2 T cell differentiation.  
Consistent with this, in 7/8 samples the (28+) subset was the major population 
observed (Figure 7.3A).  Furthermore, the median percentage of this subset in 
the thymus (72.8%) was significantly higher than that observed in the blood of 
healthy adults (57.0%; p = 0.035) (Figure 7.3B).  Nonetheless, in the very 
youngest thymus (Age=4 days) the [CD28(-)CD27(+)] subset predominated, 
again suggesting that the (28+) subset was unlikely to represent a “naïve” 
V9V2 T cell population. 
7.5 CCR7/CD62L analysis of V9V2 T cells in the neonatal 
thymus. 
V9V2 T cells in the eight neonatal thymus samples were next assessed for 
CCR7 and CD62L expression, as a [CCR7(+)CD62L(+)] subset had previously 
been suggested to be a “naïve” subset.  However, there was no evidence for 
this from this analysis; median levels of [CCR7(+)CD62L(+)] cells being 2.4% in 
the thymus, compared with 1.9% in the adult blood (Figure 7.4).  Instead, most 
cells were CCR7(-) with a generally CD62L(-) phenotype.  A caveat to this 


















































































































































































































































































































































































































 Thymus – Gated on V2(+) T cells
Figure 7.3  CD27/CD28 expression on V2(+) T cells in the thymus. 
(A) CD27/CD28 flow cytometry density plots of V2(+) T cells from all eight thymic samples are shown and ranked by increasing age (left to 
right).  Age is indicated above the associated plot. Percentage in each quadrant is indicated.  A typical peripheral blood CD27/CD28 V2 profile 
is shown for comparison (far left). (B) A comparison of the percentage of CD27(+)CD28(+) cells in thymus is shown relative to the same cells in 
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NS p = 0.34 
Figure 7.4  A comparison of CCR7/CD62L expression on V2(+) T cells in the thymus. 
(A) CCR7/CD62L flow cytometry density plots of V2(+) T cells from all eight thymic samples are shown and ranked by increasing age (left to 
right).  Age is indicated above the associated plot. Percentage in each quadrant is also indicated.  A typical peripheral blood CCR7/CD62L V2 
profile is shown for comparison (far left). (B) A comparison of the percentage of “naïve” phenotype (as defined by CCR7(+)CD62L(+)) in thymic 
V2 T cells is shown relative to the same cells in peripheral blood.  Red lines indicate median values.  Statistical differences were assessed 
using the Mann–Whitney U test with p-values indicated. 
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7.6 A novel population of cells exist in the neonatal thymus 
The final method of analysis for V9V2 T cells in the neonatal thymus samples 
involved assessment of CD27 and CD11a expression.  In the peripheral blood 
of adults, the majority of cells are CD11a(Hi) CD27(+ or -) (but not CD27(Hi)), with 
only a few cells (< 5%) showing the proposed [CD27(Hi) CD11a(Lo)] phenotype of 
a “naïve” V9V2 T cell (De Rosa et al. 2004)(Figure 7.5).  By contrast, 
CD27/CD11a staining in the eight neonatal thymus samples showed a 
significantly different profile in that the majority of cells (in all cases) displayed a 
CD27(+) (but not CD27(Hi)) and CD11a(Lo) phenotype (Figure 7.5).  This [CD27(+)
CD11a(Lo)] subset has no obviously comparable population in the adult blood, 
which may suggest that these cells are in some way more “immature” than 
those in the periphery.  Figure 7.6 shows CD27/CD11a plots from a neonatal 
thymus and adult blood to illustrate this point.  It is tempting to speculate that 
the CD27(Hi) populations are comparable (circled in red), although no direct 
evidence yet exists to support this. 
7.7 CD27 and CD11a define two V9V2 T cell thymic 
populations 
As it was possible to consistently define two populations of V9V2 thymocytes 
with CD27 and CD11a, these populations were assessed for further marker 
expression.  Figure 7.5 shows thymus V9V2 T cell population 1 [CD27(+)
CD11a(Lo)] and thymus V9V2 population 2 [CD27(Hi) CD11a(+)] in two different 
thymus samples (#7 and #8) assessed for expression of CCR7, CD62L, 
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Blood Thymus  
Figure 7.5  CD27/CD11a expression on V2(+) T cells in the thymus 
CD27/CD11a flow cytometry density plots of V2(+) T cells from all eight thymic samples are shown and are ranked by increasing age (left to 
right) (A).  Age of each patient is indicated above the associated plot. Percentage in each quadrant gate is also indicated.  A typical peripheral 
blood CD27/CD11a profile is shown for comparison (far left). (B) Density plots showing CD27 and CD11a expression on V2(+) T cells from 
representative plots in neonatal thymus and adult blood. Density plots reveal two distinct subsets in the thymus that are difficult to relate to the 
typical populations seen in adult peripheral blood.  Thymus population 1= [CD27(+)CD11a(Lo)] and thymus population 2 = [CD27(Hi)CD11a(+)]. 








































































































































Figure 7.6  CD27 and CD11a define two distinct thymic V2(+) T cell subsets. 
(A) Flow cytometry density plots showing two distinct thymic V2(+) T cell populations; Population 1 = [CD27(+)CD11a(Lo)] (outlined in black) and 
Population 2 = [CD27(Hi) CD11a(+)]  (outlined in red) in two representative thymus samples (Thymus A and Thymus B).  (A) Each thymus 
population (1 and 2) shown in (B) is characterised by surface markers CCR7, CD62L, CD16, CD45RA and CD28. 
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Interestingly, population 2 express significantly higher levels of CCR7, CD62L 
and CD16 compared to population 1 (Figure 7.6 and 7.7), but similar levels of 
CD45RA and CD28.  The high levels of CD16 were particularly surprising for 
thymic-populations as it is typically described as a late effector marker in 
cytotoxic T cells.  However, the consistently high levels of CD16 expression on 
population 2 seemed to confirm that the expression of CD16 might have a 
functional significance in the small [CD27(Hi) CD11a(+)] subset. 
7.8 Summary 
In summary, it is apparent that classically-defined “naïve” V9V2 T cells are 
not obviously identifiable in the human neonatal thymus. Many of the 
suggested “naïve” phenotypes identify thymic populations that are similar in 
proportion to those seen in adult blood.  Nonetheless, two distinct V9V2 T cell 
populations are present in all thymic samples, characterised as 
[CD27(+)CD11a(Lo)] and [CD27(Hi)CD11a(+)] that have distinct marker expression 
profiles.  The smaller [CD27(Hi)CD11a(+)] subset perhaps represent the closest 
comparison to a “naïve” subset found in adult blood and perhaps are cells about 
to be released into the peripheral blood.  By contrast, the [CD27(+)CD11a(Lo)] 
















































































































p = .0 7 *p = .0 7 p < . 01
S p = 0.49 S p > 0.99 
Thymus V9V2 population Thymus V9V2 population Thymus V9V2 population 
Thymus V9V2 opulation 



















































Figure 7.7  A comparison of surface marker expression on thymic V2(+) T cells. 
(A) A flow cytometry density plot highlights the two main V2(+) T cell populations found in the thymus. (B) Relative expression of surface 
markers; CCR7, CD62L, CD16, CD27, CD45RA and CD28 are compared in the two major thymus populations; Population 1 = 
[CD27(+)CD11a(Lo)] and population 2 = [CD27(Hi) CD11a(+)] in (B).  Red lines represent median values.  Statistical differences were assessed 
using the Mann–Whitney U test  with p-values indicated.  
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Chapter 8 
 T cell changes in bisphosphonate-
related osteonecrosis of the jaw 
(BRONJ) 
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Chapter 8  T cell changes in bisphosphonate-
related osteonecrosis of the jaw (BRONJ) 
8.1 Introduction 
The final chapter presents preliminary data investigating  T cells in a small 
cohort of eight patients with a history of bisphosphonate-related osteonecrosis 
of the jaw (BRONJ).  The pilot study was designed to investigate whether there 
was any evidence to suggest that  T cells were implicated in BRONJ by 
comparing  T cell number and phenotype to healthy controls, and to other 
patients exposed to bisphosphonates but without osteonecrosis.  As previously 
discussed, the lack of access to BRONJ jaw tissue samples due to the current 
non-interventional treatment protocols in the UK, precludes any in-depth 
investigations on these cells within tissue samples.  Therefore the pilot study 
was limited to looking and characterising  T cells (V9V2 and V1(+)) in the 
peripheral blood.  Three different control groups were used; healthy volunteers 
with no previous exposure to bisphosphonates (n=63); osteoporotic patients 
taking oral bisphosphonates (n=5) and a group of osteoporotic patients on 
yearly intravenous bisphosphonate therapy (n=5). 
8.2 BRONJ patient cohort 
Eight BRONJ patients were recruited to the pilot study, two being male and six 






























Aledronic acid Oral 70 Osteoporosis Weekly 46 Y 





Zoledronic acid Intravenous 4 Breast cancer Monthly 9 N 















Aledronic acid Oral 70 Osteoporosis Weekly 178 N 





Aledronic acid Oral 70 Osteoporosis Weekly 48 N 





Zoledronic acid Intravenous 4 
Multiple 
myeloma 
Monthly 84 Y 





Aledronic acid Oral 70 Osteoporosis Weekly 60 Y 





Clodronate Oral 1600 
Multiple 
myeloma 
Daily 24 N 
Table 8.1  BRONJ cohort bisphosphonate details. 
Summary table of the eight BRONJ patients recruited for the study. The table details general patient demographics including; age, gender, 
country of birth (geographical sub-region) and ethnicity.  Details regarding cumulative bisphosphonate exposure is described including; 
bisphosphonate drug, route of administration, dose, reason for prescription, length of time of drug prescription, and whether patients were still 
taking bisphosphonates at the time of blood analysis. 
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The majority of BRONJ patients (5/8) had taken bisphosphonates as a post-
menopausal osteoporotic therapy and the majority of these (4/5) were on the 
less potent oral form of the medication.  The remaining three BRONJ patients 
were prescribed bisphosphonates to prevent bone loss as a complication of 
multiple myeloma and breast cancer, with only two of these three patients 
prescribed the most potent monthly intravenous bisphosphonate regimen.  In 
terms of cumulative bisphosphonate exposure, BRONJ patients were 
prescribed bisphosphonates for between 24 and 178 months in the oral group 
and for between 9 and 84 months in the intravenous group with an overall 
median exposure of 47 months.  Half of the BRONJ cohort (4/8) continued to 
take, or continued to have bisphosphonates administered, despite the diagnosis 
of BRONJ. 
8.3 Control groups 
BRONJ patients were compared to three different control groups all with no 
previous history of BRONJ that included; non-bisphosphonate exposed healthy 
volunteers (n=63; Male=31, Female=32; Age range 3-69 years); oral 
bisphosphonate patients with no BRONJ (n=5; Male=1, Female=4, Age range 
56-79 years) and intravenous bisphosphonate patients (n=5; Male=1, 
Female=4; Age range 64-81 years) (Table 8.2).  Individuals within the healthy 
volunteer cohort that were > 50 years (n=16) were also considered as a 
separate sub-group in order to better age-match this group to the other typically 






























Zoledronic acid IV 5 Osteoporosis 365 36 
Y – 3 Annual 
infusions 






Zoledronic acid IV 5 Osteoporosis 365 24 
Y – 2 Annual 
Infusions 









70 (Oral) / 
5 (IV) 
Osteoporosis 
7 (Oral) / 
365 (IV) 
40 
Y – Mixture of oral
and IV 
bisphosphonates 





Pamidronate IV 30 Osteoporosis 90 125 Y 





Zoledronic acid IV 5 Osteoporosis 365 46 
Y – 4 previous 
doses 




White – Irish Aledronic acid Oral 70 Osteoporosis 7 84 Y 





Aledronic acid Oral 70 Osteoporosis 7 144 Y 





Aledronic acid Oral 70 Osteoporosis 7 96 Y 





Aledronic acid Oral 70 Osteoporosis 7 60 
N – Recently 
stopped 





Aledronic acid Oral 70 Osteoporosis 7 132 Y 
Table 8.2  Bisphosphonate control group details. 
Summary table of the ten patients recruited for study as a control group being exposed to therapeutic bisphosphonates without BRONJ. The table 
details patient demographics including; age, sex, country of birth (geographical sub-region) and ethnicity. Details regarding cumulative bisphosphonate 
exposure is described including; bisphosphonate drug, route of administration, dose, reason for prescription, length of time of drug prescription and 
whether patients were still taking bisphosphonates at the time of blood analysis.  IV=Intravenous, Y=Yes, N=No, M=Male and F=Female. 
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8.4 BRONJ disease and treatment. 
In all eight of the BRONJ patients, osteonecrosis was in the mandible and had 
mainly occurred following a dental extraction (7/8) (Table 8.3).  Exposed 
BRONJ lesions were evident in 5/8 patients and in the worst case had lasted up 
to 117 months (9.75 years). Exposure size ranged from 0-25mm on 
examination and BRONJ stage ranged from 0-3.  Treatment and management 
of each BRONJ case was very much dependent on the clinician, but in all cases 
was treated conservatively.  No interventional surgery was carried out to 
remove necrotic bone and the only operative procedures were limited to the 
removal of loose symptomatic bone sequestrae and local curettage of debris 
from lesions on a symptomatic basis. Pentoxyfylline and -tocopherol 
(Vitamin E) were frequently used in combination with tetracycline and 
chlorhexidine antimicrobial agents (Figure 8.3). 
8.5 Pain and quality of life related issues in BRONJ. 
Only 2/8 BRONJ patients reported pain at the time of interview/examination and 
both of these patients rated their pain at 4/10 (numeric pain rating scale) (Table 
8.4).  BRONJ patients were also asked to recall their worst pain with 5/10 
patients recalling at least one episode of severe pain (9 or 10 score).  However, 
in one affected individual, no BRONJ lesion associated pain was ever reported 
and they remained totally asymptomatic throughout the disease course.  The 
vast majority of BRONJ affected patients (7/8) reported that their eating had 
been affected by the condition and 5/8 were symptomatically aware of infection, 
typically due to a bad taste or drainage of pus from the lesion.  Other symptoms 
reported included; food trapping in the lesion, referred pain to the ear, sharp 
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Mandible Y 5 1 36 Y- Tetracycline N 











































Mandible Y 25 2 84 
Y- Tetracycline 
N 







Periodontitis Mandible N 0 0 117 
N – But on long-
term antibiotics 
Penicillin V since 
January 1988 
N 







NA – Teeth 
still in situ 
Mandible N 0 0 0 Y - Amoxicillin N 




Table 8.3  BRONJ disease details and treatment summary. 
A summary of BRONJ disease in the eight recruited patients in the study.  Details in the table include; precipitating factor, jaw site, BRONJ 
stage, as well as exposure period and size.  The treatment received by each patient in terms of systemic antimicrobials or drugs, topical 
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2 N 0 9 
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3 Y 4 7 





pain to ear 
4 N 0 10 
Y – Previously 
only able to eat 
soft food and 
drinking 
through straw 
N N Sleep affected 
5 Y 4 10 
Y – Mouth 
generally 
uncomfortable 









6 N 0 9 






7 N 0 0 N 














Table 8.4  Pain and Quality of life issues in BRONJ patients
Factors relating to quality of life in BRONJ including reported numeric pain rating 
scale (1-10) for pain at present as well as the worst recalled pain.  Qualitative 
data recorded from these patients included whether or not eating was affected 
and whether patients were aware of symptoms of infection.  Other symptoms 
reported by this patient group were also recorded. Y=Yes, N=No. 
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8.6 V9V2 T cells are significantly depleted in BRONJ 
patients. 
Initially, the relative percentages of both V9V2 and V1(+) T cells was 
determined in the eight BRONJ patients as a percentage of total lymphocyte 
number and compared to the three different control groups.  All groups with 
previous exposure to bisphosphonates, including the BRONJ cohort, showed 
evidence of significant depletion in V2/CD3(%) when compared to healthy 
controls with no previous bisphosphonate exposure (p < 0.01) (Figure 8.1).   
BRONJ patients had a median level of expression of 0.10% (range 0.00-
0.21%), with those patients in the oral bisphosphonate group having a value of 
0.07% (range 0.04-0.11%) and those in the IV bisphosphonate control group 
having a value of 0.13% (range 0.03-0.29%).  By contrast, healthy volunteers 
showed a median level of expression of 2.15%, (range 0.25-21.91%). 
Interestingly, there were no significant statistical differences (p > 0.05) between 
any of the BRONJ or bisphosphonate control groups although interestingly the 
three lowest V2/CD3(%) were all found in BRONJ patients (< 0.09%). This 
suggested that patients taking both oral and intravenous forms of 
bisphosphonates have depleted V9V2 T cell numbers in their peripheral blood 
compared to healthy controls. 
The lowest median age in the healthy cohort (33 years) compared to the 
BRONJ cohort (58.5years), IV bisphosphonate control group (78 years), and 
oral bisphosphonate control group (72 years) might suggest that peripheral 
blood depletion of V9V2 T cells may simply be related to age rather than 
bisphosphonate intake.  However when comparisons were made with only older 
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healthy volunteers > 50 years (n=16, median age 57 years), V9V2 T cells 
continued to be significantly depleted in BRONJ patients, (0.10% vs. 1.49%, 
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Figure 8.1  V2/CD3(%) depletion in BRONJ patients and in patients on long-
term bisphosphonate therapy. 
(A) Graph shows V9V2 T cells expressed as a percentage of total CD3(+) 
lymphocytes in the peripheral blood of different study groups; Healthy controls 
(HC), Healthy control >50 years (HC >50), Bisphosphonate-related osteonecrosis 
of the jaw patients (BRONJ), Oral bisphosphonate therapy patients (Oral BP) and 
Intravenous bisphosphonate therapy patients (IV BP).  Red lines represent 
median values with statistical differences assessed using Kruskal-Wallis test 
(ANOVA) and multiple comparison post-hoc testing with Bonferroni correction 
(p-values are indicated).  (B) Two-dimensional flow cytometry dot plots of all eight 
BRONJ patients showing depleted V2(+)CD3(+) T cell populations in peripheral 
venous blood samples.  Percentage figures are stated next to adjacent gate. 
211 
8.7 V1(+) T cells show no evidence of depletion in BRONJ 
patients compared to all other control groups. 
Following the observation that V9V2 T cells are depleted in the BRONJ 
patient group, the levels of V1/CD3(%) were also determined to investigate 
whether there might also be differences in these cells.  Figure 8.2 shows that 
the median percentages of V1/CD3(%) in BRONJ patients is 1.95% (range 
0.29-5.19%).  This compares to each of the respective control groups as 
follows; oral BP group 1.76% (range 0.12-4.56); IV BP group 0.75% (range 
0.22-1.80%); and healthy non-exposed controls 0.79% (range 0.16-4.74).  
There were no significant differences between any of these groups (p > 0.05). 



























Figure 8.2  V1
(+) T cells show no evidence of depletion in BRONJ patients and in
patients on long-term bisphosphonate therapy. 
Graph shows V1(+) T cells expressed as a percentage of total CD3(+) lymphocytes in 
the peripheral blood of different study groups; Healthy controls (HC), Healthy control > 
50 years (HC> 50), Bisphosphonate-related osteonecrosis of the jaw patients 
(BRONJ), Oral bisphosphonate therapy patients (Oral BP) and Intravenous 
bisphosphonates therapy patients (IV BP).  Red lines represent median values with 
statistical differences assessed using Kruskal-Wallis test (ANOVA) and multiple 
comparison post-hoc testing with Bonferroni correction. 
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Comparison to older healthy controls (> 50 years) also failed to show significant 
differences between these groups.  Thus, there is no evidence to support any 
significant changes in the proportion of V1(+) T cells in the blood of BRONJ 
patients or in patients taking different forms of bisphosphonates. 
8.8 No evidence for a predominating V9V2 T cell 
phenotype in BRONJ patients 
The phenotypic signature based on CD28, CD27 and CD16 was determined for 
V9V2 T cells from each individual in each of the individual cohorts to 
investigate whether a particular signature was characteristic of BRONJ disease 
or bisphosphonate treatment.  It might be hypothesised that in patients who are 
on long-term bisphosphonate therapy, that persistent activation might lead to an 
effector phenotype (i.e. phenotypic signatures 4,5 or 6).  However, there were 
no obvious dominant signatures in any of the groups (Figure 8.3).  In the eight 
BRONJ patients, five out of the six phenotypic signatures were observed (i.e. 
phenotypic signatures 1,2,2,2,3,4,6,6) (Figure 8.3).  Similarly, in the intravenous 
bisphosphonate control group the predominance of a particular phenotypic 
signature could not be determined, with all five individuals having a different 
phenotypic signature i.e. 1,2,3,4 and 5 (Figure 8.4).  This wide spectrum of 
observed phenotypes was also observed in the oral bisphosphonate control 
group who had phenotypic signatures 2,3,3,4 and 6 (Figure 8.5).  Therefore the 
idea that V9V2 T cell depletion is associated with polarisation to a particular 
phenotype is not supported by these data and instead is consistent with V9V2 
T cell phenotypes being relatively stable over time and not affected by long-term 





BRONJ 1 BRONJ 2 BRONJ 3 BRONJ 4 BRONJ 5 BRONJ 6 BRONJ 7 BRONJ 8 
V2/CD3(%) 0.01 0.09 0.21 0.15 0.01 0.00 0.10 0.20 
Gender (M/F) F F F F F M F M 
Phenotypic signature group (1-6) 4 2 6 3 1 2 6 2 
Reason for BP prescription Osteoporosis Breast cancer Osteoporosis Osteoporosis Osteoporosis Multiple myeloma Osteoporosis Multiple myeloma 
Route (Oral/IV) Oral IV Oral IV Oral Oral IV Oral 
Drug (Route) AA (Oral) ZOL (IV) AA (Oral) ZOL (IV) AA (Oral) AA (Oral) ZOL (IV) AA (Oral) 
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Figure 8.3  Range of V9V2 T cell phenotypes in BRONJ patients. 
Flow cytometry density plots are shown for each individual BRONJ patient (1-8) (A). V9V2 T cell phenotypes are shown using surface 
markers CD28, CD27 with CD16 expression shown for the CD27(-)CD28(-) subset.  Linked table (B) shows details of V2/CD3(%), gender, 
phenotypic signature, bisphosphonate drug, route of administration and length of time on medication for each individual BRONJ patient. SSC-




B        
BP IV 1 BP IV 2 BP IV 3 BP IV 4 BP IV  5 
V2/CD3(%) 0.15 0.03 0.04 0.13 0.29 
Gender (M/F) F F M F F 
Phenotypic signature group (1-6) 3 1 2 5 4 
Reason for prescription Osteoporosis Osteoporosis Osteoporosis Osteoporosis Osteoporosis 
Drug (Route) ZOL (IV) ZOL (IV) ZOL (IV) PAM (IV) ZOL (IV) 
Time on medication 
(months) 
36 24 40 125 46 











































































Figure 8.4  Range of V9V2 T cell phenotypes in osteoporotic patients taking intravenous bisphosphonates. 
Flow cytometry density plots are shown for each individual osteoporotic patient taking intravenous bisphosphonates (BP IV 1-5) (A). V9V2    T 
cell phenotypes are shown using surface markers CD28 and CD27 with CD16 expression shown for the CD27(-)CD28(-) subset.  Linked table 
(B) shows details of V2/CD3(%), gender, phenotypic signature, bisphosphonate drug, route of administration and length of time on medication 





BP oral 1 BP oral 2 BP oral 3 BP oral 4 BP oral 5
V2/CD3(%) 0.07 0.04 0.10 0.11 0.08
Gender (M/F) M F F F F
Phenotypic signature group (1-6) 3 6 2 4 3
Reason for prescription Osteoporosis Osteoporosis Osteoporosis Osteoporosis Osteoporosis
Drug (Route) AA (Oral) AA (Oral) AA (Oral) AA (Oral) AA (Oral)
Time on medication
(months)
84 144 96 60 132












































































Figure 8.5  Range of V9V2 T cell phenotypes in osteoporotic patients taking oral bisphosphonates.
Flow cytometry density plots are shown for each individual osteoporotic oral bisphosphonate patient (BP oral 1-5) (A). V9V2 
T cell phenotypes are shown using surface markers CD27 and CD28 with CD16 expression shown for the CD27(-)CD28(-) subset.  
Linked table (B) shows details of V2/CD3(%), gender, phenotypic signature, bisphosphonate drug, route of administration and 
length of time on medication for each individual patient. SSC-A = Side scatter-Area, BP = Bisphosphonate, AA = Aledronic acid, 
M=Male and F=Female. 
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8.9 Summary 
This final chapter presents evidence that V9V2 T cells are depleted in BRONJ 
patients.  In all eight of the BRONJ patients, V9V2 T cells were severely 
depleted compared to age matched healthy controls with no apparent effect on 
V1(+) T cells.  However V9V2 T cell depletion was also observed in 
bisphosphonate-treated patients both on oral and intravenous forms of the 
medication, suggesting that the V9V2 T cell depletion is a consequence of 
bisphosphonate use, rather than a feature of the disease.  In addition, we also 
observed no signatory V9V2 T cell phenotype associated with either BRONJ 
or bisphosphonate use.  The lack of a bias towards the (16+) phenotype 
suggests that simple activation of V9V2 T cells is not sufficient to drive 
differentiation of V9V2 T cells to different phenotypes, even if the activating 
signal is long-term.  Finally, the chapter also highlights the range of symptoms 
in BRONJ patients and that the condition can range from periods of severe pain 
to those who are apparently unaffected symptomatically by the condition. 
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Chapter 9 
Discussion and Future work 
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Chapter 9 Discussion 
Human V9V2 T cells are a heterogeneous population of cells with a high 
degree of functional plasticity and suggested roles in a number of disease 
processes including bisphosphonate-related osteonecrosis of the jaw (BRONJ) 
(Dieli et al. 2001, Kalyan and Kabelitz 2013, Kalyan et al. 2013).  Our 
understanding of these unconventional T cells has been somewhat hindered by 
a failure to develop a consistent system of nomenclature and system of 
phenotypic characterisation.  Therefore, the results in this thesis propose the 
use of CD28, CD27 and CD16 as more useful markers in the phenotypic 
characterisation of V9V2 T cells which can be used to identify six different 
V9V2 T cell “phenotypic signatures” at the level of the individual that predict 
different functional capabilities and offers a potential novel solution to the 
challenges of predicting responses to V9V2 T cell immunotherapeutic 
interventions. 
The thesis also examined V9V2 T cell subsets in human neo-natal thymuses 
in an attempt to understand subsets present early in development.  However, 
the hypothesised early/naïve subsets seen in the blood failed to be identified in 
the thymus with only a minority of naïve surface markers expressed by 
thymocytes.  The study does however identify two thymic subsets; 
[CD27(+)CD11a(Lo)] and [CD27(Hi)CD11a(+)] with a possible role in antigen 
presentation, which is subsequently discussed. 
The newly-defined phenotypic system is also shown to be appropriate for the 
characterisation of the V1(+) T cell population which in contrast to V9V2 
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T cells is characterised by a high proportion of “naïve” cells.  Finally, some 
preliminary evidence is discussed showing that V9V2 T cell depletion is a 
feature of patients on long-term nitrogen containing bisphosphonate therapy 
including those with a diagnosis of BRONJ. 
9.1 CD45RA is not a reliable marker for accurate 
representation of V9V2 T cells 
One of the main conclusions of the thesis, is the limitations that the 
conventionally-used markers (CD27 and CD45RA) have in consistently failing to 
describe discrete V9V2 T cell subsets.  Indeed, in reviewing the literature, it 
appears that the surface markers CD27 and CD45RA have been used to 
subset V9V2 T cells without particular justification or rationale and appearing 
to be a carry over of markers and descriptors commonly used to describe  
T cell subsets (Hamann et al. 1997, Hintzen et al. 1993). 
The results of this study indicate that CD27 and CD45RA clearly better define 
four distinct subsets in conventional  T cells compared to V9V2 T cells, 
where in particular, the wide range of expression levels make use of the 
CD45RA surface marker problematic.  The fact that populations are not clearly 
identifiable using the CD27 and CD45RA surface markers, suggests that gating 
of these populations is likely to be variable in studies using this method leading 
to inconsistent estimates of the subsets.  The reasons explaining why CD45RA 
expression is less pronounced on V9V2 T cells than on  T cells from the 
same individual are unclear, but may be due to differences in the level of 
transcription or translation of the marker in the different T cell subtypes or due 
to post-translational processing in V9V2 T cells that removes/downregulates 
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surface expression of the marker.  This practical limitation of CD45RA as a 
phenotypic marker has to date not been addressed in the literature and raises 
the question whether it is the most appropriate marker to use in describing 
V9V2 T cell subsets. 
Questions are also raised as to the usefulness of CD45RA with respect to the 
apparent over-estimation of the “naïve” V9V2 T cell subset 
[CD27(+)CD45RA(+)], despite these same markers satisfactorily identifying 
“naïve”  T cells (Hintzen et al. 1993, Hamann et al. 1997).  This finding 
echoes the beliefs of others in the field who have also questioned the use of 
[CD27(+)CD45RA(+)] as a useful “naïve” cell descriptor due to its overestimation 
of this population in comparison to the much lower estimates (typically < 5%) 
when other “naïve” marker combinations are used e.g. CD27(Hi)CD11a(Lo) (De 
Rosa et al. 2004, Morita et al. 2007).  Clearly, this suggests that there is a need 
to re-evaluate the findings and implications of studies that report a high 
percentage of (N) cells when using [CD27(+)CD45RA(+)] (Dieli et al. 2003b, 
Caccamo et al. 2006). 
The low numbers or relative absence of “naïve” V9V2 T cells in adult 
peripheral blood suggest that they convert to a non-“naïve” phenotype very 
early in life (Parker et al. 1990).  This conversion likely occurs due to early 
environmental and/or infectious challenge, that results in an isoprenoid-
mediated expansion of the population and conversion to an activated 
phenotype (Parker et al. 1990, De Rosa et al. 2004).  Therefore, the fact that 
V9V2 T cells respond to commonly found isoprenoid molecules have lead 
many to speculate that these cells use their TCR as a form of pattern 
recognition receptor.  Furthermore, the fact that these cells do not recognise 
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specific antigen epitopes, makes them very different to conventional MHC-
restricted  T cells that only recognise their specific cognate antigen.  
Additionally, and once more in contrast to  T cells, the low levels of CCR7 
expression on V9V2 T cells observed in this study implies that the majority 
are unable to recirculate through secondary lymphoid tissue, again suggesting 
that they do not sample antigen in the same way as conventional T cells. 
In bringing these observations together, it is apparent that the use of the terms 
“naïve” and “memory” as defining terms for V9V2 T cell subsets, whilst being 
appropriate in describing the stages of  T cell differentiation, may not be 
appropriate in describing unconventional V9V2 T cell populations.  Instead, 
V9V2 T cells are perhaps better thought of as cells with developing states of 
“effector potential” that have predictable characteristics once activated. 
9.2 V9V2 T cells are better identified using CD28, CD27, 
and CD16 
A thorough re-evaluation of all V9V2 T cells surface markers (that had been 
previously utilised to identify distinct V9V2 T cell subsets in other studies) 
suggested that a combination of CD28, CD27 and CD16 represented a robust 
and reliable methodology for the characterisation of V9V2 T cells.  This 
allowed all non-naïve V9V2 T cells from all individuals to be described as 
belonging to one of four subsets; (28+) cells [CD28(+)CD27(+)]; (28-) cells 
[CD28(-)CD27(+)]; (16-) cells [CD28(-)CD27(-)CD16(-)]; and (16+) cells [CD28(-)
CD27(-)CD16(+)].  Clearly, whilst CD28, CD27 and CD16 more readily identify 
distinct subsets it is also important to consider, the biological significance of 
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their expression to help explain the functional differences between the different 
subsets. 
For conventional  T cells, it is now generally accepted that effective T cell 
signalling not only requires TCR activation through recognition of MHC-
associated antigen (signal-1) but also requires the co-stimulatory molecules 
such as, CD27 and CD28, to provide an additional “signal 2” to facilitate 
effective T cell activation when bound to their respective ligands (CD70-CD27) 
and (CD80/CD86-CD28).  These molecules have been shown to be important in 
generating effective survival and proliferative responses in conventional T cells 
(Hintzen et al. 1993), but also more recently in human V9V2 T cells (Ribot et 
al. 2012).  It therefore follows that the relative expression levels of CD27 and 
CD28 on V9V2 T cell subsets may help us to define functionally distinct 
subsets; e.g. cells expressing both co-stimulatory receptors [CD28(+)CD27(+)] 

(28+) cells, one of the receptors [CD28(-)CD27(+)] (28-) cells, or when both are 
absent [CD28(-)CD27(-)] (28-27-).  In further characterising V9V2 T cells lacking 
both co-stimulatory receptors, CD16, an Fc-receptor (FcRIIIa/b) typically found 
on cytotoxic CD8 T cells and NK cells, was used to further discriminate V9V2 
T cells with cytotoxic effector function in the [CD28(-)CD27(-)] subset.  Therefore, 
the combined use of the well-characterised co-stimulatory molecules 
(CD27/CD28) in conjunction with a well-established marker of cytotoxic function 
(CD16) seem to provide an improved method of subsetting V9V2 T cells. 
Whilst all V9V2 T cell subsets demonstrated the ability to readily produce TH1-
associated cytokines on stimulation (IFN- and TNF-), there was evidence that 
the three CD28(-) subsets showed increased cytotoxic potential as judged by a 
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number of a number of cytotoxic markers e.g. perforin, granulysin and 
granzyme B, with increased levels of expression particularly in the (16-) and 

(16+) subsets.  Further differences were also observed in the proliferative 
potential of the subsets, with higher capacity in (28+) and (28-) subsets 
compared to (16-) and (16+) subsets.  Having established a better definition of 
V9V2 T cell subsets it was apparent that they had distinct functional 
characteristics in terms of their proliferative potential, cytokine-secreting 
capacity, and cytotoxic function.  Clearly, the differences in function of different 
subsets would predict that an individual’s response to infectious challenge and 
cancer will be different depending on the relative proportion of V9V2 T cell 
subsets i.e. their phenotypic signature. 
9.3 Significant individual-to-individual variation in the 
proportions of the four newly-defined V9V2 T cell 
subsets identifies at least six signature profiles 
The  T cell subset distribution of different individuals varies significantly. 
Indeed, healthy individuals can be sub-divided into at least six signature 
profiles, with differing proportions of each subset in each profile.  As the four 
subsets differ in terms of their functional attributes, it follows that the different 
V9V2 T cell phenotypic signatures predict distinct V9V2 T cell functional 
potentials for different individuals.  Thus, immunotherapeutic strategies that 
attempt to expand or activate V9V2 T cells will have different outcomes in 
individuals with different signature profiles.  This in turn suggests that patient 
stratification into V9V2 T cell signature profiles would maximise the benefits of 
V9V2 T cell therapy aimed at a particular functional outcome.  For example, 
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individuals with a predominance of (28+) cells and (28-) cells (phenotypic 
signatures 1-3) are likely to have more robust proliferative responses in 
comparison to those with a predominance of the (16-) and (16+) subsets with 
strong cytotoxic responses (phenotypic signatures 4-6).  Clearly, our ability to 
predict V9V2 T cell responses has potential to allow more accurate forecast 
of V9V2 T cell immunotherapy success which at present is relatively 
unpredictable in terms of treatment success and improving survival outcome 
(Meraviglia et al. 2010, Wilhelm et al. 2003).  Extending this concept further, a 
knowledge of an individual’s V9V2 T cell profile may also be predictive of their 
own ability to mount protective V9V2 T cell responses to infectious challenge 
or tumours. 
9.4 The (28+) cell subset may retain the potential to develop 
into IL-17-secreting V9V2 T cells. 
Unlike either human  T cells, or mouse  T cells, human  T cells do not 
readily display IL-17-secreting capacity.  Indeed, a lengthy and complicated 
activation regime in vitro is required to generate even a few IL-17-secreting 
V9V2 T cells (Caccamo et al. 2011b, Ness-Schwickerath and Morita 2011).  
Despite this, several studies have reported IL-17-secreting V9V2 T cells in 
certain diseases including tuberculosis and HIV (Peng et al. 2008, Fenoglio et 
al. 2009) (suggesting not only that V9V2 T cells can adopt this cytokine-
secreting state, but also that they may have functional implications for disease 
progression. 
Interestingly, the microarray gene expression analysis of the four newly-defined 
V9V2 T cell subsets suggest that the (28+) cell subset may retain the ability 
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to develop IL-17-secreting potential as it differentially expresses three genes; 
CCR6, RORC, and IL-23R, which are implicated in the development of an 
IL-17-secreting phenotype.  Moreover, the surface expression of CCR6 
identifies a distinct sub-population of (28+) cells lacking expression of CX3CR1 
(Fractalkine receptor) which is strongly expressed by CCR6(-) (28+) cells, and 
all (28-), (16-) and (16+) cells.  CX3CR1 is a chemokine receptor that binds the 
chemokine CX3CL1 (fractalkine) and is believed to be important in the adhesion 
and migration of lymphocytes into tissues in a number of inflammatory diseases 
(Imai et al. 1997, Cockwell et al. 2002).  It is produced in endothelial cells as a 
membrane adhesion protein as well as existing as a secreted chemotactic 
factor (Imaizumi et al. 2004).  Thus, this CCR6(+) (28+) cell subset may 
represent an IL-17-secreting V9V2 T cell progenitor population with reduced 
ability to migrate to the tissues, although the functional significance of the 
mutually exclusive expression of CCR6 and CX3CR1 clearly requires more in-
depth study.  Therefore, the characterisation of this subset, and investigation of 
whether it can be induced to adopt an IL-17-secreting phenotype under certain 
activation conditions is an obvious area of future potential research (see future 
work). 
It would also be interesting to see whether this CCR6(+)CX3CR1(-) (28+) subset 
is present in all individuals.  If not, studies that attempted to generate IL-17-
secreting V9V2 T cells from donors that lacked this population would have 
revealed predictably negative results.  In addition, if IL-17 producing subsets 
are not present in all individuals this also has implications in terms of predicting 
risk of IL-17-mediated inflammatory diseases e.g. rheumatoid arthritis and 
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psoriasis where IL-17 secreting V9V2 T cells are believed to be key in the 
pathogenesis of disease (Laggner et al. 2011, Hu et al. 2012). 
9.5 Mutually exclusive CCR6 and CX3CR1 expression in 
V9V2 T cells identify an important differentiation stage 
in their functional biology 
The mutually exclusive relationship between the chemokine receptors CCR6 
and CX3CR1 appears to identify two non-overlapping V9V2 T cells subsets; 
[CCR6(+)CX3CR1(-)] with a proposed IL-17 producing potential, and a second 
[CCR6(-)CX3CR1(+)] subset expressing the opposite pattern of chemokine 
receptors.  Whilst the identification of a subset with potential IL-17 producing 
ability is interesting, nevertheless it is clear that the majority of V9V2 T cells in 
the peripheral blood typically adopt a TH1 phenotype in preference to 
differentiation into TH17-like, IL-17-producing subsets.  It is therefore possible 
that the transition between the [CCR6(+)CX3CR1(-)] and [CCR6(-)CX3CR1(+)] 
populations within the (28+) subset may signify an important developmental 
step in  T cell biology.  Indeed, it may represent the branch-point at which 
cells can either progress down a TH1 or a TH17 pathway as the expression of 
CCR6 on V9V2 T cell subsets has previously been identified as a potential 
surface marker of cells with IL-17 producing potential (Caccamo et al. 
2011a)(Figure 9.1). 
Clearly, V9V2 T cells show a typical preference to adopt a cytotoxic TH1 
potential, as CX3CR1(+) cells also upregulate granzyme B, granulysin and 
perforin directly associated with a cytotoxic phenotype.  It is therefore possible 
that the [CCR6(+)CX3CR1(-)] subset is a “plastic” population, that has potential to 
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differentiate into many different phenotypic populations, but preferentially 
assumes a cytotoxic TH1-like phenotype.  Indeed, it has been proposed in a 
recent review that cells with an IL-17-producing potential are preferentially 
polarised to a TH1-like phenotype following repeated or specific antigen 
exposure (Ness-Schwickerath and Morita 2011).  The authors also postulate 
that IL-17 production might be restored in these “switched” V9V2 T cells if 
they are exposed to IL-17 priming cytokines (IL-1, IL-6, IL-23 and TGF-) 
perhaps in particular inflammatory or niche tissue environments in specific 
diseases (Ness-Schwickerath and Morita 2011).  This suggests that despite the 
majority of TH17-like V9V2 T cells switching to a TH1 phenotype, they retain a 
“memory” of their IL-17 secreting ability that can be restored in tissue sites of 
infection and in cancer where many of these aforementioned  “IL-17 priming 
cytokines” are produced in the local environment during inflammation (Figure 
9.1). 
9.6 The (28+) cell subset has a distinct chemokine receptor 
expression profile. 
The results from both the microarray data and flow cytometry surface marker 
analysis also revealed that the (28+) cell subset had a distinct chemokine 
receptor profile when compared to the other three subsets. As well as the 
aforementioned expression of CCR6, a significant proportion of the (28+) cell 
subset also expressed both CCR2 and CCR5.  These chemokine receptors 
have been shown to be important in the migration of both V1 and V9V2 T 




Figure 9.1 The (28+) s  set ma  re resent a “  ast  ”  o   at on that  an d fferentiate into cells with both TH1-like and TH17-like 
cytokine properties 

(28+) cells are made up of two further subsets with opposing patterns of chemokine receptor expression profiles i.e. (28+) [CCR6(+)CX3CR1(-)] 
and (28+) [CCR6(-)CX3CR1(+)] populations.  Whilst the majority of V9V2 T cells adopt a TH1-like expression profile, it is possible that the 
(28+)
[CCR6(+)CX3CR1(-)] subset represents a population that can differentiate under certain conditions into TH17-like cells with IL-17 producing
capability. 
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malignant melanoma and as observed in human hepatocellular/colorectal 
cancer patients (Lança et al. 2013, Bouet-Toussaint et al. 2008).Previous 
studies have shown wide variation in the levels of CCR2 expression (15-58%) 
as well as CCR5 expression (59-98%) on human  T cells with higher levels 
compared to conventional  T cells (Meraviglia et al. 2011), perhaps 
suggesting an inherent increased ability of  T cells in general to home to 
inflammatory/tumour sites compared to conventional  T cells.  A further study 
showed high levels of CCR2/CCR5 on CD27(-) effector V9V2     T cell subsets 
(Dieli et al. 2003b) which is in contrast to the findings of this study that observe 
the highest levels of CCR2 and CCR5 on the (28+) subset. 
This would suggest that (28+) cells show the highest homing potential to 
peripheral inflamed and tumour tissue sites despite having the lowest cytotoxic 
potential.  However, further investigation to determine the expression of the 
inflammatory chemokine receptors CCR2 and CCR5 on [CCR6(+)CX3CR1(-)] 
and [CCR6(-) CX3CR1(+)] (28+) subsets will allow us to better define these 
subsets in terms of their ability to home to inflammatory environments. 
9.7 KIR proteins are expressed at high levels in the (16+)
subset 
Two of the KIR family of proteins; Killer-cell immunoglobulin-like receptors 3 and 
4 (KIR2DL3 and KR2DL4), were expressed significantly higher in (16+) cells 
compared to the three CD16(-) subsets, with gene expression increasing across 
subsets.  Our knowledge of these immunoregulatory genes is mainly derived 
from the study of NK cells and to date they have not been extensively studied in 
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V9V2 T cells.  Therefore, the significance of an increasing level of expression 
of these genes across the subsets (i.e. (28+) (16+)) is not clear. 
KIR2DL3 is an inhibitory receptor that inhibits cytotoxic signals through its two 
ITIM domains.  It is expressed at higher levels in the subsets that display 
increased cytotoxic potential suggesting that it may be an in-built “control 
switch” that help to regulate cytotoxic responses (Rajagopalan and Long 2012).  
By contrast, KIR2DL4 is not expressed on the majority of V9V2 T cells 
(Lesport et al. 2011) being an atypical KIR protein expressed inside endosomes 
with little or no surface expression. KIR2DL4 shows extensive evolutionary 
conservation and has been proposed to have both inhibitory and activatory 
potential (Ponte et al. 1999, Rajagopalan et al. 2001).  However on balance, it 
is considered to have a net stimulatory effect despite its single ITIM tail. 
KIR2DL4 promotes only weak cytotoxic activation, but in contrast its expression 
promotes a strong pro-inflammatory effect by increasing cytokine responses 
e.g. IFN-, TNF-, IL-1 and IL-6 (Rajagopalan and Long 2012). The 
expression of these KIR proteins clearly warrants further investigation along 
with cell surface characterisation of subsets to investigate whether their 
expression is similar to NK cells where these proteins have been predominantly 
studied (Rajagopalan et al. 2006, Rajagopalan and Long 2012).  Interestingly, 
HLA-G is the only known ligand for KIR2DL4 and has been shown to be 
produced by tumours leading to an increase in serum HLA-G in these patients.  
Clearly, an increased understanding of the mechanisms that regulate V9V2 
T cell cytotoxicity and cytokine secretion is central to our understanding of 
V9V2 T cell function in disease.  In addition, it also has potential to assist in 
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developing more efficient cytotoxic V9V2 T cell immunotherapies against 
cancer. 
9.8 Phenotypic subsets remain stable over time and suggest 
a homeostatic mechanism of control 
In the analysis of V9V2 T cell from healthy volunteers, it was clear that a 
particular subset was not dominant in older individuals, suggesting that V9V2 
T cells remained relatively stable throughout life, with a slight reduction in 
percentage (relative to total lymphocytes) with increasing age.  The latter is 
consistent with studies that have also found a steady depletion of V9V2 T 
cells with increasing age (Parker et al. 1990, Caccamo et al. 2006, Michishita et 
al. 2011).  In addition, there were no statistically significant differences found in 
V9V2 T cell percentage between sexes at different ages, which again is 
supported by published findings (Cairo et al. 2010).  However, this finding is 
contradicted by one large study that found that V9V2 T cells were depleted 
with age more significantly in males (Caccamo et al. 2006).  Results presented 
in this study also suggest that ethnicity, sub-region/continent of birth and the 
development status of country of birth did not significantly affect V9V2 T cell 
percentage in the peripheral blood.  This however is not fully supported by other 
subset studies that have previously found an increase in V2/CD3(%) in a 
Caucasian cohort compared to an African American cohort (Cairo et al. 2010).  
Indeed, another study also showed there to be significant variation in 
/CD3(%) depending on the country of the participating individual, with higher 
percentages found in Asian (Non-Japanese) and Turkish participants compared 
to Japanese and Swedish recruited cohorts (Esin et al. 1996). 
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The percentage of each V9V2 T cell phenotypic subset also appeared to be 
relatively stable over time with the only significant change being a decrease in 
the (28-) subset in the oldest compared to youngest volunteers.  All other 
subsets remained relatively stable with no significant changes found across the 
age ranges.  This suggests that V9V2 T cell subsets are under some sort of 
homeostatic control.  This relative stability over time is perhaps surprising, as it 
might be assumed that effector subsets might increase with age due to 
increased and cumulative antigen exposure.  If it is also assumed that V9V2 T 
cells undergo a linear and progressive pattern of differentiation i.e. (28+)→ 

(28-)→ 16-)→ (16+) and that thymic output is minimal after adolescence, then 
replenishment of subsets must occur independent of thymic output and perhaps 
via a stem or “memory” type population subset. 
A range of phenotypic signatures were also found in the bisphosphonate-
treated and BRONJ patients which demonstrates that despite continued 
activation of V9V2 T cells, and depletion from the blood that a shift towards 
an effector-dominated phenotypic signature does not occur.  A final observation 
to support the notion that homeostatic regulation controls the stability of V9V2 
T cell subsets over time was from a healthy 33 year-old female with signature 
#6 who was phenotyped on three separate occasions over a 12-month period 
without any notable changes in her V9V2 T cell subset signature. 
9.9 A model for V9V2 T cell differentiation 
There are three datasets of experimental evidence that relate to the 
construction of a model that explains V9V2 T cell differentiation and the 
adoption of certain functional qualities. 
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1. The microarray data suggested that the four newly-defined subsets were not
equally as different from one another.  Instead, it suggested that the two most 
different subsets were the (28+) cell subset and the (16+) cell subset.  This 
could be taken to mean that these two populations are at either end of a 
differentiation pathway, which is visually supported by CD27/CD28 FACS dot 
plots (which appear to suggest a transition from (28+) cells to (28-) cells to 

(16+/-) cells).  An interesting additional observation is the relative lack of 
differences between the (28-) and (16-) cell subsets. This suggests that these 
two subsets may in fact represent a transitional state in which features of the 

(28+) cell subset are lost while features of the (16+) cell subset are gained. 
This would imply that there are two main V9V2 T cell phenotypes; the (28+) 
subset and (16+) subset, with transitional cells bridging these two effector 
states. 
2. In support of the microarray data, the probability state modelling performed
using the GemStone software also suggested two well-defined effector states 
that are defined as the (28+) and (16+) subsets.  Taking the many healthy 
individuals together (which is an important feature of this software) we were 
able to observe a CD28(+)CD16(-) phase and a CD28(-)CD16(+) phase in 
practically all samples.  The transition between these two phases differed 
slightly between individuals, but generally followed the following pattern; 
downregulation of CD28, downregulation of CD27, upregulation of CD16, 
upregulation of CD45RA. 
3. An important prediction of a model of V9V2 T cell differentiation in which
cells transition (presumably as a result of either an in-built differentiation 
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program, or in response to microbial activation) from a (28+) cell phenotype, 
through a series of transitional stages, to a (16+) cell phenotype is that the 
older a person is, the higher you would expect the (16+)/(28+) ratio to be.  It 
may also suggest that living in an environment with an increased risk of serious 
infection (such as in developing countries with low economic status), would also 
lead to higher (16+)/(28+) ratios. However, our data show no evidence for this.  
Age, country of birth, and economic status were not significantly correlated with 
an increased (16+)/(28+) ratio.  The failure to show this predicted age-related 
change may be due to the relatively modest sample size (63 individuals) or the 
fact that the sampled healthy volunteer population is taken from individuals who 
have spent the majority of their life in the UK and may not have had exposure to 
the specific infections that drive V9V2 T cell differentiation to a predominant 
phenotype.  Nonetheless, there is no evidence from demographic data to 
support an age-dependent transition through a (28+) cell to (28-) cell to (16-/+)
cell pathway. 
A model for V9V2 T cell differentiation that is consistent with these three 
datasets suggests that an individual’s V9V2 T cell signature profile is in a 
fairly stable state over long periods of time.  The nature of a V9V2 T cell naïve 
population (see later) is still open to debate, but presuming that all non-naïve 
subsets differentiate from a precursor of this type, one could envisage a 
scenario in which the early activation of naïve V9V2 T cells generates a 
spectrum of mature V9V2 T cells with a range of “effector potentials” (Figure 
9.2).  On the two extremes of this spectrum are, on one hand, the (28+) subset, 
which retains a high proliferative capacity and is capable of a certain degree of 
plasticity in cytokine production, but which has little cytotoxic potential. At the 
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other extreme is the (16+) subset, which has lost proliferative potential and 
plasticity of cytokine function, but has upregulated robust cytotoxic capacity. 
Perhaps the system is designed to provide a good quantity of all cell types, but 
in certain cases (for example in the presence of certain microbes) may be 
polarised to one extreme or the other.  Once established, the stable signature 
profile of an individual must be actively maintained despite exposure to constant 
bacterial infections. Presumably active effector cells leave the pool of cells with 
“effector potential” when they are required to participate in anti-microbial 
responses.  There may then be some sort of stem cell activity, which 
homeostatically restores the signature profile to its original state.  Whether the 
signature profile does change over time is unclear from the data presented 
here, and would require a longitudinal study. However, it remains possible that 
certain infections may push the signature profile in one direction or the other. 
This remains to be tested. 
9.10 CD27 and CD11a represent the most reliable naïve cell 
markers 
One continued area of debate, is the size and most appropriate phenotypic 
surface markers for a “naïve” subset of V9V2 T cells.  It is apparent from our 
data that estimates of the naïve subset using CD45RA i.e. (CD27(+)CD45RA(+)) 
are much higher (approximately 23%) compared to estimates using alternative 
naïve surface marker combinations e.g. [CD27(Hi)CD11a(Lo)], [CD27(Hi) CCR7(+)] 
or [CCR7(+)CD62L(+)] which estimate the “naive” subset consistently at < 5%.  
Studies by De Rosa and Morita also support these findings and suggest that 
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CD27 and CD45RA grossly overestimate the naïve subset size (De Rosa et al. 
2004, Morita et al. 2007). 
Phenotypic studies by Morita and co-workers estimate the size of the naïve 
subset to be 1.8% and hence to represent a very small subset in adult 
peripheral blood that is frequently absent and often difficult to identify (Puan et 
al. 2009, Morita et al. 2007).  This led us to consider the best markers to use to 
describe “naïve” and non-“naïve”subsets.  Care must be taken when using 
CCR7, as staining is clone and condition-dependent.  This finding is supported 
by a technique research paper which also concluded that expression of 
chemokine markers in general is temperature and technique sensitive (Berhanu 
et al. 2003).  Another of the naïve markers; CD62L, has also been shown to be 
variable in some studies and can be totally lost from the cell surface as a result 
of prolonged transportation and temperature variations (De Rosa et al. 2004).  
This led us to the conclusion that the use of [CD27(Hi)CD11a(Lo)] was the most 
reliable way to identify “naïve” cell markers in peripheral blood.  Further work on 
“naive” V9V2 T cells is planned (see below). 
9.11 Naïve cell surface markers do not predominate in the 
thymus. 
Our knowledge of the earliest stages of human V9V2 T cell development in 
the thymus is limited by the lack of a direct equivalent population in murine 
experimental models.  Indeed, we know very little about the phenotype of these 
early subsets, how they develop and whether there is any evidence of pre-




Figure 9.2 V9V2 T cell differentiation model 
V9V2 T cells appear to differentiate in a linear pattern of differentiation sequentially from (28+) (28-) (16-) (16+).  Consistent stable 
subsets [(28+) and (16+)] at the start and end of differentiation with transitional subsets [(28-) and (16-)] observed with intermediate functional 
properties as cells move between the two effector states.  V9V2 T cells appear to preferentially adopt a TH1 cytokine profile, possibly due to 
continued antigen stimulation and exposure to Phosphoantigen.  Despite this dynamic process, the size of V9V2 T cell subsets appear to 
remain relatively stable with time suggesting that homeostatic mechanisms are in place, that replenish the V9V2 T cell pool.  A “stem cell” 
subset may help to replenish V9V2 T cell pools lost due to apoptosis. 
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Previous studies have suggested that human V9V2 T cells undergo 
peripheral activation and expansion very early in life with disappearance of 
naïve phenotypes and a predominance of memory and effector phenotypes as 
a result of early antigen exposure  (Parker et al. 1990, De Rosa et al. 2004).  
Indeed, with the process of thymic involution in young adult life it is somewhat 
surprising that there are any “naïve” phenotypes remaining in the peripheral 
blood of adults which hints at an ongoing role for the thymus well into adult life.  
There is still uncertainty as to the most representative surface markers to 
describe the “naïve” V9V2 T cell subset (De Rosa et al. 2004, Morita et al. 
2007, Dieli et al. 2003b) Therefore, eight neo-natal thymus samples were 
investigated to examine  T cells during development.  As expected, V1(+) T 
cells were the predominant  T cell subset in the thymus with higher 
percentages found in the thymus compared to peripheral blood, where V9V2 
T cells predominated.  This was in agreement with several other studies, which 
also consistently found this same relationship (Parker et al. 1990, McVay and 
Carding 1999). 
We hypothesised that V9V2 T cells should largely display “naïve” surface 
markers in their organ of origin before their release into the peripheral blood.  
However, surprisingly there did not seem to be a predominance of typical 
“naïve” surface markers expressed on V9V2 T cells in the thymus with the 
majority of samples analysed showing similar expression levels to the same 
subset in peripheral blood. 
This suggests a number of possibilities.  One explanation may be that V9V2 
thymocytes are exposed to phosphoantigen within the thymus.  Alternatively it is 
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possible that antigen-exposed cells in the periphery re-circulate back through 
the thymus.  Indeed, thymic re-circulation of mature T cells has previously been 
described, but only a small minority of T cells show potential to return to the 
thymus after initial release (Sprent and Surh 2009, Nobrega et al. 2013) 
although re-circulation through the thymus has been observed to occur more 
commonly in neonates (Sprent and Surh 2009, Nobrega et al. 2013).  Finally, it 
is also possible that the “naïve” phenotype that we see in the blood is a 
developmental stage that occurs during late thymic development and 
consequently is only expressed on a small proportion of cells immediately 
before leaving the thymus.  Indeed, this is supported by one study suggesting 
that CD45 isoforms show dynamic switching at different stages of thymic 
development and that CD45RA is only expressed at a late stage of thymic 
development (Fujii et al. 1992). 
Therefore, the identity of the true “naïve” phenotype was not clarified directly 
from observing the predominant thymocyte phenotypes, as the T cell markers 
conventionally considered as “naive” i.e. CCR7, CD62L and CD45RA clearly 
were not predominant.  It was however apparent that two consistently-observed 
subsets were present in the thymus; a predominant CD27(+)CD11a(Lo) subset 
(90% of total thymocytes) and a smaller CD27(Hi)CD11a(+) subset (10%).  This 
pattern of CD27 and CD11a was very different to the subsets present in the 
peripheral blood, which made comparison of similar subsets in the different 
tissues difficult.  In the peripheral blood CD27(Hi)CD11a(Lo) characterises the 
presumed “naïve” subset, with the majority of non-naïve cells expressing 
CD11a at high levels (CD11a(Hi)).  The differences in patterns of expression 
made it impossible to be sure as to the relationship of these subsets.  However, 
within the thymus, it was apparent that the smaller CD27(Hi)CD11a(+) subset did 
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express significantly higher levels of the naïve surface markers CCR7 and 
CD62L and also surprisingly higher levels of CD16 in comparison to 
CD27(+)CD11a(Lo) cells.  The expression of CD16, usually considered as a 
cytotoxic marker, raises questions as to its presence on a thymic subset.  One 
explanation for this is that CD16 might be indicative of V9V2 T cells or 
cytotoxic cells that have antigen presenting potential (Wu et al. 2009)  Indeed, 
two separate studies have suggested that CD16 may be key receptor in both 
phagocytosis and subsequent antigen presentation specifically in V9V2 T 
cells (Wu et al. 2009, Kang et al. 1987)  The increased expression of CCR7 and 
CD62L found on this same CD27(Hi)CD11a(+) subset add further weight to a 
potential role as possible precursors to an antigen presenting subset by 
indicating an ability to enter lymph nodes. 
9.12 Higher frequency of the [CD27(Hi)CD11a(Lo)] subset in the 
V1(+) T cell population compared to V9V2 T cells may 
reflect differences in  T cell development. 
The higher representation of a so-called “naïve” [CD27(Hi)CD11a(Lo)] population 
as well as increased CD45RA expression, were clear differences between 
V1(+) and V9V2 T cell subsets.  However, the functional significance of this 
difference is uncertain.  Indeed, these results echo the findings of DeRosa and 
co-workers who also similarly found higher levels of the naïve phenotype 
[CD45RO(-)CD27(Hi)CD11a(Lo)] in V1(+) T cells in comparison with V9V2 T 
cells (De Rosa et al. 2004).  This study goes on to postulate that this may reflect 
a difference in how V1(+) and V9V2 T cells are produced and maintained 
throughout life.  They suggest that V1(+) and V9V2 T cells develop at 
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different times, in a similar manner to different subsets of murine  T cells 
(Carding and Egan 2002).  They propose that V9V2 T cells develop at or 
around birth and home to peripheral sites, where they are subsequently 
maintained by proliferation of existing cells as opposed to the thymic generation 
of new “naïve” cells.  This would explain the relatively low levels of “naïve” 
V9V2 T cells in adult peripheral blood.  By contrast, the relatively large V1(+) 
naïve T cell population observed in adult blood might hint at the thymus having 
a significant on-going role in the production of new “naïve” V1(+) cells well into 
adult life.  However, the presence of naïve V9V2 T cells in some individuals 
suggests that there is also potential for replenishment of the V9V2 T cell pool 
by the thymus. 
9.13  Depletion of V9V2 T cells in the peripheral blood is 
characteristic of patients on long-term bisphosphonates 
including BRONJ 
One of the consistent findings in all patients with a history of bisphosphonate 
exposure (including BRONJ patients), was the significant depletion of the 
V9V2 T cell subset from the peripheral blood.  This depletion is in agreement 
with another study which also found specific reduction of this T cell subset in 
patients exposed to oral and intravenous bisphosphonate therapy (Rossini et al. 
2012). The most likely explanation for this finding is that chronic 
bisphosphonate therapy and repeated TCR activation leads to Fas-mediated 
apoptosis and a consequent depletion of the V9V2 T cell subsets from the 
peripheral blood.  This effect is likely to be an immunoregulatory mechanism 
that limits the activation of V9V2 T cells after repeated activation (Gan et al. 
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2001).  Therefore V9V2 T cell depletion does not appear to be specifically 
pathognomonic of BRONJ disease, but may simply be an associational change 
that occurs in all patients receiving long-term bisphosphonate therapy (Kalyan 
et al. 2013). 
An alternative possibility, is that V9V2 T cell depletion is a clinical sign that is 
indicative of its direct role in disease causation and a necessary factor in the 
development of BRONJ.  It is possible that the observed loss of peripheral 
blood V9V2 T cells might result due to the net movement of these cells from 
the peripheral blood to the jaws/peripheral tissues.  This possibility, is further 
supported by recent evidence demonstrating that there were 4-5 times more 
V9V2 T cells found in BRONJ tissue histology samples compared to non-
bisphosphonate osteonecrotic control tissues (Mawardi H 2013).  This suggests 
that V9V2 T cells may home to the local sites of BRONJ in the disease 
process and that they may have a key role in initiating and sustaining the 
disease.  Indeed, the preferential homing of V9V2 T cells to the tissues may 
be taking place due to the upregulation of the skin/mucosal homing marker 
(47) which has been shown to occur following phosphoantigen stimulation of 
V9V2 T cells (McCarthy et al. 2013). Therefore it is likely that 
bisphosphonates as well as oral bacteria which both indirectly increase 
phosphoantigen production will also have similar effects on V9V2 T cells. 
Clearly, the potential additional activation of V9V2 T cells by oral bacteria may 
help explain the fact that osteonecrosis only occurs in the jaws where these 
necessary conditions exist.  The presence of activated V9V2 T cells and the 
subsequent release of pro-inflammatory cytokines (e.g. IFN- and TNF-) at 
tissue sites may also be important in priming conventional  T cells in the 
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tissues to a Th1 phenotype and further amplifying the local inflammatory 
response (McCarthy et al. 2013). 
If this is the case, then the loss of peripheral blood V9V2 T cells may be a 
potential useful risk indicator for the development of BRONJ and perhaps a 
useful chairside test to predict those most at risk of developing BRONJ. 
9.14 Limitations of experimental data 
9.14.1 Proliferation assay 
A limitation of the V9V2 T cell proliferation data presented in section 4.4 is 
that, by simply comparing starting and end phenotypes after culture, it is not 
possible to conclude whether changes observed are due to the proliferation of 
individual V9V2 T cell subsets or whether individual cells also change their 
surface marker expression and phenotype as a result of culture. 
An alternative approach to analysis of the current data would be to display the 
phenotype of each of the individual rounds of division of V9V2 T cells to 
determine which of the subsets at 5-days had divided and proliferated the most.  
However this method also fails to account for any shifts in phenotypes and 
changes in surface marker expression that occur due to culture and stimulation. 
Therefore, in order to resolve this in future work, each of the four V9V2 T cell 
subsets i.e. (28+), (28-), (16-), (16+) could be cell sorted and cultured with 
HMB-PP and IL-2 over 5-days to assess both proliferative potential as well as 
phenotype stability.  However, these cultures would also require non-V2 
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accessory cells to be added back into cultures in order to enable successful 
proliferation and effective V9V2 T cell expansion. 
9.14.2 Cytokine production 
A criticism of the use of PMA and ionomycin for determining cytokine secreting 
potential is that they generate a “non-physiological” cytokine release because it 
by-passes surface marker stimulation. PMA diffuses through the cell 
membrane and activates Protein kinase C (PKC) with ionomycin generating 
calcium release, which is a necessary factor in NFAT signalling (Manicassamy 
et al. 2006).  An additional problem with PMA and ionomycin stimulation is that 
it can affect the expression of surface molecules including CD3 and therefore 
makes gating using flow cytometry potentially a problem.  This highlights the 
absolute need for isotype and unstimulated controls in setting appropriate 
positive gates.  However, it represents a useful method to determine the 
differential ex vivo cytokine release potential of V9V2 T cell subsets. 
An alternate, more physiological method would be the use of anti-CD3 and/or 
anti-CD28 whereby activation of cells and cytokine production is triggered 
through surface molecules.  A final alternate “more physiological” cell activation 
would be to use a phosphoantigen (HMB-PP or IPP) to stimulate cells. 
Future experimental work could compare ex vivo (PMA/Ionomycin) stimulation 
with the aforementioned alternate stimulation protocols to determine whether 
there are differences in the types and amount of V9V2 T cell cytokine 
production when cells are activated in different ways and by different 
mechanisms. 
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Intracellular cytokine staining only measures the amount of cytokine produced 
inside each cell which does not necessarily equate to the amount of cytokine 
released into extracellular environment with the potential to exert a 
physiological/pathological effect. Therefore, whilst representing a useful 
method to compare the relative cytokine production in each V9V2 T cell 
subset, it may not truly represent the net cytokine output which is influenced by 
cytokine release, as well as the local tissue environment. 
9.14.3 Age vs. Tissue (Thymus) 
One of the most fundamental problems in comparing the phenotype of V9V2 
T cells in the blood and the thymus was that, thymic samples were only 
available from children in the first few years of life who were undergoing 
corrective cardiac operations, whereas peripheral venous blood samples were 
taken from a predominantly adult population.  Therefore, the comparison of 
circulating versus thymic V9V2 T cells was made between cells at different 
stages of development as well as from different individuals of different ages.  
However, whilst not directly comparable, the analysis of thymic V9V2 T cells 
was used to identify the “naïve” V9V2 T cell phenotype as it is thought that 
the thymus is an immune privileged site that is protected from infection.  It was 
therefore postulated that the phenotype of V9V2 T cells in this organ might 
reveal the true “naïve” phenotype before release into the circulation and 
peripheral tissues. 
Ideally, the comparison between thymic and circulating V9V2 T cells in neo-
nates/infants within the same individual will allow more robust conclusions to be 
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made.  It therefore represents a potential avenue of future research although 
this would require a new ethical approval to facilitate this. 
9.14.4 Critical appraisal of PSM 
Conventional understanding of T cell differentiation suggests that V9V2 
T cells differentiate through distinct phenotypic stages, with naïve cells 
populating the thymus, central memory cells patrolling the blood and effector 
cells located in the tissues.  These different T cell effector states are widely 
accepted and there is a presumption that T cells including V9V2 T cells also 
differentiate along this linear pathway and eventually undergo apoptosis in the 
tissues as cells become senescent.  Whilst there is some in vitro experimental 
evidence to support this premise (Dieli et al. 2003b), the stages of development 
and phenotypes of V9V2 T cells have been carried over from conventional T 
cell without much evidence to support this. 
Models derived using PSM are based on the input of “rules” or presumptions as 
to the direction of surface marker change during differentiation and the number 
of levels or intensity of surface markers as cells differentiate from an early or 
“naïve” phenotype to a late effector phenotype.  Therefore, it generates average 
models by combining phenotypic signatures right across the spectrum from 
multiple samples.  Whilst being a useful tool in averaging heterogeneous 
V9V2 T cell populations, a disadvantage is that the resulting model hides the 
extremes in phenotypic signature that occur in some individuals (phenotype 1 
and 6).  PSM, however, does allow the relationship of surface markers to be 
assessed visually along a differentiation pathway and would support a linear 
pattern of differentiation from (28+) (28-) (16-) (16+).  In support of this 
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pathway, it would appear that there are three major population subsets when 
visualised on a CD28/CD27 bivariate flow cytometry plot, which seem to 
suggest transition from CD28(+)CD27(+) to CD28(-)CD27(-) via an intermediate 
CD27(+)CD28(-) population. 
By contrast to the linear model of differentiation is the observation that 
individual phenotypic signatures appear to remain relatively stable over time.  
This might suggest that a linear pattern of differentiation is incorrect because we 
do not see an age dependent accumulation of late effector phenotypes i.e. 
increased (16+) cells with increasing age.  Alternatively, this might support a 
discrete model of differentiation, where an individual’s phenotypic signature is 
established by V9V2 T cell subsets, which are in turn established 
interdependently of each other and tightly controlled by homeostatic control. 
Interestingly, the differentiation pathway of V9V2 T cells and conventional T 
cells seems to be different when modelled using PSM and raises the question 
as to whether terms and surface markers used for conventional T cells are 
also appropriate for V9V2 T cells. 
Whilst the stimulation of cell sorted subsets with phosphoantigen and IL-2 over 
several days of culture might indicate the potential direction of V9V2 T cell 
subset differentiation in vitro, it is unclear as to the significance and relationship 
of cell subsets in the different tissue compartments in vivo.  Furthermore, 
whether or not differentiation occurs in only one direction along a linear pathway 
or whether change between subsets is far more dynamic and possibly 
reversible is a question that still remains unanswered. 
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9.15 Future work 
The experimental evidence presented in this thesis raises a number of new 
avenues of future research both in the biology of human V9V2 T cells as well 
as in our understanding of BRONJ. 
Firstly, one of the most interesting and potentially significant observations of the 
thesis was the mutually exclusive surface expression of CCR6 and CX3CR1 on 
the V9V2 (28+) T cell subset, dividing this population into two populations i.e. 

(28+) CCR6(+)CX3CR1(-) and (28+) CCR6(-)CX3CR1(+) V9V2 T cells.  This 
finding, in addition to the fact that three important IL-17-associated genes 
(CCR6, IL-23R and RORC) are differentially expressed at higher levels in (28+) 
T cells, raises questions as to whether further phenotypic division of the (28+)
subset based on CCR6 and CX3CR1 surface expression may be useful in 
identifying cells with IL-17 producing ability.  Indeed, further characterisation of 
the CCR6(+)CX3CR1(-) and CCR6(-)CX3CR1(+) (28+) subsets is warranted to 
determine whether differential expression of these chemokine receptors has a 
biological significance in terms of differences in cytokine-producing ability as 
well as chemokine receptor and cytotoxic protein expression. 
At present, the field does not have a clear understanding as to how human    
T cells make IL-17.  Thus, further understanding of the priming conditions that 
would lead to IL-17 production and the phenotypic characterisation of cells with 
this potential would markedly improve our insight into diseases in which V9V2 
T cells make IL-17.  This could be investigated by testing whether the culture of 
CCR6(+) (28+) V9V2 T cells in the presence of phosphoantigen (IPP), IL-17 
priming cytokines (IL-1, IL-6, IL-23 and TGF-) and accessory cells (dendritic 
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cells or monocytes) might preferentially polarise this specific subset to an IL-17 
producing phenotype.  Comparison could then be made to the other CCR6(-) 
subsets i.e. from the (28+), (28-), (16-) and (16+) populations, and with 
populations from the neonatal thymus.  The latter comparison is potentially 
important as it is likely that cells from younger individuals may retain greater 
ability to adopt different phenotypes. 
Indeed, there is clearly a need to confirm in a larger number of individuals, the 
V9V2 T cell population phenotypes present in the thymus to further our 
understanding of both the phenotypic changes that occur during development 
and also perhaps in defining early populations with plastic potential.  Whilst we 
have identified two distinct thymic subsets based on CD27 and CD11a i.e. 
[CD27(+)CD11a(Lo)] and [CD27(Hi)CD11a(+)], the lack of directly comparable 
subsets in comparison to the peripheral blood phenotype makes it difficult to 
determine the relationship of these subsets.  Therefore it would be beneficial to 
also investigate the surface expression of CCR6 and CX3CR1 on thymic 
V9V2 T cells, given the differential expression of these same markers on the 
presumed earliest (28+) subset in peripheral blood.  Following on from this, it 
would subsequently be possible to sort different thymic V9V2 T cell subsets 
based on different putative naïve surface marker combinations to identify cell 
subsets with potential to be polarised to different effector populations (i.e. TH1, 
TH2, TH17 etc).  A better understanding of the functional potential of these early 
subsets would lead to increased understanding of V9V2 T cell plasticity 
generally. 
Finally, the recruitment of a larger cohort of BRONJ patients will help in 
confirming the finding that V9V2 T cells are depleted in peripheral blood.  
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Examination of BRONJ tissue samples is clearly needed to confirm whether or 
not there are increased or reduced V9V2 T cell numbers within the tissues i.e. 
whether the peripheral blood depletion is due to net movement of V9V2 T 
cells to the jaw lesions or reflects the activation induced cell death due to 
chronic stimulation.  Clearly, either increase or reduction of V9V2 T cells in 
the tissues can lead to loss of normal tissue homeostasis and potential to 
directly influence the disease process. 
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Chapter 10 Appendices 





10.2 Patient information sheets 
Example of healthy volunteer patient information sheet is shown (Similar forms 






10.3 Data collection sheets 
10.3.1 Healthy volunteers 
279 
10.3.2 BRONJ group 
280 
10.3.3 Control groups 
281 
10.4 Gene microarray- All differentially expressed genes. 
All differentially expressed genes are indicated from the microarray of V9V2 T 
cell subsets.  Comparison are made between each individual V9V2 T cell 
subset as well as between subsets compared to all other grouped subsets.+- 
10.4.1 All differentially expressed genes in (28+) v. (28-). 
Genes are ranked by fold difference and all have a fold difference >2 and p < 0.05 





 Symbol Fold change p-value 
1 CCR6 3.5 <0.0001 
2 GZMK 3.2 0.0002 
3 LTB 2.7 0.0001 
4 DPP4 2.5 0.0001 
5 CD28 2.5 0.0001 
6 LTB 2.4 0.0001 
7 RORC 2.3 0.0001 
8 IL23R 2.2 0.0001 
9 MFGE8 2.1 0.0001 
10 MYC 2.1 0.01 
11 INADL 2.1 0.0001 
12 FAM102A 2.0 0.0001 
13 FGFBP2 6.1 0.011 
14 GPR56 5.4 0.03 
15 GPR56 5.0 0.0007 
16 PRSS23 4.6 <0.0001 
17 GZMB 4.3 0.0001 
18 GZMH 3.9 <0.0001 
19 GNLY 3.3 0.0002 
20 FLJ20699 3.0 <0.0001 
21 TTC38 2.9 <0.0001 
22 OSBPL5 2.5 <0.0001 
23 JAZF1 2.5 <0.0001 
24 ZEB2 2.5 <0.0001 
25 CES1 2.4 0.02 
26 RAP2A 2.3 <0.0001 
27 OSBPL5 2.3 <0.0001 
28 ILMN_1856480 2.3 0.02 
29 CYBRD1 2.2 <0.0001 
30 ITGB1 2.2 <0.0001 
31 KLRF1 2.0 <0.0001 
32 ITGAM 2.0 <0.0001 
33 LOC731007 2.0 <0.0001 
10.4.2 Differentially expressed genes in (28-) vs. (16-). 
Genes are ranked by fold difference and all have a fold difference > 2 and p < 0.05 





 Symbol Fold change p-value 
1 CD27 10.3 <0.0001 
2 LOC441763 2.6 <0.0001 
3 LOC100008588 2.3 <0.0001 
4 LOC100008589 2.3 <0.0001 
5 LOC100133565 2.2 <0.0001 
6 LOC100134364 2.2 <0.0001 
7 TYROBP 2.2 <0.0001 
8 LOC100132394 2.1 <0.0001 
9 LOC728499 2.4 <0.0001 
10 CD8A 2.3 <0.0001 
11 C5orf28 2.3 <0.0001 
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10.4.3 Differentially expressed genes in (16-) v. (16+) 
Genes are ranked by fold difference and all have a fold difference > 2 and p < 0.05 





 Symbol Fold change p-value 
1 SSBP3 6.1 <0.0001 
2 LOC646674 5.0 <0.0001 
3 LSP1 4.6 <0.0001 
4 CD3E 4.4 <0.0001 
5 ABCA2 3.8 0.0005 
6 PPDPF 3.5 <0.0001 
7 LOC641972 3.4 <0.0001 
8 LOC400174 3.4 <0.0001 
9 FLNA 3.2 <0.0001 
10 BSG 3.2 <0.0001 
11 LOC401002 3.1 <0.0001 
12 AES 3.1 <0.0001 
13 PKM2 3.1 <0.0001 
14 SMARCC2 3.0 <0.0001 
15 GATAD2B 3.0 <0.0001 
16 LSP1 2.8 0.006 
17 INO80E 2.8 <0.0001 
18 LY6E 2.7 <0.0001 
19 CHCHD10 2.7 <0.0001 
20 VAMP2 2.7 <0.0001 
21 LOC407835 2.7 <0.0001 
22 PABPC1 2.6 <0.0001 
23 CTSD 2.6 <0.0001 
24 FAM100A 2.6 <0.0001 
25 PACS1 2.5 <0.0001 
26 SH3BP1 2.5 0.0001 
27 FKBP1A 2.5 <0.0001 
28 FKSG30 2.5 0.001 
29 LSP1 2.5 <0.0001 
30 BANF1 2.5 <0.0001 
31 MGRN1 2.4 <0.0001 
32 DCAF15 2.4 <0.0001 
33 PKN1 2.4 <0.0001 
34 PFN1 2.3 <0.0001 
35 PTMS 2.3 <0.0001 
36 HMGA1 2.3 <0.0001 
37 PARP10 2.3 <0.0001 
38 JOSD2 2.3 <0.0001 
39 GTF3C1 2.3 <0.0001 
40 PKM2 2.3 <0.0001 
41 ARHGEF1 2.3 0.002 
42 IL32 2.2 <0.0001 
43 PTMA 2.2 <0.0001 
44 RAB5C 2.2 <0.0001 
45 ARHGEF1 2.2 0.0005 
46 LOC642489 2.2 <0.0001 
47 CLPTM1 2.2 <0.0001 
48 LOC644914 2.2 0.01 
49 G6PD 2.2 <0.0001 
50 KIR2DL3 2.2 <0.0001 
51 PARP10 2.2 <0.0001 
52 PA2G4 2.2 <0.0001 
53 ARRB2 2.2 <0.0001 
54 TSC22D4 2.2 0.03 
55 ZMAT3 2.1 0.0005 
56 APBB1IP 2.1 <0.0001 
57 BAT2 2.1 <0.0001 
58 C16orf56 2.1 0.003 
59 MRPL2 2.1 <0.0001 
60 SMARCB1 2.1 <0.0001 
61 BAT1 2.1 <0.0001 
62 PKM2 2.1 <0.0001 
63 ABTB1 2.1 <0.0001 
64 LOC642828 2.1 <0.0001 
65 GPAA1 2.1 <0.0001 
66 CNPY3 2.1 0.001 
67 FAM108A2 2.1 <0.0001 
68 FAM108A3 2.0 0.009 
69 CNOT3 2.0 <0.0001 
70 PNPLA2 2.0 <0.0001 
71 BCL2L1 2.0 0.0001 
72 GZMK 4.8 <0.0001 
73 LOC100132761 4.5 <0.0001 
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74 LOC100130332 3.6 <0.0001 
75 CALML4 3.5 <0.0001 
76 HLA-DQA1 3.4 <0.0001 
77 MRPS25 3.0 <0.0001 
78 ILMN_1873034 2.9 <0.0001 
79 TPM2 2.9 <0.0001 
80 FOSB 2.9 <0.0001 
81 LOC100132564 2.8 <0.0001 
82 ILMN_1916256 2.7 <0.0001 
83 CYB561 2.6 <0.0001 
84 INTS1 2.6 <0.0001 
85 CPSF1 2.5 <0.0001 
86 GRAMD1A 2.5 <0.0001 
87 NELF 2.4 <0.0001 
88 LTB 2.4 <0.0001 
89 DBN1 2.4 <0.0001 
90 HEATR1 2.4 <0.0001 
91 DPP7 2.3 <0.0001 
92 ILMN_1823130 2.3 <0.0001 
93 LRCH4 2.3 <0.0001 
94 C7orf27 2.3 <0.0001 
95 RNF126 2.3 <0.0001 
96 HMHA1 2.2 <0.0001 
97 ZDHHC11 2.2 <0.0001 
98 TP53I13 2.2 <0.0001 
99 SPSB3 2.2 <0.0001 
100 ILMN_1819304 2.2 <0.0001 
101 LRCH4 2.2 <0.0001 
102 RASAL3 2.1 <0.0001 
103 TPD52L2 2.1 <0.0001 
104 ILMN_1879482 2.1 <0.0001 
105 PIGQ 2.1 <0.0001 
106 U2AF1L2 2.1 <0.0001 
107 C21orf2 2.1 <0.0001 
108 UPLP 2.1 <0.0001 
109 LRSAM1 2.1 <0.0001 
110 MIR1974 2.1 0.0001 
111 PLA2G4B 2.1 <0.0001 
112 E4F1 2.1 <0.0001 
113 LOC731682 2.1 0.02 
114 CARD11 2.1 <0.0001 
115 IL15 2.1 0.0002 
116 CYB561 2.0 <0.0001 
117 PRR14 2.0 <0.0001 
118 CERKL 2.0 <0.0001 
119 SLC26A11 2.0 <0.0001 
120 SCAP 2.0 <0.0001 
121 SPRYD3 2.0 <0.0001 
122 ABTB1 2.0 <0.0001 
123 SIPA1 2.0 <0.0001 
10.4.4 Differentially expressed genes in (28+) v. (16-) 
Genes are ranked by fold difference and all have a fold difference > 2 and p < 0.05 





 Symbol Fold change p-value 
1 CD27 12.9 0.003 
2 GZMK 8.2 <0.0001 
3 PDE4B 6.3 0.001 
4 DUSP2 5.1 <0.0001 
5 CSDA 4.2 0.001 
6 MYC 4.1 0.001 
7 LTB 4.1 <0.0001 
8 RPS23 4.0 <0.0001 
9 LTB 3.9 <0.0001 
10 CCR6 3.8 0.02 
11 TMEM14C 3.5 <0.0001 
12 CXCR4 3.5 <0.0001 
13 FAM46C 3.5 <0.0001 
14 MYC 3.3 0.001 
15 AXUD1 3.3 <0.0001 
16 LOC100132673 3.3 <0.0001 
17 LOC647307 3.3 0.03 
18 ZFP36 3.2 <0.0001 
19 LOC100129882 3.2 <0.0001 
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20 DPP4 3.2 0.02 
21 CXCR4 3.1 <0.0001 
22 VAV3 3.0 0.01 
23 LOC100134364 3.0 <0.0001 
24 IFITM3 3.0 0.08 
25 LOC100008589 3.0 <0.0001 
26 LOC100132394 3.0 <0.0001 
27 SIPA1L2 2.9 0.032 
28 LOC91561 2.9 <0.0001 
29 RPLP0 2.8 <0.0001 
30 MFGE8 2.8 0.001 
31 LASS6 2.8 0.05 
32 NR4A2 2.7 0.001 
33 TNFAIP3 2.7 <0.0001 
34 SIK1 2.7 0.01 
35 LOC649049 2.7 <0.0001 
36 CD28 2.7 0.0001 
37 FAM118A 2.6 0.024 
38 TIPARP 2.6 <0.0001 
39 RORC 2.6 0.65 
40 RPL13L 2.6 <0.0001 
41 ISG20 2.6 <0.0001 
42 LOC100131866 2.5 <0.0001 
43 FAM102A 2.5 <0.0001 
44 SCD 2.5 0.0013 
45 CNN2 2.5 <0.0001 
46 NINJ1 2.5 <0.0001 
47 PDE4B 2.5 0.22 
48 IRS2 2.4 0.0013 
49 LOC642934 2.3 <0.0001 
50 DUSP5 2.3 <0.0001 
51 ZFP36L2 2.3 <0.0001 
52 LOC253039 2.3 0.001 
53 LOC645688 2.3 <0.0001 
54 SLC7A5 2.3 <0.00010 
55 METTL1 2.2 0.001 
56 LOC148430 2.2 <0.0001 
57 ADCY3 2.2 0.001 
58 JUNB 2.2 <0.0001 
59 MTP18 2.2 <0.0001 
60 LOC440927 2.2 <0.0001 
61 IL23R 2.2 0.0001 
62 LOC388564 2.2 <0.0001 
63 LOC729679 2.2 <0.0001 
64 NR4A2 2.2 <0.0001 
65 LOC642989 2.2 <0.0001 
66 LOC642035 2.2 0.0001 
67 CD7 2.2 <0.0001 
68 DNAJB9 2.1 <0.0001 
69 LOC127295 2.1 <0.0001 
70 LRIG1 2.1 0.0013 
71 IL18R1 2.1 <0.0001 
72 LOC388339 2.1 <0.0001 
73 BEXL1 2.1 <0.0001 
74 LOC727984 2.1 <0.0001 
75 C17orf45 2.1 <0.0001 
76 FKBP5 2.1 <0.0001 
77 STS-1 2.1 0.001 
78 SLAMF1 2.1 0.001 
79 TRAT1 2.1 <0.0001 
80 LOC728820 2.1 <0.0001 
81 RPL14 2.1 <0.0001 
82 TCEAL4 2.0 <0.0001 
83 LOC100132795 2.0 <0.0001 
84 LOC729236 2.0 <0.0001 
85 LOC645173 2.0 <0.0001 
86 LOC388556 2.0 <0.0001 
87 ZNF683 10.5 <0.0001 
88 CD8A 10.2 <0.0001 
89 CD8A 9.3 <0.0001 
90 FGFBP2 8.4 <0.0001 
91 GPR56 8.2 <0.0001 
92 CX3CR1 7.6 <0.0001 
93 CX3CR1 6.9 <0.0001 
94 GPR56 6.6 <0.0001 
95 PRSS23 5.9 <0.0001 
96 PATL2 5.6 <0.0001 
97 GZMB 5.5 <0.0001 
98 KIR2DL1 5.4 <0.0001 
99 LOC197135 5.2 <0.0001 
100 GZMH 5.0 <0.0001 
101 LOC100133678 5.0 <0.0001 
102 HBB 4.8 <0.0001 
103 KIR3DS1 4.6 <0.0001 
104 GNLY 4.6 <0.0001 
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105 GNLY 4.4 <0.0001 
106 ILMN_1913060 4.3 <0.0001 
107 TTC38 4.2 <0.0001 
108 GNLY 4.2 <0.0001 
109 FLJ20699 4.0 <0.0001 
110 HLA-DQA1 3.9 <0.0001 
111 ITGAX 3.9 <0.0001 
112 PDGFRB 3.6 <0.0001 
113 LGALS1 3.5 <0.0001 
114 PALLD 3.5 <0.0001 
115 LAIR2 3.4 <0.0001 
116 TXNDC3 3.3 <0.0001 
117 JAZF1 3.3 <0.0001 
118 AKR1C3 3.3 <0.0001 
119 HBA2 3.3 <0.0001 
120 ASCL2 3.2 <0.0001 
121 CES1 3.1 <0.0001 
122 ERBB2 3.1 <0.0001 
123 KIR2DL1 3.1 <0.0001 
124 CD8A 3.1 <0.0001 
125 PATL2 3.1 <0.0001 
126 LAIR2 3.1 <0.0001 
127 RAP2A 3.0 <0.0001 
128 SGCE 2.9 <0.0001 
129 KIR2DL4 2.9 <0.0001 
130 KIR2DL4 2.9 0.006 
131 OSBPL5 2.8 <0.0001 
132 ITGB1 2.8 <0.0001 
133 KIR3DL3 2.8 <0.0001 
134 RHOB 2.8 <0.0001 
135 KIR2DS5 2.8 <0.0001 
136 PTGDR 2.8 <0.0001 
137 CYBRD1 2.8 <0.0001 
138 ZEB2 2.7 <0.0001 
139 RAB11FIP5 2.7 <0.0001 
140 MIAT 2.7 <0.0001 
141 PROK2 2.6 <0.0001 
142 TSHZ3 2.6 <0.0001 
143 SLC1A7 2.6 <0.0001 
144 HBA2 2.6 <0.0001 
145 OSBPL5 2.6 <0.0001 
146 IFNG 2.6 <0.0001 
147 ILMN_1856480 2.5 <0.0001 
148 GARNL4 2.5 <0.0001 
149 ITGB1 2.5 <0.0001 
150 PTGDR 2.5 <0.0001 
151 PRF1 2.5 <0.0001 
152 CLDND2 2.5 <0.0001 
153 OASL 2.5 <0.0001 
154 LOC730024 2.5 <0.0001 
155 PLOD1 2.4 <0.0001 
156 KLRF1 2.4 <0.0001 
157 GDPD5 2.4 <0.0001 
158 ILMN_1819608 2.4 <0.0001 
159 SIGLECP3 2.4 <0.0001 
160 ITGB1 2.4 <0.0001 
161 CACNA2D4 2.3 <0.0001 
162 PRKAR1A 2.3 <0.0001 
163 LOC728499 2.3 <0.0001 
164 FLJ14213 2.3 <0.0001 
165 CENPK 2.3 <0.0001 
166 SPG11 2.3 <0.0001 
167 VCL 2.3 <0.0001 
168 LOC731007 2.3 <0.0001 
169 CEP78 2.2 <0.0001 
170 RHOBTB3 2.2 <0.0001 
171 D4S234E 2.2 0.0001 
172 ITGAM 2.2 <0.0001 
173 CYBRD1 2.2 <0.0001 
174 KIR3DL1 2.2 0.0001 
175 ATPGD1 2.2 <0.0001 
176 ATPGD1 2.2 <0.0001 
177 AKR1C4 2.1 <0.0001 
178 PHGDH 2.1 <0.0001 
179 ZNF365 2.1 <0.0001 
180 EPDR1 2.1 <0.0001 
181 FGR 2.1 <0.0001 
182 KIR2DS3 2.1 0.0001 
183 PLEK 2.1 <0.0001 
184 PODN 2.1 <0.0001 
185 HLA-DRB4 2.1 0.0002 
186 LOC23117 2.1 <0.0001 
187 FAM46A 2.1 <0.0001 
188 LOC642909 2.1 <0.0001 
189 CEP78 2.0 <0.0001 
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190 ZDHHC11 2.0 <0.0001 
191 SUSD1 2.0 <0.0001 
192 ZNF439 2.0 <0.0001 
193 FNDC3B 2.0 <0.0001 
194 LOC649143 2.0 <0.0001 
195 NMUR1 2.0 <0.0001 
10.4.5 Differentially expressed genes in (28+) v. (16+) 
Genes are ranked by fold difference and all have a fold difference > 2 and p < 0.05 





 Symbol Fold change p-value 
1 GZMK 37.1 <0.0001 
2 CD27 16.5 <0.0001 
3 LTB 9.2 <0.0001 
4 LTB 7.2 <0.0001 
5 LOC100132761 6.4 0.02 
6 PDE4B 6.12 <0.0001 
7 MYC 5.4 <0.0001 
8 DUSP2 5.3 <0.0001 
9 ILMN_1873034 5.3 <0.0001 
10 MYC 4.6 <0.0001 
11 CCR6 4.4 <0.0001 
12 LOC100133565 4.3 0.03 
13 FAM102A 4.0 <0.0001 
14 LOC100008589 4.0 0.01 
15 CNN2 3.9 0.0001 
16 CD160 3.9 <0.0001 
17 LOC148430 3.8 <0.0001 
18 CSDA 3.7 <0.0001 
19 LOC100132673 3.7 <0.0001 
20 GRAMD1A 3.7 <0.0001 
21 MFGE8 3.6 <0.0001 
22 DPP4 3.6 <0.0001 
23 HLA-DMA 3.6 0.02 
24 SIPA1L2 3.6 <0.0001 
25 LOC100008588 3.5 0.0004 
26 LOC651149 3.5 <0.0001 
27 TMEM14C 3.5 <0.0001 
28 CD7 3.4 <0.0001 
29 LOC100131866 3.4 <0.0001 
30 LOC91561 3.3 <0.0001 
31 UBASH3A 3.3 0.02 
32 AXUD1 3.2 <0.0001 
33 CYB561 3.2 <0.0001 
34 ZFP36 3.1 0.0259 
35 DPP7 3.1 <0.0001 
36 C8orf55 3.1 <0.0001 
37 FOSB 3.0 0.0001 
38 LOC100130332 3.0 <0.0001 
39 TRAT1 2.9 <0.0001 
40 FAM118A 2.9 <0.0001 
41 LOC442232 2.9 <0.0001 
42 CD28 2.9 <0.0001 
43 RPL14 2.9 <0.0001 
44 SLC7A5 2.9 0.001 
45 RNF126 2.9 <0.0001 
46 LOC729679 2.8 <0.0001 
47 CYB561 2.8 0.0001 
48 HPCAL1 2.8 <0.0001 
49 RPL13L 2.8 <0.0001 
50 LOC286444 2.8 <0.0001 
51 LOC644907 2.8 <0.0001 
52 TP53I13 2.7 <0.0001 
53 ILMN_1916904 2.7 <0.0001 
54 LOC649049 2.7 <0.0001 
55 MIR1974 2.7 <0.0001 
56 SIPA1 2.7 <0.0001 
57 C17orf45 2.7 <0.0001 
58 RORC 2.7 <0.0001 
59 ADCY3 2.7 <0.0001 
60 FAM46C 2.6 <0.0001 
61 C11orf2 2.6 <0.0001 
62 MRPS25 2.6 <0.0001 
63 PARP3 2.6 <0.0001 
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64 SIK1 2.6 <0.0001 
65 LRCH4 2.6 <0.0001 
66 CPSF1 2.6 <0.0001 
67 PDE4B 2.5 0.002 
68 NINJ1 2.5 <0.0001 
69 UPLP 2.5 <0.0001 
70 LOC100130562 2.5 <0.0001 
71 UBAC2 2.5 <0.0001 
72 P2RY11 2.5 <0.0001 
73 LOC653156 2.5 <0.0001 
74 SIRPG 2.5 <0.0001 
75 SIRPG 2.4 <0.0001 
76 INADL 2.4 <0.0001 
77 NCK2 2.4 <0.0001 
78 C7orf27 2.4 <0.0001 
79 HEXDC 2.4 <0.0001 
80 DYNLL2 2.4 <0.0001 
81 LOC653737 2.4 0.008 
82 CMTM7 2.4 <0.0001 
83 FBL 2.4 <0.0001 
84 IRF1 2.4 <0.0001 
85 FAM102A 2.4 <0.0001 
86 IL23R 2.4 <0.0001 
87 SUSD3 2.4 <0.0001 
88 LOC387825 2.4 <0.0001 
89 SCAP 2.4 <0.0001 
90 CCDC109B 2.4 <0.0001 
91 INTS1 2.3 <0.0001 
92 RPL13 2.3 <0.0001 
93 SLAMF1 2.3 0.0001 
94 TPD52L2 2.3 <0.0001 
95 DUSP5 2.3 <0.0001 
96 LOC441506 2.3 <0.0001 
97 LOC100129685 2.3 <0.0001 
98 LOC652624 2.3 <0.0001 
99 LYL1 2.3 <0.0001 
100 RORC 2.3 <0.0001 
101 STS-1 2.3 0.02 
102 C10orf35 2.3 <0.0001 
103 CECR5 2.3 <0.0001 
104 UROS 2.3 <0.0001 
105 RPLP0 2.3 0.0001 
106 WDR74 2.3 <0.0001 
107 LOC391019 2.2 0.002 
108 TCEAL4 2.2 <0.0001 
109 MTP18 2.2 0.0003 
110 VEGFB 2.2 <0.0001 
111 VARS2 2.2 <0.0001 
112 HMHA1 2.2 <0.0001 
113 POLR3H 2.2 <0.0001 
114 PDXK 2.2 0.003 
115 LOC441013 2.2 <0.0001 
116 IL18R1 2.2 0.001 
117 ADORA2A 2.2 0.01 
118 METTL1 2.2 <0.0001 
119 LOC728431 2.2 <0.0001 
120 ABLIM1 2.2 <0.0001 
121 TMEM14C 2.2 <0.0001 
122 SMAP2 2.2 <0.0001 
123 RPS6KB2 2.2 <0.0001 
124 LOC729742 2.2 <0.0001 
125 LOC401676 2.2 <0.0001 
126 SYPL1 2.2 <0.0001 
127 BTBD2 2.2 <0.0001 
128 LOC390354 2.2 <0.0001 
129 DENND5A 2.2 0.0001 
130 HNRPA1L-2 2.2 <0.0001 
131 LOC728820 2.1 0.0001 
132 C16orf58 2.1 <0.0001 
133 LOC339192 2.1 <0.0001 
134 RPL12P6 2.1 <0.0001 
135 DGCR6 2.1 <0.0001 
136 ISG20 2.1 <0.0001 
137 IL23R 2.1 0.0001 
138 PARP10 2.1 <0.0001 
139 LOC100130562 2.1 <0.0001 
140 C17orf70 2.1 <0.0001 
141 CAPS 2.1 <0.0001 
142 EMD 2.1 <0.0001 
143 TUBA1C 2.1 <0.0001 
144 LIMS1 2.1 <0.0001 
145 LOC644511 2.1 <0.0001 
146 LOC728820 2.1 <0.0001 
147 LOC648249 2.1 <0.0001 
148 LOC388564 2.1 <0.0001 
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149 SLC25A22 2.1 <0.0001 
150 ALDOC 2.1 <0.0001 
151 BMS1 2.1 <0.0001 
152 B4GALT1 2.1 0.01 
153 LOC440991 2.1 <0.0001 
154 LOC653232 2.1 <0.0001 
155 SPSB3 2.1 <0.0001 
156 LOC728060 2.1 0.008 
157 LOC100132795 2.1 <0.0001 
158 SNORA24 2.1 <0.0001 
159 NFE2L3 2.1 <0.0001 
160 DIMT1L 2.1 <0.0001 
161 KLHL22 2.1 0.03 
162 LOC401115 2.1 <0.0001 
163 STMN3 2.1 0.002 
164 LOC389156 2.1 <0.0001 
165 PTGES2 2.1 <0.0001 
166 MFSD3 2.1 <0.0001 
167 FAM173A 2.0 <0.0001 
168 DPH5 2.0 0.0002 
169 GNL1 2.0 <0.0001 
170 TRMT1 2.0 <0.0001 
171 LOC389156 2.0 <0.0001 
172 CARD11 2.0 <0.0001 
173 GTPBP6 2.0 <0.0001 
174 C19orf66 2.0 <0.0001 
175 AVPI1 2.0 <0.0001 
176 PRKCZ 2.0 <0.0001 
177 RPS29 2.0 <0.0001 
178 PUS1 2.0 <0.0001 
179 LOC388556 2.0 <0.0001 
180 DNAJB9 2.0 0.003 
181 TRAF5 2.0 0.008 
182 LOC158345 2.0 <0.0001 
183 LOC388707 2.0 <0.0001 
184 SPRYD3 2.0 <0.0001 
185 FGFBP2 11.0 <0.0001 
186 CX3CR1 10.0 0.0004 
187 GPR56 9.9 <0.0001 
188 CX3CR1 9.1 <0.0001 
189 SSBP3 9.0 <0.0001 
190 GPR56 8.0 0.0009 
191 PRSS23 6.8 <0.0001 
192 GZMB 6.8 <0.0001 
193 LOC646674 6.5 <0.0001 
194 TTC38 5.7 <0.0001 
195 FLJ20699 5.4 <0.0001 
196 GNLY 5.3 <0.0001 
197 KIR2DL4 5.3 <0.0001 
198 KIR2DL3 5.1 <0.0001 
199 SPON2 4.9 0.03 
200 RAP2A 4.7 0.01 
201 LSP1 4.7 <0.0001 
202 ZEB2 4.6 <0.0001 
203 GZMH 4.5 <0.0001 
204 ERBB2 4.3 <0.0001 
205 CD3E 4.1 <0.0001 
206 ABCA2 4.0 0.0002 
207 LAIR2 4.0 <0.0001 
208 GNLY 3.9 <0.0001 
209 CYBRD1 3.7 <0.0001 
210 FLNA 3.7 <0.0001 
211 KIR3DL1 3.6 0.001 
212 ITGB1 3.6 <0.0001 
213 MGC52282 3.6 0.006 
214 LAIR2 3.6 <0.0001 
215 JAZF1 3.5 <0.0001 
216 LOC400174 3.4 <0.0001 
217 LOC401002 3.4 <0.0001 
218 LOC641972 3.4 <0.0001 
219 KIR2DL3 3.3 <0.0001 
220 LYN 3.3 0.0105 
221 PRF1 3.3 <0.0001 
222 BSG 3.2 <0.0001 
223 GATAD2B 3.2 <0.0001 
224 CYBRD1 3.2 <0.0001 
225 AES 3.2 <0.0001 
226 LSP1 3.1 0.0009 
227 VAMP2 3.0 <0.0001 
228 SUSD1 3.0 0.0002 
229 SMARCC2 3.0 <0.0001 
230 ATPGD1 3.0 <0.0001 
231 FAM100A 2.9 <0.0001 
232 TSHZ3 2.9 <0.0001 




234 TRK1 2.9 <0.0001 
235 GDPD5 2.9 <0.0001 
236 PKM2 2.8 <0.0001 
237 PKN1 2.8 <0.0001 
238 FKSG30 2.7 0.005 
239 PFN1 2.7 <0.0001 
240 LSP1 2.7 <0.0001 
241 RAB11FIP5 2.7 <0.0001 
242 LOC730024 2.7 <0.0001 
243 OASL 2.7 <0.0001 
244 SMAD7 2.7 <0.0001 
245 FAM46A 2.7 0.0003 
246 ASCL2 2.7 <0.0001 
247 FLJ14213 2.6 <0.0001 
248 OSBPL5 2.6 <0.0001 
249 BCL9L 2.6 <0.0001 
250 LY6E 2.6 <0.0001 
251 FGR 2.6 <0.0001 
252 ABI3 2.6 <0.0001 
253 APOBEC3C 2.6 <0.0001 
254 PTMS 2.6 <0.0001 
255 C16orf56 2.6 <0.0001 
256 SETBP1 2.6 <0.0001 
257 SSBP3 2.5 <0.0001 
258 MYO1G 2.5 <0.0001 
259 INO80E 2.5 <0.0001 
260 PACS1 2.5 <0.0001 
261 PTPN12 2.5 <0.0001 
262 SH3BGRL3 2.5 <0.0001 
263 APBB1IP 2.5 <0.0001 
264 ARHGEF1 2.5 0.0004 
265 FAM108A2 2.5 <0.0001 
266 CEP78 2.5 0.04 
267 CEP78 2.5 0.003 
268 PTK2B 2.4 0.005 
269 FNDC3B 2.4 <0.0001 
270 LRRFIP1 2.4 <0.0001 
271 LOC653438 2.4 <0.0001 
272 CLPTM1 2.4 <0.0001 
273 LOC729495 2.4 <0.0001 
274 CTNNA1 2.4 <0.0001 
275 PPDPF 2.4 0.02 
276 FCAR 2.4 <0.0001 
277 LOC407835 2.4 <0.0001 
278 RAB5C 2.4 <0.0001 
279 RPTOR 2.4 0.04 
280 ACTB 2.4 <0.0001 
281 RTN4 2.4 <0.0001 
282 ZYX 2.3 <0.0001 
283 RHOBTB3 2.3 <0.0001 
284 FAM108A3 2.3 0.0004 
285 SH3BP1 2.3 0.002 
286 CTSD 2.3 0.0003 
287 VCL 2.3 <0.0001 
288 GTF3C1 2.3 <0.0001 
289 FKBP1A 2.3 <0.0001 
290 ITGAM 2.3 <0.0001 
291 STXBP2 2.3 <0.0001 
292 PARP10 2.3 <0.0001 
293 PARP10 2.3 <0.0001 
294 GNPTAB 2.3 <0.0001 
295 PKN1 2.3 <0.0001 
296 SEMA3E 2.3 <0.0001 
297 AES 2.3 <0.0001 
298 FNDC3B 2.3 <0.0001 
299 FAR1 2.3 <0.0001 
300 ADD3 2.3 0.0001 
301 HSPA6 2.3 <0.0001 
302 BANF1 2.3 <0.0001 
303 PA2G4 2.3 <0.0001 
304 LOC644988 2.3 <0.0001 
305 DCAF15 2.3 <0.0001 
306 RAB5C 2.3 <0.0001 
307 ARHGEF1 2.3 0.0003 
308 CENPT 2.3 <0.0001 
309 G6PD 2.3 <0.0001 
310 JOSD2 2.2 <0.0001 
311 ADAMTS1 2.2 <0.0001 
312 ADAM8 2.2 <0.0001 
313 TSC22D4 2.2 0.02 
314 OSBPL5 2.2 <0.0001 
315 DUSP8 2.2 <0.0001 
316 MYL12A 2.2 <0.0001 
317 STIM1 2.2 <0.0001 
318 LOC644914 2.2 0.02 
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319 GFI1 2.2 0.008 
320 XRCC2 2.2 0.001 
321 RTN4 2.2 <0.0001 
322 DRAP1 2.2 <0.0001 
323 GNAI2 2.2 <0.0001 
324 FAM63A 2.2 <0.0001 
325 CAPNS1 2.2 <0.0001 
326 ZNF69 2.2 0.0001 
327 ARRB2 2.2 <0.0001 
328 ILMN_1872419 2.2 <0.0001 
329 LOC729495 2.1 <0.0001 
330 UBL3 2.1 <0.0001 
331 FKBP14 2.1 0.004 
332 LOC642489 2.1 0.0005 
333 MGRN1 2.1 <0.0001 
334 CEBPA 2.1 0.0001 
335 PKM2 2.1 <0.0001 
336 ACTN4 2.1 <0.0001 
337 HCG2P7 2.1 <0.0001 
338 CAPNS1 2.1 <0.0001 
339 SSBP4 2.1 <0.0001 
340 SASH3 2.1 <0.0001 
341 PLEKHA1 2.1 0.002 
342 CNOT3 2.1 <0.0001 
343 PDZD4 2.1 <0.0001 
344 GHDC 2.1 <0.0001 
345 SLCO4C1 2.1 <0.0001 
346 S1PR5 2.1 <0.0001 
347 ILMN_1900734 2.1 0.0003 
348 VCL 2.1 0.0000 
349 SHROOM4 2.1 0.0000 
350 CD3G 2.1 0.002 
351 PTPN6 2.0 0.0000 
352 PTPN12 2.0 0.0000 
353 LSS 2.0 0.001 
354 ILMN_1864166 2.0 0.0000 
355 BAT1 2.0 0.0000 
356 ACTR3 2.0 0.0000 
357 LMF2 2.0 0.002 
358 MBTD1 2.0 0.0000 
359 SYTL1 2.0 0.0009 
10.4.6 Differentially expressed genes in (28+) v. Others (grouped) 
Genes are ranked by fold difference and all have a fold difference > 2 and p < 0.05 







Symbol Fold change p-values 
1 GZMK 5.9 <0.0001 
2 CCR6 4.0 <0.0001 
3 LTB 4.0 <0.0001 
4 LTB 3.7 <0.0001 
5 PDE4B 3.6 <0.0001 
6 MYC 3.2 <0.0001 
7 DPP4 3.1 <0.0001 
8 SIPA1L2 2.9 <0.0001 
9 MYC 2.8 <0.0001 
10 DUSP2 2.8 0.04 
11 CD28 2.8 <0.0001 
12 MFGE8 2.7 <0.0001 
13 FAM102A 2.7 <0.0001 
14 RORC 2.6 <0.0001 
15 AXUD1 2.5 <0.0001 
16 TMEM14C 2.5 <0.0001 
17 CSDA 2.5 <0.0001 
18 ILMN_1873034 2.5 <0.0001 
19 LOC91561 2.4 0.01 
20 FAM118A 2.4 <0.0001 
21 IL23R 2.4 <0.0001 
22 LOC100131866 2.3 <0.0001 
23 SIK1 2.3 <0.0001 
24 LOC148430 2.2 0.04 
25 INADL 2.2 <0.0001 
26 RPLP0 2.2 <0.0001 
27 LOC651149 2.2 0.04 
28 FAM46C 2.2 <0.0001 
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29 LOC442232 2.1 <0.0001 
30 RORC 2.1 <0.0001 
31 RPL13L 2.1 <0.0001 
32 ADCY3 2.1 <0.0001 
33 IL23R 2.1 <0.0001 
34 LOC649049 2.1 <0.0001 
35 FAM102A 2.0 <0.0001 
36 LASS6 2.0 <0.0001 
37 ZNF683 8.3 <0.0001 
38 FGFBP2 8.2 <0.0001 
39 GPR56 7.4 <0.0001 
40 CX3CR1 7.3 0.03 
41 CX3CR1 6.6 <0.0001 
42 GPR56 6.2 <0.0001 
43 PRSS23 5.8 <0.0001 
44 GZMB 5.4 <0.0001 
45 TTC38 4.2 <0.0001 
46 GNLY 4.2 <0.0001 
47 FLJ20699 4.2 <0.0001 
48 GZMH 4.1 <0.0001 
49 LGALS1 3.9 <0.0001 
50 GNLY 3.6 <0.0001 
51 ERBB2 3.5 <0.0001 
52 ZEB2 3.5 <0.0001 
53 LAIR2 3.4 <0.0001 
54 LAIR2 3.1 <0.0001 
55 JAZF1 3.0 <0.0001 
56 CYBRD1 3.0 <0.0001 
57 ITGB1 2.8 <0.0001 
58 ASCL2 2.7 <0.0001 
59 OSBPL5 2.6 <0.0001 
60 PRF1 2.6 <0.0001 
61 TSHZ3 2.5 <0.0001 
62 CYBRD1 2.5 0.01 
63 LOC731007 2.5 <0.0001 
64 RAB11FIP5 2.4 <0.0001 
65 EPDR1 2.4 <0.0001 
66 SUSD1 2.4 <0.0001 
67 OSBPL5 2.4 <0.0001 
68 ATPGD1 2.3 0.03 
69 FLJ14213 2.3 <0.0001 
70 LOC730024 2.3 0.0200 
71 ITGAM 2.2 <0.0001 
72 FGR 2.1 <0.0001 
73 PTPN12 2.1 <0.0001 
74 HSPA6 2.1 <0.0001 
75 ADAMTS1 2.1 <0.0001 
76 MYO1G 2.1 0.01 
77 FNDC3B 2.1 <0.0001 
78 VCL 2.0 <0.0001 
79 GNPTAB 2.0 <0.0001 
80 FNDC3B 2.0 <0.0001 
81 RHOBTB3 2.0 <0.0001 
10.4.7 Differentially expressed genes in (28-) vs. Others (grouped). 
Genes are ranked by fold difference and all have a fold difference > 2 and p < 0.05 
with values stated in the table below.  Genes in red are higher in (28-) subset. 

(28-)
 v Others Symbol Fold change p-value 
0 
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10.4.8 Differentially expressed genes in (16-) vs. Others (grouped). 
Genes are ranked by fold difference and all have a fold difference > 2 and p < 0.05 
with values stated in the table below.  Genes in red are higher in (16-) subset. 

(16-)
 v Others Symbol Fold change p-value 
1 CD8A 2.7 <0.0001 
2 PATL2 2.6 <0.0001 
3 LOC197135 2.4 <0.0001 
4 LOC728499 2.1 <0.0001 
5 PATL2 2.0 <0.0001 
6 CD8A 2.0 <0.0001 
10.4.9 Differentially expressed genes in (16+) vs. Others (grouped). 
Genes are ranked by fold difference and all have a fold difference > 2 and p < 0.05 
with values stated in the table below.  Genes in red are higher in (16+) subset. 

(16+)
 vs. Others Symbol Fold change p-value 
1 SSBP3 7.6 <0.0001 
2 LOC646674 5.4 <0.0001 
3 LSP1 4.4 <0.0001 
4 ABCA2 4.1 0.0002 
5 CD3E 4.0 <0.0001 
6 FLNA 3.4 <0.0001 
7 LOC401002 3.3 <0.0001 
8 LOC400174 3.3 <0.0001 
9 LOC641972 3.2 <0.0001 
10 GATAD2B 3.2 <0.0001 
11 AES 3.0 <0.0001 
12 BSG 3.0 <0.0001 
13 VAMP2 2.9 <0.0001 
14 SMARCC2 2.9 <0.0001 
15 LSP1 2.9 0.003 
16 PKM2 2.9 <0.0001 
17 PPDPF 2.7 0.0009 
18 FAM100A 2.7 <0.0001 
19 INO80E 2.6 <0.0001 
20 LSP1 2.6 <0.0001 
21 KIR2DL3 2.6 <0.0001 
22 PACS1 2.5 <0.0001 
23 PKN1 2.5 <0.0001 
24 TTC38 2.5 <0.0001 
25 ZEB2 2.5 <0.0001 
26 C16orf56 2.4 0.0001 
27 KIR2DL4 2.4 0.006 
28 LOC407835 2.4 <0.0001 
29 FKSG30 2.4 0.011 
30 ARHGEF1 2.4 0.001 
31 SH3BP1 2.4 0.0004 
32 FCAR 2.4 <0.0001 
33 LY6E 2.4 <0.0001 
34 PFN1 2.4 <0.0001 
35 FLJ20699 2.3 0.03 
36 KIR2DL3 2.3 0.03 
37 TSC22D4 2.3 0.007 
38 BCL9L 2.3 <0.0001 
39 GTF3C1 2.3 <0.0001 
40 PARP10 2.3 <0.0001 
41 PTMS 2.3 <0.0001 
42 DCAF15 2.3 <0.0001 
43 CLPTM1 2.3 <0.0001 
44 CTSD 2.3 <0.0001 
45 SEMA3E 2.3 <0.0001 
46 ARHGEF1 2.3 0.0004 
47 FKBP1A 2.3 <0.0001 
48 PARP10 2.2 <0.0001 
49 LRRFIP1 2.2 <0.0001 
50 SMAD7 2.2 0.003 
51 BANF1 2.2 <0.0001 
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52 RAB5C 2.2 <0.0001 
53 APBB1IP 2.2 <0.0001 
54 CENPT 2.2 <0.0001 
55 FAM108A3 2.2 0.002 
56 FAM108A2 2.2 <0.0001 
57 LOC644914 2.2 0.01 
58 FAM63A 2.2 <0.0001 
59 PA2G4 2.2 <0.0001 
60 SSBP3 2.2 <0.0001 
61 MGRN1 2.2 <0.0001 
62 JOSD2 2.2 <0.0001 
63 ARRB2 2.1 <0.0001 
64 PKN1 2.1 <0.0001 
65 G6PD 2.1 <0.0001 
66 2.1 <0.0001 
67 STXBP2 2.1 <0.0001 
68 BAT2 2.1 <0.0001 
69 APOBEC3C 2.1 <0.0001 
70 XRCC2 2.1 0.0002 
71 ERBB2 2.1 0.04 
72 LOC653438 2.1 <0.0001 
73 PKM2 2.1 <0.0001 
74 STIM1 2.1 <0.0001 
75 GDPD5 2.1 0.02 
76 MBTD1 2.1 <0.0001 
77 RAB5C 2.1 <0.0001 
78 SHROOM4 2.1 <0.0001 
79 LOC642489 2.0 0.0001 
80 ZNF69 2.0 <0.0001 
81 ADD3 2.0 0.01 
82 ITGB1 2.0 0.01 
83 FKBP14 2.0 0.03 
84 SH3BGRL3 2.0 0.004 
85 LOC729495 2.0 <0.0001 
86 ABI3 2.0 0.003 
87 ABTB1 2.0 <0.0001 
88 LOC729495 2.0 0.0005 
89 LOC644988 2.0 <0.0001 
90 CD27 12.4 0.004 
91 LOC100132761 5.4 <0.0001 
92 LOC100132564 4.0 0.0002 
93 ILMN_1873034 4.0 0.001 
94 LOC100133565 3.9 <0.0001 
95 CD160 3.4 0.0006 
96 LOC100008588 3.3 <0.0001 
97 GRAMD1A 3.2 <0.0001 
98 CALML4 3.1 <0.0001 
99 HLA-DMA 2.9 0.01 
100 LOC100130332 2.9 <0.0001 
101 CD7 2.8 <0.0001 
102 HEATR1 2.8 <0.0001 
103 DPP7 2.8 <0.0001 
104 CYB561 2.7 0.0004 
105 RNF126 2.6 <0.0001 
106 MRPS25 2.5 <0.0001 
107 C8orf55 2.5 0.0005 
108 TP53I13 2.5 0.0000 
109 CYB561 2.4 0.0006 
110 SIPA1 2.4 <0.0001 
111 LRCH4 2.4 <0.0001 
112 CPSF1 2.4 <0.0001 
113 RPL14 2.3 0.0002 
114 INTS1 2.3 <0.0001 
115 C7orf27 2.3 <0.0001 
116 LOC653156 2.2 0.02 
117 DBN1 2.2 <0.0001 
118 LOC729679 2.2 0.004 
119 C11orf2 2.2 <0.0001 
120 HMHA1 2.2 <0.0001 
121 HPCAL1 2.2 0.0003 
122 UPLP 2.2 0.0031 
123 LOC286444 2.2 0.001 
124 C17orf45 2.2 0.0001 
125 CERKL 2.2 0.0001 
126 SCAP 2.2 <0.0001 
127 LOC644907 2.2 0.0001 
128 HEXDC 2.2 <0.0001 
129 TPD52L2 2.2 <0.0001 
130 UBAC2 2.2 <0.0001 
131 CMTM7 2.1 0.03 
132 SIRPG 2.1 <0.0001 
133 BTBD2 2.1 <0.0001 
134 CARD11 2.1 <0.0001 
135 PARP10 2.1 <0.0001 
136 IRF1 2.1 0.0001 
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137 ILMN_1823130 2.1 0.03 
138 SIRPG 2.0 0.02 
139 RPS6KB2 2.0 <0.0001 
140 FBL 2.0 <0.0001 
141 UROS 2.0 <0.0001 
142 P2RY11 2.0 0.02 
